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Summary 
Epilepsy is a disorder of the brain manifested with the recurrent unprovoked seizures. 
It affects about 71 million people globally. Epileptic seizures may involve a sudden 
loss of conscious, rapid muscles rigidity and contractions, violent convulsions and falls 
if a person is standing or sitting. Epilepsy can be controlled by antiepileptic drugs 
(AEDs) and adherence to treatment has been shown to improve quality of life, reduce 
seizure frequency, injuries, and death. Epileptic seizures negatively impact the lives 
of people with epilepsy (PWE) and those around them especially in LMIC. It is 
estimated that 80% of PWE live in LMICs. Excess mortality in PWE in developed 
countries is estimated to be up to 2 times higher than general population. There is 
scant data on excess mortality in PWE in SSA.  Scarcity of evidence on the impact of 
epilepsy has resulted in PWE being marginalized in health services planning and 
provision despite having high psychological, economic, morbidity and mortality burden 
relative to the general population. 
This thesis provides needed knowledge on uncertainties of epilepsy in SSA in relation 
to mortality, risk factors, and causes of death in PWE. The knowledge and evidence 
were generated from five studies using empirical data from community-based studies. 
Systematic review 
The first thesis objective was aimed at reviewing and summarizing available evidence 
on excess mortality in PWE compared to general population in LMIC. Systematic 
review in Chapter 3 identified only 7 studies in LMIC over the period of 25 years. 
Estimated excess mortality of ranged from 1.3-7.2 times higher in PWE than general 
population (median=2.6).  
x 
 
Meta-analysis of this systematic review indicated that up to 80% of total variability’s in 
the estimate of excess mortality (SMR) was only due to differences between studies. 
These differences may be due to methodological variations between studies or other 
unknown factors. The estimated excess mortality of 2.6 was median value and not 
pooled estimate as large variability’s between studies could not allow combined 
estimate of 7 studies. 
In conclusion, until this systematic review was done, there were no sufficient data to 
provide empirical evidence of excess mortality in PWE in LMIC. 
SEEDS study: Excess mortality 
At the time the systematic review was completed, new data on mortality of PWE were 
emerging from SEEDS studies. SEEDS studies had already followed PWE for over 8 
years and documented deaths in people with and without epilepsy. Chapter 4 of this 
thesis was dedicated at pooling and generating new evidence of excess mortality in 
PWE from SEEDS studies.  
The pooled excess mortality was 4.8 times higher in PWE than general population 
(95% CI: 4.2-5.6). SEEDS estimate is higher than summary findings from systematic 
review in reported in the literature in Chapter 4. SEEDS studies were conducted to 
account for methodological limitations encountered in most epilepsy studies related to 
screening, diagnosis, mortality and causes of death assessment, and population 
representativeness.  
SEEDS study: Risk factors 
The studies also identified modifiable risk factors potential for intervention programs 
and mitigating the negative impact of epilepsy. 
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Causes of death automation 
In addition to summarizing excess mortality in PWE, systematic review in Chapter 3 
summarized causes of deaths in PWE from different studies. Summary estimates from 
different studies in LMIC indicated most PWE died of direct causes which are status 
epilepticus (SE) and sudden death in epilepsy (SUDEP) and indirect (injuries) causes 
of epilepsy death. These studies compiled causes of death information from variety of 
sources including physicians, verbal autopsies and death certificates. 
In Chapter 5, this thesis assessed the application of automated tools in ascertaining 
causes of death in PWE. The assessment indicated that, the use of automated tools 
is potentials, convenient and affordable alternative to post-mortem and physician 
death certification. Unlike the use of other sources of cause of death information, 
automated tool estimated lower number of epilepsy-related deaths (27.5%) compared 
to around 50% when physician make diagnosis of cause of death. Chapter 5 also 
provides valuable information and recommendation needed for further development 
and refinement of these tools especially with regards to coding SUDEP, SE, and 
injuries. 
National estimates 
Chapter 6 and 7 provides national and community-based estimates of mortality of 
epilepsy and other neurological disorders from national (SAVVY) and community-
based studies (HDSS). The findings indicate epilepsy the second leading cause of 
death after cerebrovascular disorders. The estimates of mortality rate in the population 
ranged from 7-8 and 4-8 deaths per 100,000 populations in SAVVY and HDSS 
respectively. 
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HDSS data 
HDSS sites have become platform for monitoring demographic indicators in most SSA. 
Analysis of HDSS data was aimed at ascertaining whether there has been declining 
trends in epilepsy and other neurological disorders over time. In Chapter 7 of this 
thesis, results of the analysis indicated epilepsy mortality did not change over the past 
15 years. 
Synthesis 
This thesis generated new insights into the epidemiology of epilepsy in SSA. Limited 
data of studies of burden of epilepsy mortality in SSA point to either lack of interest in 
the subject, resources limitations from governments and funding bodies, and lack of 
knowledge of the negative impact of epilepsy. This study provides vigorous evidence 
of excess mortality needed for advocacy to health care providers, governments, and 
funding bodies for increased investment in care, preventions and reduction of the 
negative impact of epilepsy in SSA. The community and health care providers will 
benefit from evidence on modifiable risk factors for incidence and excess mortality 
from SEEDS study. 
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Epilepsy 
Epilepsy is a disorder of the brain manifested with the recurrent unprovoked seizures, 
caused by abnormal excessive or synchronous neuronal activity in the brain (Fisher 
et al., 2005). It affects about 71 million people globally (Ngugi et al., 2010b). Epileptic 
seizures may involve a sudden loss of conscious, rapid muscles rigidity and 
contractions, violent convulsions and falls if a person is standing or sitting. Other forms 
of epileptic seizures may involve impaired responsiveness “staring”, muscles spasms, 
and cognitive and sensory dysfunction. Epileptic seizures negatively impact the lives 
of people with epilepsy (PWE) and those around them. Un-employability, poor 
enrolment and dropout in schools, psychological, injuries due to accidents and deaths 
are among negative consequence of epilepsy. There is no cure for epilepsy; however 
antiepileptic drugs (AEDs) are the most effective therapeutic option for managing 
epileptic seizures. Treatment failure has been reported in 30% and epilepsy-related 
deaths constitute up to 65% of reported deaths in those under AED prescription (Kwan 
et al., 2004, Loscher et al., 2011, Radhakrishnan, 2009b). AED are prescribed for the 
rest of life and adherence to treatment has been shown to improve quality of life, 
reduce seizure frequency, injuries, and death. There is substantial funding gap in 
research by both governments and funding bodies thus possibly explaining little 
progress in the reduction of incidence and mortality of epilepsy (Chin, 2013, Meador 
et al., 2011). 
Epilepsy is a complex disease, not easy to diagnose (specifically non-convulsive) in 
most sub-Saharan Africa (SSA) countries, and manifested in many different forms. 
Therefore, standard case definitions and classifications of different types of epilepsy 
constitute an important component of studies of epidemiology of epilepsy. International 
League Against Epilepsy (ILAE) published a comprehensive report on standards of 
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epidemiologic studies and surveillance of epilepsy (Thurman et al., 2011a). The 
proposed standards define epilepsy, classification of epileptic seizures, and set the 
basis for future studies and allow meaningful interpretations and comparison over 
time. In the next sections of this chapter, a comprehensive review of types, causes 
and diagnosis of epilepsy in SSA in provided prior to the descriptions of the 
epidemiological profile of epilepsy in SSA.  
Types of epileptic seizures 
Epilepsy is classified on the basis of the manifestation of seizures and syndromes. An 
epileptic seizure is defined as ‘‘a transient occurrence of signs and/or symptoms due 
to abnormal excessive or synchronous neuronal activity in the brain’’ (Fisher et al., 
2005). Three main seizures types are generalized, focal and those with an 
undetermined origin (Table 1-1) (Thurman et al., 2011a). Seizures may involve 
movements of body parts (convulsive) or non-motor. Generalized seizures affect the 
whole brain. Seizures are thought to originate within bilaterally distributed cortical or 
cortical-subcortical networks that become rapidly engaged without a specific source 
of origin and can involve cortical and subcortical structures, but not necessarily the 
entire cortex. Focal seizures originate within neuronal networks limited to one cerebral 
hemisphere. Seizures of unknown onset are classified as undetermined. Although 
many epilepsy syndromes can include both focal and generalized seizure, neurologist 
always tries to establish whether epilepsy is the result of focal pathology, as it can 
have implications for treatment especially surgical option (Preux et al., 2005a). 
Screening methods employed in many studies in sub-Saharan Africa are capable of 
detecting convulsive epilepsies which accounts for 50-60% of epilepsy cases, 
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therefore reported prevalence estimates should always be interpreted with caution as 
they are likely to underestimate the true burden of epilepsy (Adamolekun, 1995). 
Table 1-1: Classification of seizure types 
Seizure classification 
Generalised Focal Undetermined 
Convulsive and other motor seizures 
Generalized convulsive and 
other motor seizures 
Focal onset with secondary 
generalization, focal motors 
Undetermined 
Impaired responsiveness and other non-motor 
Generalized absence  Dyscognitive focal seizures, sensory, 
psychic, and autonomic 
Undetermined impaired 
responsiveness  
Unknown 
Generalized seizure, 
unspecified 
Focal seizure, unspecified Seizure, unspecified 
Causes of epileptic seizures  
ILAE proposed three categories for the aetiology/causes of epilepsy: genetic, 
structural/metabolic, and unknown causes (Table 1-2) (Berg et al., 2010). Disparities 
in epilepsy prevalence in sub-Saharan Africa and developed countries can be linked 
to causes/aetiology of epilepsy. Epilepsy cases with no identifiable causes or risk 
factor (primary/idiopathic epilepsy) are common in both developed and developing 
countries (Preux et al., 2005a, Adamolekun, 1995). In many cases of primary epilepsy, 
there is a genetic origin (Weber et al., 2008, Sisodiya et al., 2011, Knoth et al., 2011, 
Poduri et al., 2011). In SSA, identifiable causes (secondary epilepsy) in children are 
thought to be identifiable genetic causes or syndromes, perinatal adverse events such 
as difficulties crying and breathing at birth and head injuries (Ngugi et al., 2013c). 
Metabolic and structural causes of epilepsy are the major causes of epileptic seizures 
in adults. Parasites infection with Plasmodium falciparum, HIV, Toxocara canis, 
Toxoplasma gondii, Onchocerca volvulus, and Taenia solium has been linked with 
epilepsy among adults in several studies and reviews (Carter et al., 2004, 
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Satishchandra et al., 2008, Ngugi et al., 2010b, Pion et al., 2009, Quet et al., 2010). 
At old ages epilepsy may be related to chronic diseases such as malignancy cancers, 
stroke and other chronic disease associated with brain dysfunction (Timmons et al., 
2002, Brodie et al., 2005). 
Table 1-2: Classification of seizure aetiology 
Genetic/presumed genetic 
Specific genetic epilepsy syndromes, genetic and chromosomal developmental, 
and encephalopathies. 
Structural/Metabolic 
Infections, traumatic brain injury, stroke, neoplasia, mesial temporal sclerosis, 
degenerative neurologic diseases, metabolic or toxic insults to the brain, perinatal 
insults hypoxic-ischemic,  encephalopathy, malformations of cortical or other 
brain development, neurocutaneous syndromes and inborn errors of metabolism 
Unknown or Undetermined 
Epilepsy of unknown/undetermined aetiology 
Diagnosis 
Epilepsy diagnosis is based on the detailed description of the seizure by the patient 
and witnesses, and may not need any specific investigation (Moshe et al., 2015). 
Family and personal history, the age onset, seizure type, neurological and cognitive 
status are key features of initial diagnosis of epilepsy disorder. Epilepsy diagnosis in 
clinical and research setting uses two different definitions of epilepsy. In a clinical 
setting, a clinician uses a conceptual definition of epilepsy as a disorder characterized 
by an enduring predisposition to generate epileptic seizures and by neurobiology, 
cognitive, psychological and social consequences of this condition. Researchers, on 
the other hand; use the operational definition of epilepsy if any of the following 
conditions are present: 
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1. At least two unprovoked (or reflex) seizures occurring > 24 h apart. 
2. One unprovoked (or reflex) seizure and a probability of further seizures similar to the general 
recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years. 
3. Diagnosis of an epilepsy syndrome. 
Epilepsy is considered to be resolved for individuals who had an age-dependent 
epilepsy syndrome but are now past the applicable age or those who have remained 
seizure-free for the last 10 years, with no seizure medicines for the last 5 years (Fisher 
et al., 2014). 
For practical purposes, the first criterion of at least “two or more unprovoked seizures 
occurred at least 24 hours apart” in the past 5 years is used as a case definition of 
active convulsive epilepsy (ACE). Most epilepsy studies conducted in SSA have 
focused on ACE such as clonic, tonic or clonic-tonic, because non-convulsive epileptic 
seizures are difficult to diagnose in door-to-door cross-sectional surveys. ACE 
accounts for approximately less than 50% of epilepsy cases in most studies conducted 
in SSA, therefore prevalence estimates in SSA should be interpreted with care as they 
are likely to miss non-convulsive forms of epilepsies. 
Comprehensive epilepsy diagnosis demand trained neurologist and neuroimaging 
equipment for confirming the diagnosis. Diagnosis of underlying epilepsy syndrome 
can be complex and requires specialized training especially when it is necessary to 
differentiate epileptic seizures and seizures caused by other disorders [7, 26, 27]. 
Neurophysiological test with electroencephalogram (EEG) is used to detect unusual 
brain activities associated with epilepsy. EEG does not always confirm the diagnosis 
but is helpful for classifying the epileptic seizures and epilepsy syndromes. Magnetic 
resonance imaging (MRI) may be used to detect the possible cause of epilepsy such 
as defects or lesion in the structure of brain. Prolonged electrocardiographic (ECG) 
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monitoring with an implantable ECG recorder is used to rule out cardiac abnormalities 
related-seizures from epileptic seizures. Computerized tomography (CT) is more 
accessible in SSA and is used to assess gross pathological changes but cannot be 
used to diagnose epilepsy. One study in 2007 documented only 75 EEGs and 25 CT 
scanners in tropical African countries, however, most of these machines were 
frequently out of order. In the same review of 43 studies of epilepsy aetiology’s, only 
25 studies used EEG in analysing unusual brain activities associated with epilepsy 
(Preux et al., 2005b).  
Prevalence and incidence 
In 2010, epilepsy was estimated to affects 71 million people globally most of whom 
are living in rural developing countries. In developed countries epilepsy was estimated 
to affect 6.8 million (5.8 per 1000) while in developing countries, 62 million people were 
affected. In developing countries, majority of PWE were residing in rural areas 45 
million (15.4 per 1000) compared to 17 million (5.9 per 1000) in urban areas (Ngugi et 
al., 2010b). Paul et al in 2010 estimated epilepsy affected 5.4 million people in SSA 
(Paul et al., 2012). Studies in SSA were implemented using different epilepsy case 
definitions and methodology, hence less likely to produce true estimates epilepsy 
prevalence. In 2013, Studies of Epidemiology of Epilepsy in Demographic Surveillance 
Sites (SEEDS) estimated prevalence of ACE in five SSA using standardized methods 
endorsed by ILAE (Ngugi et al., 2013c). The estimated prevalence from SEEDS 
studies ranged from 7.4-15.5 (median=8.1 cases per 1000 people). Applying 
estimated prevalence of ACE from SEEDS to the current SSA population, ACE is 
estimated to affect 8.5milion people using 2018 UN population estimates. Estimates 
of the incidence of epilepsy are also higher in developing countries with the estimate 
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of 81.7 cases per 100,000 population than developed countries with an incidence of 
45.0 per 100,000 population (Ngugi et al., 2011).  
Epilepsy mortality 
Mortality statistics are vital in understanding population health and diseases trends 
(Pakpoor et al., 2017). Several studies have linked higher coverage of civil and vital 
statistics with improved health outcomes in several countries (Phillips et al., 2015). 
Few developing countries contribute to World Health Organization’s (WHO) Civil and 
Vital Registration (CVR) database therefore disproportionally represented in most 
mortality and statistical reports (World Health Organization, 2017). There are also few 
epidemiological data in developing countries and most available ones are incomplete 
hospital-based, thus provide little information about the health status in the community 
(Winkler et al., 2009c). Estimating epilepsy-related mortality requires complete 
coverage of vital registration and clinical data in the entire community. In most SSA 
unfortunately, most deaths (>75%) occurs at home, autopsies are not done on routine 
bases, and death certificates are unreliable hence low coverage of vital registration 
and cause of death statistics (Carpio et al., 2005). The overall autopsy rate is 
estimated to probably be <5% in public hospitals and almost none exists in private 
hospitals. Alternatively, countries have used two approaches in establishing mortality 
statistics; mortality census survey or continuous mortality surveillance on selected 
communities. The former also known as Health and Demographic Surveillance 
System (HDSS) are population-based continuous surveillance of migration, births, 
deaths and their causes (Network;, 2002). Causes of deaths in HDSS are ascertained 
using verbal autopsy. Global burden of disease (GBD) analysis uses among other 
sources cause of death statistics generated from HDSS sites in different parts of 
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African and Asian countries in producing country and regional estimates of causes of 
death statistics (IHME, 2016, Lozano et al., 2012, Naghavi et al., 2013). Mortality 
census surveys are conducted on national representative samples of death identified 
by key informants or during post-census surveys (Mudenda et al., 2011, Ngo et al., 
2010, Statistics; et al., 2012). Demographic Health Surveys (DHS) also capture 
mortality data, specifically childhood, maternal and adult deaths, however, causes of 
deaths are normally not ascertained.   
Mortality in people with epilepsy 
PWE are at increased risk of injuries and death due to the presence of unprovoked 
seizures. The increased risk is routinely reported as excess or premature mortality. 
Excess mortality in epilepsy relative to general population measures how much death 
rate in PWE exceeds that of the general population, estimated as a ratio of mortality 
rate in PWE to mortality rate in general population. Ratio greater than 1 indicates 
mortality higher in PWE than general population and ratio less than 1 indicates 
mortality is higher in general population than in PWE. When the ratio is greater than 
1, the multiplicative interpretation is always preferred stated as “times higher in PWE 
than general population”. In developed countries, systematic reviews provided 
evidence of excess mortality in PWE compared to general population   ranging of the 
magnitude ranging from 1.6-3 times higher than the general population in community-
based studies of substantial good quality. In clinical setting and in symptomatic 
epilepsy patients, mortality is reported to range from 2.2-6.5 and 7-50 times higher 
than general population respectively (Nevalainen et al., 2014, Forsgren et al., 2005b, 
Neligan et al., 2010). Given the fact that, comprehensive individual medical records 
are almost non-existence in most SSA countries; there are no reliable data on 
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estimates of mortality rate in cohorts of PWE. In addition, long-term follow-up of PWE 
is required in order to establish precise estimate of mortality in PWE; unfortunately 
drop outs are substantial on most cohorts due to household’s motilities and migration. 
Most available data on mortality in epilepsy in SSA are coming from small and short-
term population-based cohorts in areas with high epilepsy prevalence, therefore likely 
to yield to higher estimates mortality in epilepsy (Pion et al., 2009, Terra et al., 2011, 
Kaiser et al., 2007). 
There are limited epidemiological studies SSA, however few studies that have 
reported mortality of 3 to 7 time higher in PWE than the general population as 
measured by standardized mortality ratio (SMR). These include those conducted Kilifi 
in Kenya 6 times, West Uganda 7 times, and Vusai in India 4 times higher than general 
population (Ngugi et al., 2014c, Kaiser et al., 2007, Carpio et al., 2005). Based on 
current literature at my exposure, there are no permanent clinical cohorts of PWE in 
SSA, however, there known three clinical cohorts elsewhere in LMIC which include 
study in rural Ecuador with mortality estimates in PWE of 6 times and Chile 3 times 
higher than the general population (Carpio et al., 2005, Devilat Barros et al., 2004).   
Causes of death in people with epilepsy 
Availability of cause of death in PWE may facilitate effective development of preventive 
measures aimed to prevent acquired epilepsy and/or reduce premature mortality (Mu 
et al., 2011a). However, similar to mortality, data on causes of death in epilepsy are 
not available in most SSA countries due to aforementioned reasons related to 
coverage of vital statistics. Causes of death in epilepsy are categorized into epilepsy-
related/direct, indirect and unrelated. Epilepsy-related causes of epilepsy include 
status epilepticus and sudden death in epilepsy. Indirect causes are those associated 
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with events such as falls, burns, drowning and road traffic accidents. Contribution of 
epilepsy-related causes accounts for majority of death in PWE epilepsy in SSA 
compared to developed country due to low coverage of interventions aimed at 
managing seizures. Estimate of epilepsy-related deaths in selected studies from SSA 
ranges from 30 to 60% (Ngugi et al., 2014c, Carpio et al., 2005, Kamgno et al., 2003b, 
Kaiser et al., 2007). In developed countries where epileptic seizures are properly 
managed, epilepsy-related causes of deaths are lower than causes unrelated to 
epilepsy such as neoplasms, cerebrovascular diseases, and cardiac diseases leading 
causes of death in PWE (Forsgren et al., 2005b, Cockerell et al., 1994, Nilsson et al., 
1997, Lhatoo et al., 2005, Benn et al., 2009). Higher epilepsy-related deaths in 
developed countries are only reported in clinical cohorts specifically in individual with 
drug resistance and newly diagnosed epilepsies (Nevalainen et al., 2013).  
Epilepsy treatment 
Since there is no cure for epilepsy, AEDs has remained the most effective therapeutic 
option for managing epileptic seizures in both developed and developing countries. 
Surgical treatment are not routinely done in most SSA countries, however they are 
effective in treating specific types of epilepsies for which epileptogenic is well 
established (Cherian et al., 2002, Butler, 2005). Other potential and non-invasive 
treatment possibly never experimented in SSA is Ketogenic diet, with reported rates 
of seizure freedom as high as 55% and seizure reduction as high as 85% after three 
months following diet initiation (Martin et al., 2016). PWE in most SSA countries are 
not receiving appropriate treatment with AED because epilepsy is not a high priority 
disease in most countries. Most efforts are directed towards high priority diseases 
such as malaria, tuberculosis (TB), HIV/AIDS, maternal and newborn health. 
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Coverage indicator of epilepsy treatment known as “treatment gap” is defined as the 
number of PWE who have not accessed biomedical services or are not on treatment 
or are on inadequate treatment, expressed as a percentage of the total number with 
epilepsy (Meinardi et al., 2001). Treatment gap studies in SSA estimated more than 
80% of PWE do not receive appropriate treatment (Amos et al., 2011, Ba-Diop et al., 
2014b, Carter et al., 2012, Coleman et al., 2002, Hunter et al., 2016, Mbuba et al., 
2012). Global study of treatment gap disparities reported an epilepsy treatment gap of 
more than 75% in developing countries compared with less than 10% in developed 
countries. 
Intervention programs 
Although WHO initiated global efforts on neurology and public health many countries 
in SSA are still lagging behind in terms of training, diagnosis, treatment and disease 
management (Janca et al., 1997). Effective intervention in reducing the incidence of 
epilepsy always target the root causes of preventable epilepsy which include reducing 
the spread of parasitic infections, brain injuries (accidents and perinatal-related), and 
chronic diseases (cerebrovascular, neoplasm and neurodegenerative). The negative 
consequence of epileptic seizures such as road traffic injuries, falls, burns and 
drowning are effectively managed with increased access to affordable AED. A 
systematic review of clinical trials of effectiveness and delivery of intervention for 
epilepsy indicated little evidence of effectiveness towards managing all aspects of 
epilepsy in both low and high-income countries (Mbuba et al., 2009). With regards to 
SSA, intervention programs were documented only in Kenya on AED and South Africa 
on cognitive behavior (Feksi et al., 1991, Lundgren et al., 2006). 
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Epilepsy in Tanzania 
Tanzania as many other SSA lacks morbidity and mortality data on neurological 
disorders due to insufficient coverage of civil and vital registration systems (Dalal et 
al., 2011, Dewhurst et al., 2012). Epilepsy was initially documented in scientific 
literature in Mahenge district in Morogoro region by Dr. Louise Jilek-Aall who was a 
physician from Canada. Dr. Jilek-Aall documented high prevalence and mortality 
associated with epilepsy and established a clinic with financial support from abroad to 
provide AED in PWE. The program supported around 164 of whom, 86 (52.4%) 
achieved complete seizure suppression and 59 (36.0%) experienced a reduction in 
seizure frequency.  
Head nodding syndrome characterized with head nodding, mental retardation and 
stunted growth disorder is a rare disorder believed to be possibly a new epilepsy 
disorder in SSA was also observed to affects a number of people in Mahenge (Winkler 
et al., 2010, Winkler et al., 2008c, Aalljilek, 1965). Several studies years later have 
been conducted in different parts of Tanzania in areas with high prevalence of epilepsy 
and estimated prevalence of epilepsy ranging from 2.9 to 15 cases per 1000. Two 
studies were conducted in Hai in adults (Hunter et al., 2012) and children (Burton et 
al., 2012b), Kilombero (Ngugi et al., 2013c), Manyara/Hydom (Winkler et al., 2009b), 
Nachingwea/Lindi (Dent et al., 2005), Ulanga (Rwiza et al., 1992) (Table 1-3). 
Convulsive epileptic seizures (clonic-tonic and clonic) accounts for the majority of 
epilepsies in Tanzania (Hunter et al., 2012, Rwiza et al., 1992).  Most seizures are 
linked to parasitic infections and perinatal events (Winkler et al., 2008a, Winkler et al., 
2009a). National estimate of epilepsy mortality was first published in 2005 in a study 
of Adult Morbidity and Mortality Project (AMMP) conducted in 1992-1995 that 
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estimated epilepsy mortality rate of 15 and 5 deaths per 100,000 population in males 
and females respectively (Aspray, 2005).  
Mortality estimates in PWE are limited in Tanzania and many SSA countries. Jilek-Aall 
et al described mortality in PWE in Mahenge cohort of 164 people diagnosed with 
epilepsy and observed deaths in 110 (67.1%) deaths in a 30 years follow-up. High 
treatment gap (>60%) has been reported in most community-based studies (Hunter et 
al., 2012, Hunter et al., 2016, Jilek-Aall et al., 1992b). Most primary health care 
facilities and hospitals in Tanzania are not equipped with necessary imaging tools and 
trained neurologist. Several efforts have been done to improve diagnosis including 
developing inexpensive tools for screening and classifying neurological disorders in 
health facilities with limited resources (Feigin et al., 2015, Winkler et al., 2009c). 
Table 1-3: Studies of epilepsy prevalence in Tanzania 
   Prevalence of ACE (%) 
District/town Period Population Crude Age-adjusted 
Hai  2009 15+ 3.84(3.45-4.20) 2.91(2.58-3.24) 
Hai  2009 2-14 2.91 (2.4–3.5)  
Kilombero  2009 All ages 3·9 (3·5–4·3) 15·5 (14·7–16·3) 
Manyara/Hydom  2003 All ages 11.2(8.9-13.9) 9.1 
Nachingwea/Lindi  1999 All ages 8.6(6.0–11.1) 7.4 
Ulanga  1992 All ages 5.8‐37.0 10.2(5.1-37.1) 
 
Knowledge gap and justification for this thesis 
Despite improved care and treatment, mortality burden in people with epilepsy is 
estimated to be up to 3 times higher than general population in HIC. If that is the case, 
what is the situation in SSA? Conceptual map in Figure 1-1 provide a recap of 
pathways to mortality impact of epilepsy based on review of epilepsy situation in SSA 
in the previous sections of this thesis. 
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Figure 1-1 Conceptual map of burden of epilepsy in SSA 
Multiple factors explain why burden of epilepsy mortality may be higher in SSA 
compared to high income countries and why it is imperative to conducts mortality 
studies. Major risk factors common in SSA are infections, brain trauma, adverse 
perinatal events, and high seizures frequency due to lack of care (up to 90% do not 
receiving AED. Lastly lack of knowledge on epilepsy in SSA is hampering the uptake 
of AED, increase informal care through spiritualism and witchcraft, and ultimately 
increase stigma towards PWE. 
Epilepsy studies are underfunded by governments and research agencies and 
consequently leading to scarcity of data on prevalence, mortality, morbidity and social-
economic impact of epilepsy. Substantial funding is directed toward care and 
management for the three priority diseases, i.e. malaria, HIV/AIDS and tuberculosis 
and maternal and newborn health. A systematic assessment of available evidence on 
mortality in PWE in SSA is high needed.  
The second reason why epilepsy studies are not easily funded is that they are 
expensive to conduct in SSA. These studies require expert neurologist, larger 
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population-based studies and extensive follow-up in order to establish mortality 
estimates, risk factors, causes of death, and trends. These population-based cohorts 
are rare in SSA and this thesis is set to evaluate new evidence emerging from these 
population-based cohorts in SSA countries. 
Effective intervention for mitigating the mortality impact of epilepsy require modifiable 
risk factors be identified and what PWE are dying off. However, it is unfortunate that 
most SSA lack monitoring and devaluating platform needed to understand causes of 
death and risk factors. As identified earlier, civil and vital registration and clinical 
cohorts (medial records) are almost absent in most countries. This thesis is also set 
to generate evidence on risk factors and causes of death from recently established 
population-based cohort on SSA. 
The focus of this thesis mortality; however, it should be emphasized that epilepsy is 
associated with high burden of disabilities as well as social and economic impacts that 
is beyond this thesis. This thesis evaluate mortality rate of epilepsy and secular trend 
in population; and in PWE to evaluate excess (premature mortality), causes of death 
and risk factors  
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 Thesis goal and objectives
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Thesis aim 
The aim of this thesis is to examine the uncertainties of epilepsy in relation to mortality, 
risk factors and cause of death in people with epilepsy sub-Saharan Africa. 
Thesis objectives 
The following five objectives are proposed; 
1. Conduct a systematic review of premature mortality in people with epilepsy in 
low- and middle-income countries. 
2. Estimate excess mortality in people with epilepsy in SSA and assess 
associated risk factors. 
3. Describe causes of death in people with epilepsy in SSA using automated 
software’s.  
4. Estimate cause-specific mortality rate of neurological disorders in Tanzania. 
5. Describe secular trends in mortality of neurological disorders mortality in 
Tanzania from health and demographic surveillance sites in Tanzania. 
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Structure of the thesis and overview of methods  
This thesis is structured towards systematically providing knowledge and evidence 
on the magnitude of mortality, associated risk factors, and causes of deaths in 
PWE in SSA countries. The thesis structure and organization is summarized in Figure 
2-1. The central ring represents the five target knowledge area as per thesis goal. The 
outer ring summarizes the approach adopted for each objective and provides a 
specific chapter for which detailed information can be found.  
 
Figure 2-1: Thesis structure summary 
Systematic review 
Systematic review is the entry point of the thesis aimed at gathering all available 
evidence on the epidemiological profile of epilepsy in LMIC. The review constitutes a 
systematic assessment of studies of magnitude of mortality in epilepsy relative to 
general population, risk factors and causes of death in PWE in LMIC. The study 
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systematically compiled, reviewed qualities, and summarized measures of epilepsy 
mortality from peer reviewed and published scientific articles. The study was published 
in Epilepsia; Official Journal of the International League Against Epilepsy is presented 
in Chapter 3 of this thesis. 
SEEDS study 
SEEDS study provides new and vigorous evidence of excess mortality in epilepsy in 
SSA from the large a multi-centre evaluation implemented in five sites of Ifakara in 
Tanzania, Kilifi in Kenya, Agincourt in South Africa, Iganga-Mayuge in Uganda, and 
Kintampo in Ghana. SEEDS studies in the first phase estimated prevalence of ACE at 
7·8 per 1000 people in Kilifi, 7·0 in Agincourt, 10·3 in Iganga-Mayuge, 14·8 in Ifakara, 
and 10·1 in Kintampo. 
This thesis focuses on the second phase of the SEEDS project aimed to estimate the 
magnitude of excess mortality in PWE and associated risk factors. The full manuscript 
of this study is prepared for submission to Epilepsy & Behavior and is presented in 
Chapter 4. 
Verbal autopsy automation 
Causes of death statistics are valuable public health tools needed in developing 
effective preventative measures aimed at reducing premature mortality in people with 
epilepsy. Probabilistic and mathematical-based models have recently emerged as 
convenient and affordable alternative to physician in assigning causes of death in 
developing countries.  
Verbal autopsy automation study evaluates the use of these models in predicting 
causes of death in PWE and their implication on the accuracy of causes of death, 
prevention and control of epilepsy in SSA. The full manuscript for this study is prepared 
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for submission to Epilepsia; an Official Journal of the International League Against 
Epilepsy and is detailed in Chapter 5. 
SAVVY study 
SAVVY is an analytical an analytical study focuses on national estimates mortality of 
neurological disorders in Tanzania. The study explores mortality estimates of 
neurological disorder and the contribution of epilepsy. The study is based on an 
analysis of national representative sample of mortality and causes of death survey 
(SAVVY). The study was published in Global Health Action journal. Details of the study 
are presented in Chapter 6. 
HDSS study 
Health and Demographic Surveillance Systems (HDSS) provides a platform for 
monitoring demographic indicators and causes of death statistics in population based 
study. HDSS study constitute an analytical work on estimating levels and secular 
trends of neurological disorders (cerebrovascular, epilepsy and meningitis) in HDSS 
sites in Tanzania. The rationale of this study is to ascertain trend of epilepsy mortality 
in Tanzania. The full manuscript for this study is prepared for submission to journal of 
Stroke and Cerebrovascular Diseases and is presented in Chapter 7.  
The thesis is concluded in Chapter 8 with extensive discussions and synthesis of the 
findings from five studies in light of strength and methodological limitations. 
Recommendation and implications for public health are provided as well. All 
references are provided at the end of the thesis.  
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Abstract 
Background 
To determine the magnitude, risk factors and causes of premature mortality associated 
with epilepsy in low and middle income countries (LMIC).  
Methods 
We conducted a systematic search of the literature reporting mortality and epilepsy in 
the World Bank-defined LMIC. We assessed the quality of the studies based upon the 
representativeness, ascertainment of cases, diagnosis, and mortality and extracted 
data on the standardized mortality ratio (SMR), mortality rate, and incidence of death 
in epilepsy. We examined the risk factors for death and reviewed the causes of death. 
Results 
The annual mortality rate was estimated at 19.8 (range 9.7-45.1) deaths per 1000 
people with epilepsy (PWE) with a weighted median SMR of 2.6 (range 1.3-7.2) among 
higher-quality population-based studies. Clinical cohort studies yielded 7.1 (range 1.6-
25.1) deaths per 1000 PWE. The weighted median SMRs were 5.0 in males and 4.5 
in females; relatively higher SMRs within studies were measured among children and 
adolescents, those with symptomatic epilepsies, and those reporting less adherence 
to treatment. The main causes of death in PWE inhabiting LMICs include those directly 
attributable to epilepsy, which yield a mean proportional mortality ratio (PMR) of 27.3% 
(range 5%-75.5%) derived from population-based studies. These direct causes 
comprise status epilepticus, with reported PMRs ranging from 5%-56.6%, and sudden 
unexpected death in epilepsy, with reported PMRs ranging from 1%-18.9%. Important 
causes of mortality indirectly related to epilepsy include drowning, head injury, and 
burns. 
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Discussions 
Epilepsy in LMIC has a significantly greater premature mortality, as in high-income 
countries, but in LMIC the excess mortality is more likely to be associated with causes 
attributable to lack of access to medical facilities such as status epilepticus, and 
preventable causes such as drowning, head injuries and burns. This excess premature 
mortality could be substantially reduced with education about the risk of death and 
improved access to treatments, including AEDs.   
Keywords: Seizures, convulsions, death, case fatality, developing countries, 
resource-poor countries, premature mortality 
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Introduction 
Standardized mortality in people with epilepsy (PWE) in high-income countries (HIC) 
is estimated to be up to 4 to 15 times higher than the general population in community-
based studies and selected high-risk populations, respectively (Forsgren et al., 2005a, 
Nevalainen et al., 2014). Comparable estimates of mortality in epilepsy in low- and 
middle-income countries (LMIC) are scarce, because vital registration of deaths is 
incomplete or absent in most countries, and many studies examining mortality in PWE 
in LMIC have methodological limitations. 
 Worldwide, approximately 80% of PWE live in LMIC (Newton et al., 2012b, Ngugi et 
al., 2010a). The high prevalence and incidence of epilepsy in LMIC is most likely 
associated with higher incidence of adverse perinatal events, head injuries, and 
parasitic infections (Mbuba et al., Ngugi et al., 2010a, Banerjee et al., 2010, Kochen 
et al., 2005, Meinardi et al., 2001, Meyer et al., 2010). 
Some studies in LMIC (Banerjee et al., 2010, Diop et al., 2005b, Jilek-Aall et al., 
1992a) have suggested that mortality in epilepsy is higher than in HIC (Nevalainen et 
al., 2014). This may be caused by selection bias of studies in areas endemic with 
specific causes, selection of higher-risk cohorts to follow, or lack of access to 
comprehensive treatment (Mbuba et al., 2008). The epilepsy treatment gap (defined 
as the proportion of PWE who either have not accessed biomedical services or are 
not on treatment with anti-epileptic drugs (AEDs) or are receiving inadequate 
treatment (Meinardi et al., 2001) is more than 75% in LMIC, compared with less than 
10% in HIC (Meyer et al., 2010). The large treatment gap may increase mortality from 
complications such as status epilepticus, accidents including burns and drowning, and 
sudden unexpected death in epilepsy (SUDEP). 
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We conducted a systematic review to estimate the magnitude of premature mortality 
associated with epilepsy in LMIC, and to identify the risk factors and causes of death 
among PWE. A companion review focuses on mortality in high-income countries 
(Thurman et al., 2016a). 
Methods 
Literature search.  We searched the Medline, EMBASE, and LILACS databases with 
terms in the following three categories: 
 epilepsy, seizure, or convulsions 
 mortality, death, or SUDEP 
 low-income countries, middle-income countries, developing countries, resource-poor countries, 
Africa, Asia, China, India, "Latin America," "Central America," or "South America"  
We included only reports indexed with at least one term in each of the three categories, 
and restricted our search to reports on human subjects from LMIC as defined by the 
World Bank (World Bank, 2015). Low-income economies in 2014 were those with 
annual gross national incomes (GNI) per capita of $1,045 or less, while middle-income 
economies were those with GNI per capita ranging from $1,046 to $12,735. The 
search period was from 1990 to 28th February 2014. We used the criteria for the 
diagnosis of epilepsy suggested by the International League Against Epilepsy (ILAE) 
for epidemiological studies, originally in 1990 (ILAE, 1993) and confirmed in 
2011(Thurman et al., 2011b).  
Two reviewers (FL and CRN) evaluated the retrieved citations in a two-stage process. 
In the first stage they independently reviewed the titles and available abstracts to 
identify potentially relevant reports meriting full review (Figure 3-1). The reviewers 
compared their selections and resolved the list of publications to arrive at a single list 
for the second stage of analysis. In the second stage they reviewed the full papers 
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and assessed whether the articles met the inclusion criteria below. For those meeting 
these criteria, they extracted the measures of mortality, risk factors, and causes of 
death. 
Inclusion criteria.  Original reports of mortality among PWE in LMIC, derived from 
general populations, clinical cohorts (hospital- or treatment program-based), and 
case-control studies, were included. Studies that did not report quantitative estimates 
of mortality in epilepsy were excluded. 
Data extraction. Data on the epilepsy were extracted according to the ILAE guidelines, 
in particular age at onset, seizure type, and the underlying etiology (Thurman et al., 
2011b). Age at onset, i.e., first occurrence of unprovoked seizure, helps identify 
epilepsy syndromes. Three main categories of seizure type as classified by ILAE 
(generalized, focal, and undetermined) were identified (Thurman et al., 2011b). The 
ILAE proposed three main categories of etiology: genetic, structural/metabolic, and 
unknown causes (Thurman et al., 2011b). Epilepsy etiology is classified as genetic 
when genetic defects are the known or presumed to be prime cause of the disease. 
Structural/metabolic causes (formerly known as symptomatic epilepsies) are 
considered when a structural lesion or metabolic condition is known to predispose to 
epilepsy. 
Estimates of mortality were extracted from the measures reported in the papers which 
included case fatality ratio (CFR), proportional mortality ratio (PMR), mortality rate 
(MR), and standardized mortality ratio (SMR) according to standard definitions 
(Rothman et al., 2008). Deaths were categorized occurring: (i) as a direct 
consequence of epilepsy or seizures (i.e. status epilepticus, or SUDEP); (ii) as indirect 
causes (i.e. accidents due seizures—such as falls, burns, or drowning—or drug 
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reactions to AEDs); (iii) as a consequence of underlying diseases of which epilepsy is 
a manifestation; or (iv) unrelated to epilepsy. The definitions and classification of 
SUDEP are mainly consistent with the earlier recommendations of Nashef (Nashef, 
1997) which have been updated since publication of most the studies we reviewed 
(Nashef et al., 2012). 
Quality of studies.  The reviewers employed quality assessment criteria for studies of 
mortality in epilepsy that included the following five elements classified by ILAE’s 
Commission on Epidemiology Task Force on the Burden of Mortality (Supplement 
Table S1). These address the most important design features of epidemiologic studies 
of epilepsy, which we employed in preference to less specific conventional evaluation 
checklists proposed for observational studies (Stroup et al., 2000). 
 Representativeness of the study population.  Provides the basis of generalizability of the study 
findings. Studies conducted in clinical settings or untreated populations may not be 
representative of entire populations of PWE. 
 Accuracy of diagnosis of epilepsy.  Evaluates methods employed to diagnose cases of epilepsy; 
if quantifiable, can be expressed as a positive predictive value. The use of the case definition 
provided by ILAE and diagnosis by trained neurologists is a reference standard that may reduce 
the number of false positives and negatives. 
 Epilepsy case ascertainment.  Evaluates completeness (sensitivity) of methods employed to 
screen the population for cases of epilepsy. This is important in population-based studies of 
epilepsy prevalence or incidence. A door-to-door survey is thought to generate an optimum 
number of cases in screening of a community. 
 Mortality ascertainment.  Evaluates the completeness of identifying death occurrence in a 
cohort or population of PWE. This depends upon the proportion of PWE followed until death or 
end of the study. Short follow-up of epilepsy individuals, high migration patterns and loss to 
follow-up are critical issues in establishing mortality rates. 
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 Accuracy of cause of death. Evaluates the validity of cause-of-death determinations, especially 
for causes of interest associated with epilepsy. Accurate determination of the cause of death is 
essential to determine the proportion of deaths directly or indirectly related to epilepsy. 
Autopsies are the reference standard, but are rarely performed in LMICs. Verbal autopsies are 
most commonly used in LMIC (Aspray, 2005, Baiden et al., 2007, Mateen et al., 2012). 
A scale with five items was developed to score the quality of studies with respect to 
each quality measure listed above. The scoring of each item was generated from 4-5 
sub-items, each with 5 points, with a total score ranging from 0 to 20 (Table S1). The 
total score of the quality was the sum of scores of each quality item, with 100 
representing the highest quality. 
Statistical analysis.  Total, median, and range were used to generate summary 
measures of mortality across studies. We disaggregated the estimates by study 
designs (population-based vs. clinical cohort), sex, type of seizure, etiology, and other 
risk factors. Summary estimates were also identified as reported, whether SMRs, 
PMRs, or MRs. If not reported as such, we calculated CFRs and MRs when the reports 
provided sufficient information to allow this. 
We also examined heterogeneity statistics, which measure the extent to which SMRs 
vary between studies, including the I2 statistic, which is the percentage of between-
study heterogeneity that is explained by variability in the treatment epilepsy effect on 
mortality relative to sampling error (Higgins, 2008).  
Results 
Search results.  Results of the systematic search are described in Figure 3-1. A total 
of 17 articles met inclusion criteria, of which one reported studies from 4 sites (Carpio 
et al., 2005) and two  reported the follow-up of the same cohort (Ding et al., 2006, Ding 
et al., 2013). There were 12 population-based studies (Banerjee et al., 2010, Carpio 
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et al., 2005, Ding et al., 2013, Houinato et al., 2013, Kaiser et al., 2007, Kamgno et 
al., 2003a, Kochen et al., 2005, Mu et al., 2011b, Ngugi et al., 2014b, Nicoletti et al., 
2009) and 8 clinical cohorts (Almeida et al., 2010, Carpio et al., 2005, Devilat et al., 
2004, Jilek-Aall et al., 1992a, Terra et al., 2011, Terra et al., 2010, Terra et al., 2009, 
Thomas et al., 2001) South America provided 8 studies, (Almeida et al., 2010, Carpio 
et al., 2005, Devilat et al., 2004, Kochen et al., 2005, Nicoletti et al., 2009, Terra et al., 
2011, Terra et al., 2010, Terra et al., 2009) Asia 6 studies (Banerjee et al., 2010, 
Carpio et al., 2005, Ding et al., 2006, Ding et al., 2013, Mu et al., 2011b, Thomas et 
al., 2001) and Africa 6  studies (Carpio et al., 2005, Houinato et al., 2013, Jilek-Aall et 
al., 1992a, Kaiser et al., 2007, Kamgno et al., 2003a, Ngugi et al., 2014b).  
Nine studies were conducted in rural populations only (Carpio et al., 2005, Ding et al., 
2013, Houinato et al., 2013, Jilek-Aall et al., 1992a, Kaiser et al., 2007, Kamgno et al., 
2003a, Mu et al., 2011b, Ngugi et al., 2014b, Nicoletti et al., 2009), 6 in urban only 
(Banerjee et al., 2010, Carpio et al., 2005, Kochen et al., 2005, Terra et al., 2011, 
Thomas et al., 2001) and 5 in both urban and rural populations (Almeida et al., 2010, 
Carpio et al., 2005, Devilat et al., 2004, Terra et al., 2010, Terra et al., 2009).  
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Figure 3-1: Summary results of search strategy 
Quality of studies. Supplement Table S2 provides summary characteristics of 
population-based studies, all of which included all ages. Population-based studies 
were mainly of good quality, where 7 out of 12 studies had a quality score of ≥80% 
(Table 3-1) (Banerjee et al., 2010, Kochen et al., 2005, Carpio et al., 2005, Kaiser et 
al., 2007, Houinato et al., 2013, Ngugi et al., 2014b, Nicoletti et al., 2009). Door-to-
door surveys were implemented in most studies, where neurologists made diagnoses 
of epilepsy. Over 85% of deaths were estimated to be captured in these cohorts and 
verbal autopsy was used to diagnose causes of death. Most studies used an 
operational definition of epilepsy as defined by ILAE in the diagnosis of epilepsy, 
although studies of 3 populations were restricted to active convulsive epilepsies. 
Clinical cohort studies were of low quality (≤50%), largely due to poor sample 
representativeness of the general population (Table S3). There was insufficient 
information published in most studies to determine the basis of the diagnosis of 
epilepsy.  Individuals in clinical cohorts often had epilepsy described as intractable or 
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refractory (Almeida et al., 2010, Terra et al., 2011, Terra et al., 2010). Cohorts of 
children with severe forms of epilepsy were also enrolled in several studies (Terra et 
al., 2011, Terra et al., 2010, Terra et al., 2009, Devilat et al., 2004). In health care 
settings, causes of death were available from medical records, death certificates, and 
verbal autopsy for deaths occurring in the communities. 
Mortality.  From 7 population-based studies with quality scores ≥80% (Table 3-1) 
(Banerjee et al., 2010, Kochen et al., 2005, Carpio et al., 2005, Kaiser et al., 2007, 
Houinato et al., 2013, Ngugi et al., 2014b, Nicoletti et al., 2009), the pooled annual 
mortality rate was 19.8 deaths per 1000 PWE (range 9.7-45.1), with a weighted 
median SMR of 2.6 (range 1.3-7.2) and an overall CFR of 8.1% (range 3.3-31.6%). 
The weighted mean follow-up period was 5.8 years (range 1.5-10), with 6,665 person-
years observation. 
Eight clinical cohorts (Table 3-2) (Almeida et al., 2010, Carpio et al., 2005, Devilat et 
al., 2004, Jilek-Aall et al., 1992a, Terra et al., 2011, Terra et al., 2010, Terra et al., 
2009, Thomas et al., 2001) in sum enrolled substantially larger numbers of PWE 
compared to higher-quality population-based studies. There were 3,856 PWE enrolled 
across these cohorts, of which 88.3% were followed to the end of the studies. The 
weighted mean follow-up period was 12.4 years, during which 240 deaths were 
observed, with a pooled annual mortality rate of 7.1 (range 1.6-25.1) deaths per 1000 
PWE. Two out of the 8 studies reported SMRs of 3.2 and 6.3 (Carpio et al., 2005, 
Devilat et al., 2004). The overall CFR in these clinical cohort studies was 7.0% (range 
1.3-75.3 %). 
Mortality risk by age.  Figure 3-2 summarizes 3 population-based studies reporting 
SMRs among PWE by age of death (Carpio et al., 2005, Ding et al., 2006, Mu et al., 
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2011b). Overall, these showed the highest SMRs in the youngest age groups, 
declining markedly after young adulthood, with a continuing decline with increasing 
age. We found insufficient data to characterize the risk of mortality by age of epilepsy 
onset. 
 
Figure 3-2: Mortality in epilepsy by age at death 
Mortality risk by sex.  Figure S1 summarizes mortality estimates for males and females 
from 6 population-based studies and 6 clinical cohorts. Of four studies (Mu et al., 
2011b, Banerjee et al., 2010, Kaiser et al., 2007, Kamgno et al., 2003a, Ding et al., 
2013) comparing SMRs, two reported higher values among males, with a weighted 
median SMR of 5.0 for males compared to 4.5 for females. Most studies reporting 
PMRs showed higher mortality in males. 
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Table 3-1: Mortality rates estimates from population-based studies 
Country-
Location 
Population Quality 
Cohor
t size 
PWE 
follow
ed 
Duration 
of FU 
(years) 
Person
- years 
Death
s in 
PWE 
SMR 95% CI CFR 95% CI 
MR in 
PWE 
95% CI 
High quality              
Kenya-Rural 232,164 100 754 754 2.7 2,048 61 6.5 5.00-8.30 8.1 6.1-10 29.8 22.8-38.3 
Argentina-Urban 70,000 90 106 96 8 768 8 2.45 1.14-4.65* 8.3 2.8-13.9 10.4 4.5-20.5 
Uganda-Rural 4,743 90 61 57 7 399 18 7.2 4.40-11.6 31.6 
19.5-
43.6 
45.1 26.7-71.3 
Bolivia-Rural 55,675 85 118 103 10 1,030 10 1.34 0.68–2.39 9.7 4.0-15.4 9.7 4.7-17.9 
Benin-Rural 11,688 80 160 150 1.5 225 5   3.3 0.5-6.2 22.2 7.2-51.9 
India-Urban 52,377 80 337 337 5 1,685 20 2.58 1.50-4.13 5.9 3.4-8.5 11.9 7.3-18.3 
India-Vusai 16,000 80 51 51 10 510 10 3.9  19.6 8.7-30.5 19.6 9.4-36.1 
Summary 442,647  1,587 1,548 5.8† 6,665 132 2.6‡  8.1‡  19.8 16.7-23.5 
Low quality              
India-Persis 14,010 65 109 104 14 1,456 34 0.76 0.51-1.01 32.7 
23.7-
41.7 
23.4 16.2-32.6 
Cameroon- Rural NR 60 271 128 10 1,280 37   28.9 
21.1-
36.8 
28.9 20.4-39.8 
China-Rural 5,840,000 50 3,568 2,998 4.5 13,491 106 4.9 4.0-6.1 3.5 2.9-4.2 7.9 6.4-9.5 
China-Rural 3,185,000 50 2,455 1,986 6.1 12,114 206 2.9 2.6-3.4 10.4 9.0-11.7 17.0 14.8-19.5 
Mali-Urban/Rural 7,158 40 36 31 12 372 13   41.9 
24.6-
59.3 
34.9 18.8-59.8 
Summary 9,112,561+  8,894 7,233 6.0† 32,850 431  2.9‡  10.4‡  13.1 11.9-14.4 
†Mean weighted by study person-years 
‡Median weighted by study person-years 
§ Follow-up study of cohort described in Ding 2006 
PWE: People with epilepsy 
FU: Follow-up 
SMR: Standardized mortality ratio 
CFR: Case fatality ratio 
MR: Mortality rate per 1000 PWE
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Table 3-2: Mortality rates estimates from clinical cohort studies 
Country-Location Quality 
Cohort 
size 
PWE 
followed  
Duration 
of FU 
(years) 
Person-
years 
Deaths 
in 
PWE 
SMR CFR Mortality 
SMR 95% CI % 95% CI MR 95% CI 
Ecuador- Urban 50 420 379 3 1,137 7 6.3 2.0-10.0 1.8 0.5-3.2 6.2 2.5-12.7 
Brazil-Urban/Rural 45 550 550 10 5,500 16   2.9 1.5-4.3 2.9 1.7-4.7 
Brazil-Urban 35 1012 987 10 9,870 53   5.4 4.0-6.8 5.4 4.0-7.0 
Tanzania, Rural 35 164 146 30 4,380 110   75.3 68.4-82.3 25.1 20.6-30.3 
India-Urban 25 447 246 12 2,952 18   7.3 4.1-10.6 6.1 3.6-9.6 
Brazil-Urban, Rural 25 267 267 13 3,471 9   3.4 1.2-5.5 2.6 1.2-4.0 
Chile-Urban/Rural 5 NR NR 6 NR 16 3.21 1.5-5.0     
Brazil-Urban/ Rural 5 996 835 8 6,680 11   1.3 0.5-2.1 1.6 0.8-2.9 
Summary: all studies  3856 3410 12.4
† 33,990 240 4.8    7.1 6.2-8.0 
†Mean weighted by study person-years 
‡ Median weighted by study person-years 
PWE: People with epilepsy 
FU: Follow-up 
SMR: Standardized mortality ratio 
CFR: Case fatality ratio 
MR: Mortality rate per 1000 PWE 
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Cause-specific mortality in epilepsy. Table 3-3 presents 8 population-based studies 
that reported cause-specific proportional mortality rates in PWE (Banerjee et al., 2010, 
Carpio et al., 2005, Ding et al., 2013, Kaiser et al., 2007, Kamgno et al., 2003a, Mu et 
al., 2011b, Ngugi et al., 2014b, Nicoletti et al., 2009). Among PWE, the weighted 
median PMR for all causes of death directly or indirectly attributable to epilepsy was 
47%. Direct causes comprised status epilepticus (median PMR 13%), and possible or 
probable SUDEP (median PMR 13%; Table S4). Indirect causes included accidents 
(falls, road traffic, drowning, and burns; Table S5).  Among accidents, the median PMR 
was 15% (range 3.3%-45%) for drowning, (Banerjee et al., 2010, Ding et al., 2006, 
Kaiser et al., 2007, Kamgno et al., 2003a, Mu et al., 2011b) and 7.5% for road traffic 
accidents (Mu et al., 2011b, Banerjee et al., 2010, Ngugi et al., 2014b, Ding et al., 
2006); the remaining causes did not have sufficient data for a summary (Table S5). 
Among these population studies, the median sum of all listed accident-related PMRs 
was 36% of all deaths in people with epilepsy. Other important causes of death in 
these populations that were not attributable to epilepsy included cerebrovascular 
diseases, tuberculosis, malaria, heart disease, and cancer (Table S6).  
Six clinical cohort studies reported causes of death as PMRs for individuals with 
epilepsy (Table 3-3) (Carpio et al., 2005, Terra et al., 2011, Jilek-Aall et al., 1992a, 
Almeida et al., 2010, Terra et al., 2010, Devilat et al., 2004). The median PMR for 
direct and indirect causes of death attributable to epilepsy was 39.3% and 24% 
respectively. Median PMRs for deaths due to status epilepticus and SUDEP in clinical 
cohorts were 14.8% and 11.1% respectively (Table S4). Data regarding causes of 
death indirectly attributable to epilepsy and causes not attributable to epilepsy were 
not sufficiently large to enable generalization.  
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Mortality risk by seizure type or frequency. Mortality risk by seizure type was reported 
from two population-based and two clinical cohorts in which median PMRs were 
consistently higher for focal epilepsy (population-based – 55% and clinical cohort – 
73%) than for generalized epilepsy (population-based – 39% and clinical cohort – 
26%; Table S7). Two studies reported increased mortality among PWE with a higher 
frequency of seizures (Kaiser et al., 2007, Terra et al., 2009) (Table S8). 
Risk by duration of epilepsy. Two studies reported on mortality by duration of epilepsy 
(Ngugi et al., 2014b, Kaiser et al., 2007) (Table S9). The study in rural Kenya reported 
the highest mortality rate (45 per 1000 person-years) for PWE with epilepsy duration 
of <1 year. In Uganda, SMRs were 8.6 (95% C.I. 4.5-16.5) for PWE of duration <5 
years, 3.6 (1.1-11.4) for those of epilepsy duration 5-9 years, and 23.8 (8.9-65.5) for 
those of epilepsy duration 10-14 years. 
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Table 3-3: Estimates of proportional mortality ratio by cause  
Country-Location Quality 
Number 
of PWE 
followed 
Number of 
deaths 
Causes of death (%) 
Direct Indirect Unrelated Undetermined 
Population-based        
Kenya-Rural 100 754 61 44.3 11.4 34.3 9.8 
Uganda-Rural 90 61 18 33.0 17.0 44.4 5.6 
Bolivia-Rural 85 103 10 10 20 50 20 
India-Urban 80 337 20 5 30 45 20 
Cameroon-Rural 60 271 37 75.5 10.8 13.7  
China, Rural 50 2,998 106 21.6 58.8 19.6  
China, Rural 50 1,986 206 14.1 32.5 39.3 14.1 
Mali-Rural & Urban 40 36 13 38.0 NR 62.0 NR 
Summary population based  6,546 471 27.3* 20.0* 41.9* 14.1* 
Ecuador, Urban 50 379 7 42 30 28  
Brazil, Urban-Rural 45 550 16   62.5  
Brazil, Urban 35 987 53 15.1  84.9  
Tanzania, Rural 35 164 110 17.3 18.2 32.7 31.8 
Brazil-Urban, Rural 25 267 9 77.8    
Chile, Santiago 5 NR 16 39.3    
Summary: Clinical cohort  >2,347 211 39.3* 24.1* 47.6*  
*Median percentage 
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Risk by epilepsy etiology.  Symptomatic epilepsies appeared to have higher mortality 
rates compared to cryptogenic epilepsy, (Almeida et al., 2010, Devilat et al., 2004, 
Kochen et al., 2005, Nicoletti et al., 2009) although only two studies provided direct 
comparisons (Almeida et al., 2010, Nicoletti et al., 2009) (Table S10). 
Risk by treatment adherence.  Five population-based studies reported mortality risk 
by treatment adherence, (Mu et al., 2011b, Kaiser et al., 2007, Ngugi et al., 2014b, 
Kamgno et al., 2003a, Nicoletti et al., 2009) treatment allocation, (Kamgno et al., 
2003a) time since last treatment, (Nicoletti et al., 2009) and dose allocation (Mu et al., 
2011b) (Table S11). In Kenya, mortality rates were higher for individuals who did not 
adhere to AED treatment than for those who adhered to treatment (48 vs. 16 deaths 
per 1000 person-years) (Ngugi et al., 2014b). In Uganda, the SMR was 7.4 for those 
with self-reported good AED adherence compared to 8.0 for those with poor 
adherence (Kaiser et al., 2007). In Cameroon, treatment with AEDs alone was 
associated with 14% of deaths compared to 27% in those using AEDs and traditional 
medicine (Kamgno et al., 2003a). In one Chinese study, PWE receiving higher daily 
doses of phenobarbital (201-240 mg) had a lower mortality of 9% compared to those 
receiving medium doses (90-180 mg) with 47% mortality and low doses (30-90 mg) 
with mortality of 50% (Mu et al., 2011b). In a Bolivian study, recent access to AEDs 
was associated with lower mortality than absence of treatment for an extended period 
(Nicoletti et al., 2009).  
Meta-analysis. Meta-analysis revealed high heterogeneity across population-based 
studies as well as clinical cohort studies, and among high- and low-quality studies as 
well as short and long follow-up studies (Figures S2 and S3). Accordingly, a formal 
meta-analytic synthesis was not attempted.  
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1.1 Discussion 
Limitations. There are substantial limitations to these data. The studies that met our 
inclusion criteria represented only a small number of communities in Sub-Saharan 
Africa, Asia, and South America, while other major regions of the world, such as North 
Africa and the Middle East, were entirely unrepresented. The quality of the studies 
reviewed varied considerably. The large heterogeneity observed illustrates the high 
degree of uncertainty in the estimation of the true occurrence of epilepsy-related 
mortality across LMICs. Ascertainment bias, a major concern in many of the studies, 
is likely to yield underestimates of the mortality of epilepsy in LMIC. Some population-
based studies included only cases with convulsive epilepsies, while others may have 
incompletely ascertained cases with non-convulsive epilepsies. Most clinical cohorts 
over-represented people with severe forms of epilepsy, such as one Brazilian study 
with 72% of enrollees who reported daily seizures (Terra et al., 2011) and another that 
enrolled people with refractory epilepsy awaiting or having undergone epilepsy surgery 
(Almeida et al., 2010). The diagnosis of epilepsy in many studies was not made by 
clinicians with training in the diagnosis of epilepsy; thus the specificity of the estimates 
and causes of death in epilepsy in some studies should be viewed with caution. Most 
of the causes of death were ascertained by review of clinical records or verbal autopsy. 
No studies were identified using post-mortem examination data. The specificity of 
verbal autopsies varies depending on the other common causes of death in the 
population, the tool used, and the experience of the person administering the tool 
(Aspray, 2005).  
Interpretation.  This is the first systematic review of mortality associated with epilepsy 
encompassing all LMIC, although previous reviews of mortality in Africa (Diop et al., 
2005b) and Latin America (Escalaya et al., 2015) are noteworthy. The incidence of 
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epilepsy varies substantially across regions comprising LMICs and is higher in regions 
with high incidence of encephalitis and meningitis and with endemic parasitic 
infections such as malaria and neurocysticercosis (Kaiser et al., 2007, Nicoletti et al., 
2009, Ngugi et al., 2014b). The availability of basic public health services as well as 
specialized health care for epilepsy also varies considerably among LMICs (World 
Health Organization, 2015). Both factors may strongly influence epilepsy-related 
mortality. Thus, any generalizations drawn from the modest number of studies we 
have reviewed should be applied to other LMIC regions with great caution. 
Despite their limitations, these data from LMIC provide clear evidence that the burden 
of premature mortality, as measured by SMRs, is higher among PWE than in 
corresponding general populations.   
SMRs are especially high in children and young adults with epilepsy.  This finding 
might be explained in part by: (a) the comparatively lower mortality rates in general 
populations of young age, and (b) the increased mortality of recent-onset epilepsy, 
given that epilepsy onset is more frequent at young ages.  
The burden of premature mortality among PWE in LMICs appears to be somewhat 
higher in males, as indicated by the PMRs from several studies. This could reflect a 
higher incidence among males of symptomatic epilepsies (especially from head 
injury), which have an increased mortality risk.  It could also reflect increased mortality 
from hazardous occupations with an increased risk of drowning, falls, or other fatal 
injuries occurring consequent to seizures.   
These data also indicate that among the most important causes of death in PWE are 
those directly related to epilepsy, in particular status epilepticus, previously recognized 
to have a high case fatality ratio in LMICs (Newton et al., 2013).  The proportion of 
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deaths from status epilepticus appears substantially higher in LMICs compared to 
HICs (Thurman et al., 2016a). This difference might be explained in part by better 
access to AED treatment, better management of seizures, and better access to prompt 
treatment for prolonged seizures in HICs compared to LMICs.  
SUDEP was identified as another cause directly related to epilepsy in several LMIC 
studies.  The estimated proportions must, however, be viewed with caution as causes 
of death were seldom diagnosed through post-mortems and diagnoses of SUDEP 
made by verbal autopsy or clinical history may be inaccurate (Shorvon et al., 2011).  
Nevertheless, many of the risk factors associated with SUDEP are more common in 
LMIC than in HIC, e.g., structural causes of the epilepsy and frequent seizures, and 
thus SUDEP may represent a greater burden in these regions than indicated by some 
studies. Specific studies to examine SUDEP occurrence in LMIC populations are 
needed.   
In comparison to HIC, a higher proportion of PWE in many LMIC regions also die due 
to indirect causes, especially accidents. Many of these causes, e.g. drowning and 
burns, are potentially preventable through education and safety measures. For other 
causes, e.g., seizure-caused fatal injuries incurred during work or while driving a 
vehicle, further studies are needed to understand the frequency and circumstances of 
these injuries and to identify appropriate prevention measures that are specific for 
different localities.  
Comparing Mortality in LMIC and HIC.  Overall, the relative premature mortality risk 
associated with epilepsy in LMIC appears somewhat higher than the risk reported in 
HICs. In the best quality LMIC studies, the weighted median SMR of 2.6 modestly 
exceeds the corresponding value of 2.2 in HIC (Thurman et al., 2016a).  Such 
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comparisons of SMRs between studies are, however, fraught with potential error,  
especially given differing age distributions among study populations (with generally 
larger proportions of young people in LMIC), problems with case finding (greater in 
LMIC), and differing overall mortality rates in the study base populations (usually 
higher in LMIC). Thus, the magnitude of the disparity suggested by SMRs may be 
deceptive and it appears likely that the actual burden of premature mortality with 
epilepsy, if this were measured as incidence rates in entire populations, would be 
much higher in LMIC.   
Implications 
A limited number of studies demonstrate substantially elevated risks of premature 
mortality among PWE in LMIC of three continents.  Much of this may be attributed to 
the restricted distribution of healthcare resources in these countries, resources often 
far more limited than in HIC (World Health Organization, 2015).  Thus, lack of access 
and decreased adherence to medical management with AEDs places PWE at 
increased risk of fatal medical or injury-related complications of frequent seizures.  
Lack of access to prompt medical interventions for prolonged seizures places PWE at 
increased risk of death from status epilepticus. This mortality could be significantly 
reduced with improved access to health care including AEDs, and with education 
about the risks of epilepsy and ways to reduce these risks. 
The limited existing data on epilepsy-related mortality in LMIC are, however, not 
sufficient to guide the development of such prevention programs.  Too many countries 
and local regions are not described.  The circumstances of fatalities from medical 
complications, e.g., status epilepticus, are uncertain.  What proportion were 
associated with no AED treatment and in what proportion was AED use interrupted or 
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reduced because of inability to afford its cost?  The types and circumstances of fatal 
injuries arising from seizures are also uncertain.  Where do drownings in PWE occur, 
how many are occupational, and which occupations are involved?  How do fatal burns 
occur?  In how many traffic fatalities are PWE pedestrians, vehicle passengers, or 
vehicle drivers?  How do local laws address motor vehicle driving by PWE?  How many 
injuries involve falls from heights and how many of these are occupational?  How do 
risks vary according to local resources, customs, and industries (e.g., climbing trees 
to pick fruit)? 
More epidemiological studies, involving more LMIC localities, are needed.  As with 
future studies in HIC, studies in LMIC should be performed in conformity with current 
guidelines for epidemiologic studies (ILAE, 1993, Thurman et al., 2011b).  
Representative population samples and incident cohorts should be studied, where 
acute symptomatic seizures are distinguished from single unprovoked seizures and 
from epilepsy, and where convulsive and non-convulsive forms of epilepsy are also 
distinguished.  Finally, epileptogenic conditions and all risk factors implicated in the 
mortality of epilepsy should be clearly described. The collection of such higher quality 
information will enable us to identify many measures necessary to prevent much of 
the premature mortality in LMIC. 
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Supporting Information 
Table S1 Criteria and grading for assessing qualities of mortality studies 
Sensitivity of Epilepsy Case Ascertainment (20/20) 
 20/20 = Screening methods appear likely to ascertain nearly all (≥ 85%) cases in population 
 15/20 = Screening methods appear likely to ascertain most (70 - 84%) cases in population 
 10/20 = Screening methods appear likely to ascertain majority (50 - 69%) of cases in 
population 
 5/20 = Screening methods appear unlikely to ascertain majority of cases in population OR 
information published is insufficient to assess 
 0/20 N/A = Not applicable: not a population-based study or sensitivity of methods of epilepsy 
case ascertainment not relevant to quality of study. 
Sensitivity of Mortality Case Ascertainment (20/20) 
 20/20 = Fatalities appear likely to be recorded in nearly all (≥ 85%) cases in study population 
 15/20 = Fatalities appear likely to be recorded in most (70 - 84%) cases in study population 
 10/20 = Fatalities appear likely to be recorded in majority (50 - 69%) of cases in study 
population 
 5/20 = Fatalities appear unlikely to be recorded in majority of cases in study population OR 
information published is insufficient to assess 
Accuracy of Diagnoses of Epilepsy (20/20) 
 20/20 = Cases are diagnosed (or confirmed) by specialist  clinician (i.e., with neurologic 
training), AND ILAE case definition applied 
 15/20 = Cases are often diagnosed by non-specialist clinician, OR minor deviation from ILAE 
case definition 
 10/20 = All or substantial proportion of cases diagnosed based on self-report or non-clinical 
sources with specified criteria judged to have fair positive predictive value 
 5/20 = All or substantial proportion of cases diagnosed with poorly defined criteria from non-
clinical sources; positive predictive value judged to be poor OR information published is 
insufficient to assess 
Accuracy of Diagnoses of Cause of Death (20/20) 
 20/20 = Determined mainly from either autopsy, ME/coroner investigation, or other clinical 
investigation (e.g., review of medical records, structured interview of survivors or “verbal 
autopsy”) 
 15/20 = Determined largely or wholly from death certificate data, when such data are judged 
to have good positive predictive value for the specific causes of interest 
 10/20 = Determined largely or wholly from death certificate data, when such data are judged 
to have only fair positive predictive value for the specific causes of interest 
 5/20 = Other sources of data deemed to have poor positive predictive value for the causes 
of interest OR information published is insufficient to assess 
 0/20 = Cause of death not studied 
Representativeness of the study population (20/20) 
 20/20 = Cohort studies of incident epilepsy whose enrolled cases appear highly 
representative of the population of interest 
 15/20 = Studies of prevalent epilepsy whose enrolled cases appear highly representative of 
the population of interest 
 10/20 = Studies of epilepsy whose enrolled cases appear somewhat representative of the 
population of interest 
 5/20 = Studies of epilepsy whose enrolled cases appear poorly representative of the 
population of interest or where representativeness cannot be assessed. 
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Table S2: Summary of characteristics and quality of population-based studies of mortality in epilepsy 
     Key: DC Clinical Diagnosis; KI: Key informants, MR: Medical records, N/A: Not Available; NR Not Recorded;  PBS: Population-based screening, PHC: Primary health care,  
      VA Verbal          Autopsy 
    *These studies describe the same cohort. †Convulsive epilepsy only. 
    †Using ILAE guideline
Country-Location Dates Source 
Population 
(denominator) 
Epilepsy 
cases 
Case 
ascert- 
ainment (%) 
Diagnosis 
Mortality 
captured 
% 
Cause 
of Death 
Represen- 
tativeness 
Quality 
Argentina-Urban 1991-1998 PBS 70,000 106 ≥85 Neurologist† ≥85 DC Highly 90 
Benin- Rural 2006-2007 
PBS + 
MR+ KI 
11,688 160 ≥85 Neurologist† ≥85 N/A Highly 80 
Bolivia-Rural 1994-2004 PBS 55,675 118 ≥85 ILAE ≥85 NR Highly 85 
Cameroon- Rural 1991-2001 KI NR 271 50-69 Physicians† 70-84 NR Somewhat 60 
China-Rural 2000-2004 PHC 3,185,000 2455† N/A NR 70-84 VA Somewhat 50 
China-Rural  PHC 5,840,000 3568† N/A NR 70-84 VA Somewhat 50 
China-Rural 2000-2008 PHC 3,185,000 2455† N/A NR 70-84 VA+DC Somewhat 50 
India- Rural 1985-1999 PBS 14,010 109 ≥85 Neurologist ≥85 N/A Poorly 65 
India- Urban 2003-2005 PBS 52,377 337 ≥85 Neurologist† ≥85 N/A Highly 80 
India- Urban 1989-1994 PBS 16,000 51† ≥85 NR ≥85 VA Somewhat 80 
Kenya- Rural 2007-2010 PBS 232,164 754† ≥85% Neurologist† ≥85 VA Highly 100 
Mali-Urban, Rural 1988-2000 KI 7,158 36† 50 - 69 NR 70-84 NR Poorly 40 
Uganda- Rural 1994-2001 PBS 4,743 61 ≥85 ILAE ≥85 VA Somewhat 90 
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Table S3: Summary of characteristics and quality of clinical cohort studies of mortality in epilepsy 
Key: N/A – Not Available; N/R – Not recorded 
 
 
Country-Location Dates 
Source of clinical 
cohort 
Epilepsy 
cases 
Case Diagnosis Mortality 
Cause 
of 
Death 
Representative
ness 
Quality 
Ecuador-Urban 1997-2000 Tertiary Hospital 420 N/A ILAE ≥85 N/A Somewhat 50 
Brazil-Both 1992-2002 Tertiary Hospital 550 N/A Clinical ≥85 N/A Poor 45 
Brazil-Urban 2000-2010 Tertiary Hospital 1012 N/A N/R ≥85 SR Poor 35 
Tanzania-Rural 1960-1990 District Hospital 164 N/A N/R ≥85 N/A Somewhat 35 
India-Urban 1985-1997 Tertiary Hospital 447 N/A N/R 50 - 69 N/A Somewhat 25 
Brazil-Both 1995-2008 Tertiary Hospital 267 N/A N/R > 80 N/I Poor 25 
Brazil-Both 2000-2008 Tertiary Hospital 996 N/A N/R N/R N/I Poor 5 
Chile-Both 1996-2002 Tertiary Hospital  N/A N/R N/R N/I Poor 5 
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Table S4: Estimates of proportionate mortality ratio.(PRM) from SUDEP and status 
epilepticus among people with epilepsy 
  PMR (%) 
Country-Location Quality SUDEP SE 
Population based studies 
Kenya-Rural 100 6.6a 37.7a 
Uganda-Rural 90 11.1 22.2 
India-Urban-Vasai 80 20 a  
Bolivia-Rural 85  10 
India-Urban 80  5 
Cameroon-Rural 60 18.9 56.6 
China, Rural 50 14.7b 6.9 
China, Rural 50 1b 13.1 
Median All Population Studies  12.9 13.1 
Clinical cohort studies 
Ecuador, Urban 50 14.3 c 23 
  28.6 b  
Brazil, Urban-Rural 45 2.9 b  
Brazil, Urban 35 13.2 15.1 
Tanzania, Rural 35  14.5 
Brazil, Urban-Rural 25 11.1  
Chile-Santiago 5 31.25 b  
Urban/Rural  6.25 c  
Brazil-Urban, Rural 5 1.38  
Median All clinical cohorts  11.1 14.8 
aCases described as possible. 
bCases described as probable. 
cCases described as definite. 
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Table S5: Estimates of proportionate mortality ratio (PMR) in epilepsy bytype of injury 
   
PMR by type of injury 
Country-Location Quality Falls Drowning Traffic injury Burns Suicide 
Population-based       
Kenya-Rural 100 3.3 3.3 1.6 1.6  
Uganda-Rural 90 
 
5.6 
 
11.1 
 
Bolivia-Rural 85   10  10 
India-Urban 80  15 15   
Cameroon-Rural 60 
 
10.8 
   
China, Rural 50  37 2.9   
China, Rural 50 5.9 45.1 4.9  2.9 
Clinical cohort       
Brazil, Urban 35 1.9 1.9    
Tanzania, Rural 35 
 
12.7 
 
5.5 
 
 
 
Table S6: Estimates of causes of death reported in standardized mortality ratio (SMR) and 
mortality rate (MR) 
Country, 
Location 
Quality Measure Causes Estimate (95% C.I.) 
China, 
Rural 
50 SMR 
Cerebrovascular 1.14 (0.36–3.61) 
Cardiac disease 1.60 (0.50–5.22) 
Influenza and pneumonia 1.05 (0.26–4.32) 
Malignant neoplasm 1.94 (0.90–4.18) 
Other diseases 11.41 (4.03–32.43) 
China, 
Rural 
 
50 
 
SMR 
 
Drowning 39.0 (26.4–55.5) 
Toxic effects 17.0 (6.9–35.7) 
Falls 9.8 (3.6–21.7) 
Suicide 8.2 (4.5–14.0) 
Transport injury 6.0 (2.8–11.4) 
Myocardial infarction 3.6 (1.6–7.2) 
Digestive system diseases 4.4 (2.3–7.7) 
Pneumonia 2.9 (0.7–7.8) 
Cerebrovascular 2.2 (1.5–3.1) 
Neoplasms 1.1 (0.7–1.8) 
Brazil 5 MR Unrelated to epilepsy 22.2 
                  MR: Mortality rate per 1,000 people with epilepsy 
 
 
 
 
Table S7: Proportionate Mortality Ratio (PMR %) by Type of Seizure 
 
 
 
PMR for epilepsy type 
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Location Source Quality Generalized  Focal Unknown 
Argentina-Urban Population 90 37.5 50 12.5 
Bolivia-Rural Population 85 40 60  
Brazil, Urban-
Rural 
Clinical Cohort 45 14.3 85.7  
India, Urban Clinical Cohort 25 38.9 61.1 
 
Table S8: Estimates of mortality in epilepsy by seizure frequency 
Location Source Quality Measure Frequency SMR/MR 
Uganda-
Rural 
Population 90 
Standardized mortality 
ratio 
High  
(>1 per week) 
14.7  
(8.5—24.8) 
Low  
(<1 per week) 
1.4  
(0.4—5.7) 
Brazil Cohort 5 Mortality rate 
Daily 0.63 
2-4 per week 0.50 
1 per month 0.13 
     
Table S9: Estimates of mortality in epilepsy by duration of epilepsy in population-based 
studies 
Country-Location Quality Measure 
Duration of 
epilepsy (years) MR/SMR 
Kenya-Rural 100 Mortality rate (MR) 
<1 45.9(22.9–91.7) 
1–5 30.8(19.1–49.5) 
6–10 35.9(20.4–63.2) 
>10 31.1(20.9–46.4) 
Uganda-Rural 90 
Standardized mortality 
ratio (SMR) 
0-4 8.6 (4.5-16.5) 
5-9 3.6 (1.1-11.4) 
10-14 23.8 (8.9-65.5) 
Table S10: Estimates of proportionate mortality ratios in epilepsy by etiology 
   
Etiology 
  
Country-
Location 
Quality Measure Cryptogenic 
Sympt- 
omatic 
Remote 
seizure 
Undete- 
rmined 
Brazil, Urban-
Rural 
45 PMR 21.4 78.6   
Chile-
Urban/Rural 
5 PMR  81.3   
Argentina-
Urban 
95 PMR   75 25 
Bolivia-Rural 85 
PMR   60  
SMR 0.74(0.2–1.8)*  3(1.2–6.3)  
    * Idiopathic, PMR: Proportionate mortality ratio (%),       SMR: Standardized mortality ratio 
Table S11: Estimates of mortality in epilepsy by treatment 
Country-
Location Quality Measure Treatment Result 
Kenya-Rural 100 Mortality rate 
Adherence 16.1 (9.5–27.2) 
Non adherence 48.8 (36.7–65.0) 
Uganda-Rural 90 
Standardized 
mortality ratio 
Good adherence 7.4 
Poor adherence 8.0 
Cameroon-
Rural 
60 
Proportionate 
mortality ratio 
AED 13.6 
AED + Traditional 27.3 
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China, Rural 50 
Proportionate 
mortality ratio 
Phenobarbital 
Dose: 30–60 mg. 47.2 
Phenobarbital 
Dose: 90–180 mg. 44.3 
Phenobarbital 
Dose: 210–240 mg. 8.5 
Bolivia-Rural  
Proportionate 
mortality ratio 
Treatment in past year 20 
No treatment in past year 80 
Treatment in last month 20 
No treatment in last month 80 
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Figure S1: Standardized Mortality Ration and Proportionate Mortality Ratio of epilepsy by sex 
 
          SMR: Standardized mortality ratio 
          PMR: Proportionate mortality ratio (%) 
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Figure S2: Forest plot of excess mortality in epilepsy by quality of studies 
 
Figure S3: Forest plot of excess mortality in epilepsy by duration of cohort follow-up 
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Abstract 
Objective 
To estimated excess mortality in people with epilepsy (PWE) using data from the 
Studies of Epidemiology of Epilepsy in Demographic Surveillance Sites in three sub-
Saharan African countries. 
Methods 
We followed those with and without epilepsy and documented deaths from three sites; 
Agincourt (South Africa), Ifakara (Tanzania) and Kilifi (Kenya) for durations  (median) 
of 7, 6 and 8 years respectively. We estimated excess mortality in PWE compared to 
those without epilepsy using standardized mortality ratio. 
Findings 
A total of 199 deaths in PWE and 16,801 in general population were observed from 
the time of diagnosis. Mortality rates in PWE were estimated at 31.5 deaths per 1,000 
person years (95%CI: 19.4-43.6) in Agincourt, 23.9 (95%CI: 11.7-36.1) in Ifakara and 
24.6 (95%CI: 19.5-29.6) in Kilifi. Pooled estimates of excess mortality, as measured 
by standardized mortality ratio (SMR), was 4.8 (95% CI: 4.2-5.6) times higher in PWE 
than in those without epilepsy. Adjusting for age, SMRs were 3.20 (95%CI: 2.41-4.27) 
in Agincourt, 4.66 (95%CI: 3.46-6.29) in Ifakara and 6.22 (95%CI: 5.15-7.50) in Kilifi. 
Conclusions 
This study demonstrates evidence of excess mortality in PWE in sub-Saharan African 
countries. Observed risk factors may be managed by improving access to antiepileptic 
drugs, preventive measures against accidents, reducing perinatal adverse events at 
birth, preventing parasite infections with proper management of domesticated animals 
and hygiene, empowering PWE with education and decent low risk jobs and managing 
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co-morbidities such as cerebrovascular, cardiovascular, and motor and cognitive 
impairment. 
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Introduction 
Epilepsy is a neurological disorder that significantly impacts social and economic well-
being and survival in people with epilepsy (PWE); this impact is often more 
pronounced in sub-Saharan African countries when compared with high-income 
countries (Bhalla et al., 2014, Radhakrishnan, 2009a, Wilmshurst et al., 2014). With 
poor access to antiepileptic drugs (AED) and health care services, mortality in PWE 
has been found to be higher than that of general population (Kaiboriboon et al., 2014, 
Devinsky et al., 2016). Untreated epilepsies are associated with increased seizure 
frequency and higher mortality rates in status epilepticus, Sudden Death in Epilepsy 
(SUDEP) and accidents (falls, road traffic, drowning, and burns) (Radhakrishnan, 
2009a, Ba-Diop et al., 2014a, Birbeck et al., 2012, Hunter et al., 2016). Seizures are 
also associated with stigma, which often leads to exclusion from social and economic 
protective factors of excess mortality such as education, marriage, and employment 
(Wo et al., 2015, Heersink et al., 2015, Mushi et al., 2011).  
In sub-Saharan Africa, there is a paucity of evidence for understanding the magnitude 
of excess mortality in PWE and risk factors for deaths (Diop et al., 2005a). Recent 
systematic review highlighted the limited number of studies that estimate mortality in 
PWE (Levira et al., 2017). The review also revealed considerably large heterogeneity 
between studies, illustrating the high degree of uncertainty in the estimation of the true 
occurrence of epilepsy-related mortality across Low and Middle Income countries 
(LMICs).  
Studies of Epidemiology of Epilepsy in Demographic Surveillance (SEEDS) were 
designed to systematically collect comparable data on the prevalence and mortality in 
PWE in population-based house-to-house surveys in 5 sub-Saharan African countries 
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(Tanzania, South Africa, Uganda, Kenya and Ghana) (Ngugi et al., 2013a). This study, 
using data from SEEDS sites, aims to estimate country-specific and overall excess 
mortality in PWE and assess risk factors associated with excess mortality. 
Methods 
Study settings and populations 
The initial SEEDS study was conducted in Health and Demographic Surveillance 
System (HDSS) in Agincourt, South Africa, Ifakara, Tanzania and Kilifi, Kenya 
(Geubbels et al., 2015, Kahn et al., 2012, Scott et al., 2012). HDSS sites were 
established by enumerating the entire population (households and residents) in 
selected area. Following the establishment, continuous updates of residency status 
and vital events (migration, birth and deaths and their causes) have been conducted 
on a regular basis ranging from 1 to 3 visits in every enumerated household per year. 
Total populations at the start of the study in three HDSS were 83,121, 104,889 and 
233,881 residents in Agincourt, Ifakara and Kilifi, respectively (Ngugi et al., 2013a). 
People with ACE were identified in a three stages screening process of the entire 
population (Ngugi et al., 2012). ACE was defined as presence of at least “two or more 
unprovoked seizures occurred at least 24 hours apart” in the past 12 months (Thurman 
et al., 2011a). Estimates of prevalence of ACE in three sites have been published 
elsewhere in the literature (Ngugi et al., 2013a). After screening cohorts of people with 
ACE were established and followed as part of normal HDSS updates. 
Baseline census and risk factors 
Data on risk factors for ACE and mortality in PWE were collected by trained clinicians 
and field workers during baseline epilepsy surveys. General and adult specific (such 
as alcohol consumption) data on social and demographic, historical and clinical factors 
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were directly collected from individuals aged 18 years and older. For study participants 
younger than 18 years of age, or with cognitive impairment, the mother or caregiver 
was interviewed. Child and mother’s specific data were collected including questions 
about antenatal (such as severe abdominal pain, vaginal bleeding, or infection during 
pregnancy) and perinatal events (difficulties breathing, feeding, or crying after birth, as 
recalled by the mother).  
Clinical classification of seizures on the basis of electroencephalography (EEG) 
features of ACE in SEEDS cohorts has been published elsewhere (Kariuki et al., 2013, 
Kariuki et al., 2014, Kariuki et al., 2016). In summary, EEGs were performed on all 
participant diagnosed with ACE using 16 channel digital recording system (Grass 
Technologies, Warwick, RI, USA) according to the 10–20 international system with 
hyperventilation and photic stimulation. EEG activities were coded and classified in 
four categories of normal, mild, moderate or severe excess of generalized/diffused 
slow of cerebral function. Binary classification was recorded as normal and abnormal 
(mild, moderate and severe). Identification of origin of epileptic seizures in the brain 
was done by analyzing waves, spikes, polyspike, and burst of interictal epileptiform 
discharges (IEDs). IEDs were classified as generalized (involving the entire brain), 
focal (involving a region of the brain) or multifocal (involving 3 or more discrete brain 
regions). An EEG summary indicator was categorized as abnormal if there was 
evidence of an abnormal background, focal changes, interictal epileptiform activity or 
an abnormal response to hyperventilation and photic stimulation. 
Nutritional status was defined using body mass index (BMI; weight/height2) and 
categorized using the standard World Health Organization categories <18 
(underweight), 18-24 (normal), 25-30 (over weight), and 30+ (obese). Detailed 
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information on definitions and categories of risk factors have been published 
previously (Kariuki et al., 2014). 
Follow-up of ACE and general population 
Both people diagnosed with ACE and the general population of the HDSS remained 
under continuous surveillance. Median follow-up durations were 7, 6 and 8 years in 
Agincourt, Ifakara and Kilifi, respectively (Table 4-1). Deaths in those diagnosed with 
ACE were compared with the general population. These were documented in 
longitudinal databases and extracted for analysis from all sites. 
Statistical analysis 
Mortalities from ACE were estimated using survival analysis models. Exposure time 
was estimated from individual’s residence episodes started at the study start date in 
each site and ended at out-migration, death or at the end of analysis period. Mortality 
rate estimates were stratified by risk factors and rate ratio compared over different 
levels of factors. Mortality rate ratios were estimated using the Mantel-Haenszel 
method. Standardized Mortality Ratios (SMRs) were estimated to assess excess 
mortality in ACE compared to general population. The INDEPTH standard life table 
was used as standard population in comparing mortality between the three sites 
(Sankoh et al., 2014b) Stata software version 13  (StataCorp LP, College Station, 
Texas) was used for descriptive statistics and statistical analysis (Boston et al., 2003).  
Standard Protocol Approvals, Registrations, and Patient 
The study protocol was approved by Ifakara Health Institute’s Institution Internal 
Review Board and National Institute of Health Research and Commission of Science 
and Technology, Tanzania. All participants were enrolled through written consent. 
61 
 
Data Availability Statement 
SEEDS baseline data is available through INDEPTH Network’s data sharing policy. 
Site specific mortality status is available with prior permission from respective HDSS 
site Manager\Leaders. 
Results 
A total of 199 deaths were observed in the cohort of 1,268 individuals with ACE from 
the three sites. These deaths occurred between the time of diagnosis to the most 
recent HDSS survey for which data were available. In the general population, 16,801 
deaths occurred in the total population of 506,813 residents in the sites (Table 1). 
Mortality rates in general population were 9.7deaths per 1000 person years (95%CI: 
9.6-10.1) in Agincourt, 7.7 (95%CI: 7.5-7.9) in Ifakara and 5.0 (4.9-5.1) in Kilifi. 
Mortality rates in PWE were similar across the sites when adjusted for INDEPTH 
standard population. Estimated mortality rates were 31.5 deaths per 1000 person 
years (95%CI: 19.4-43.6) in Agincourt, 23.9 (95%CI: 11.7-36.1) in Ifakara and 24.6 
(95%CI: 19.5-29.6) in Kilifi. Mortality rate stratified by site and risk factors are 
presented in Supplement Table S1. 
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Table 4-1: Key summary findings by population 
 
Agincourt Ifakara Kilifi Total 
 
GP PWE GP PWE GP* PWE GP PWE 
Initial cohort size  83,121  245 104,889  366 233,881  697  21,891  1,308  
Lost to follow-up  2  4  27  33  
Final cohort         
Sex 
        
Males 38,961 128 103,980 171 98,889  340 241,830  639  
Females 42,052 115 108,443 191 113,697  327 264,192  633  
Age 
        
0-5 9,634  9 55,150  20 12,668  22   77,452  51  
6-18 9,240  43 55,416  113 85,393  233 160,049  389  
19-49 39,961  138 80,691  190 83,910  344  04,562  672  
50+ 2,183  53 21,166  39 31,449  71   64,798  163  
Total 81,018  243 212,423  362 213,420  670 506,861  1,275  
Residency status 
        
Alive 59,924  166 126,676  222 115,855  369 302,455  757  
Out-migration 17,892  41 80,096  97 91,157  192  89,145  330  
Deaths 3,202  36 5,651  43 6,409  109   15,262  188  
Follow-up (years) 7.4 7.4 3.3 6.3 8.1 8.6 
  
Mortality rate 
        
Crude 8.8  34.4  7.7  23.8  5.0  26.0  
  
Adjusted 7.5  32.7  7.9  23.9  4.7  24.6  
  
95% CI Lower 7.2  20.7  7.7  11.7  4.6  19.5  
  
95% CI Upper 7.8  44.6  8.1  36.1  4.8  29.6  
  
                                          GP:General Population ;PWE: People with Epilepsy; CI: Confidence interval
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In analysis of risk factors for mortality in PWE, controlling for site, high mortality rates 
were observed for those who ate soil  (RR=1.70, 95% CI:1.27-2.26), snored more than 
3 nights per week  (RR=1.42, 95% CI: 1.04-1.93), adults who were 
divorced/separated/widowed  (RR=2.30, 95%CI: 1.46-3.63), adults who were illiterate  
(RR=1.69, 95%CI: 1.21-2.36), those with onset of epilepsy at ages between 29-49 
years  (RR=1.88, 95% CI: 1.01-3.50) or 50 years and above  (RR=4.67, 95% CI: 2.71-
8.05), those with daily seizures  (RR=1.54, 95%CI: 1.03-2.28), those with seizures that 
occurred both day and night  (RR=1.80,95%CI: 1.05-3.09), those with severe general 
EEG diagnosis  (excessive slow cerebral function)  (RR=2.27, 95% CI: 1.34-3.83), 
those with burn marks  (RR=1.46, 95%CI: 1.05-2.02),  those with systolic blood 
pressure above 140mmHg  (RR=2.58, 95%CI: 1.82-3.66) or a diastolic blood pressure 
greater than 90mmHG  (RR=2.78, 95%CI: 1.90-4.06), those with pre-existing 
neurologic deficits (RR=1.78, 95%CI:1.31-2.43) or cognitive impairment  (RR=2.11, 
95%CI:1.57-2.84). The observed overall estimates were similar across sites based on 
test of unequal RR controlling for site (Table 4-2). 
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Table 4-2: Rate ratio and (95% CI) of mortality in epilepsy by site and risk factors 
Risk factor Agincourt Ifakara Kilifi Overall chi p-value 
Males 2.12 (1.15-3.92)† 1.22 (0.67-2.22) 1.09 (0.75-1.58) 1.29 (0.98-1.71) 3.42 0.181 
Head injury 4.03 (2.09-7.79)† 2.48 (0.89-6.96) 1.23 (0.72-2.09) 1.84 (1.26-2.69)† 8.29 0.016 
Eat soil 1.23 (0.68-2.23) 1.74 (0.95-3.19) 1.93 (1.31-2.85)† 1.70 (1.27-2.26)† 1.57 0.455 
Snore > 3 nights a week 1.00 (0.54-1.86) 1.38 (0.76-2.52) 1.70 (1.09-2.66)† 1.42 (1.04-1.93)† 1.88 0.391 
Marital status-Single Ref 1 1 1     
Marital status-Married 3.35 (1.50-7.52)† 0.42 (0.16-1.08) 1.04 (0.61-1.78) 1.16 (0.79-1.70) 2.3 0.002 
Marital status-Previous married 3.58 (1.55-8.26)† 1.28 (0.42-3.84) 2.16 (1.14-4.07)† 2.30 (1.46-3.63)† 2.26 0.324 
Illiterate adult 2.88 (1.54-5.41)† 2.15 (0.98-4.71) 1.22 (0.76-1.95) 1.69 (1.21-2.36)† 5.07 0.079 
Adult consuming alcohol 3.15 (1.57-6.31)† 0.73 (0.25-2.16) 1.09 (0.54-2.20) 1.42 (0.92-2.21) 7.35 0.025 
Difficulties crying after birth 1.84 (0.22-5.77) 3.34 (1.09-0.25)† 1.16 (0.36-3.77) 1.84 (0.87-3.89) 1.72 0.424 
Age onset 6-12 Ref 1 1 1     
Age onset 29-49 3.47 (1.22-9.85)† 1.21 (0.24-5.98) 1.25 (0.49-3.19) 1.88 (1.01-3.50)† 2.42 0.299 
Sickle cell disease     7.51 (1.86-0.44)† 3.54 (0.88-4.26) 2.22 0.33 
> 12 seizure per year 0.73 (0.36-1.49) 2.42 (1.12-5.21)† 1.08 (0.64-1.82) 1.16 (0.81-1.66) 5.39 0.068 
Seizure frequency-Monthly Ref 1 1 1     
Seizure frequency-Daily 0.71 (0.22-2.36) 1.55 (0.77-3.11) 1.87 (1.10-3.17)† 1.54 (1.03-2.28)† 2.18 0.336 
Seizure time-Night       
Seizure time-Day & Night 1.67 (0.65-4.33) 1.41 (0.59-3.35) 2.47 (0.91-6.74) 1.80 (1.05-3.09)† 0.71 0.7 
EEG GB-Severe 3.12 (1.17-8.32)† 1.45 (0.19-1.26) 2.12 (1.10-4.08)† 2.27 (1.34-3.83)† 0.63 0.728 
No BCG vaccine scar 0.81 (0.39-1.68) 0.69 (0.21-2.22) 1.69 (1.13-2.54)† 1.28 (0.91-1.79) 4.45 0.108 
Burn marks 1.88 (0.97-3.63) 1.26 (0.56-2.83) 1.39 (0.91-2.12) 1.46 (1.05-2.02)† 0.75 0.686 
Systolic blood pressure: > 140 2.32 (1.23-4.36)† 3.17 (1.25-8.08) 2.65 (1.66-4.23)† 2.58 (1.82-3.66)† 0.31 0.857 
Diastolic blood pressure: > 90 2.29 (1.21-4.35)† 2.51 (0.90-7.04) 3.39 (2.01-5.72)† 2.78 (1.90-4.06)† 0.95 0.623 
Pre-existing neurological 1.19 (0.66-2.17) 2.74 (1.33-5.66) 1.98 (1.30-3.00)† 1.78 (1.31-2.43)† 3.36 0.186 
Cognitive impairment 1.53 (0.84-2.78) 2.25 (1.04-4.86) 2.41 (1.64-3.54)† 2.11 (1.57-2.84)† 1.61 0.448 
Motor impairment 0.75 (0.32-1.77) 4.07 (1.57-0.54) 2.75 (1.87-4.07)† 2.16 (1.56-2.99)† 9.63 0.008 
                 Ref: Reference category, EEG: Electroencephalogram, BCG: Bacillus Calmette–Guérin  
                 CI: Confidence interval, GB: General background, †: Statistically significant (P-value < 5%) 
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Site specific analysis identified risk factors that were significantly associated with 
increased mortality in PWE but not observed in the overall analysis. In Agincourt, high 
mortality rates were observed in males (RR=2.12, 95% CI: 1.15-3.92), those with 
previous history of head injuries (RR=4.03, 95%CI: 2.09-7.79), adults who were 
married (RR=3.35, 95%CI: 1.50-7.52), and adults who consumed alcohol (RR=3.15, 
95% CI: 1.57-6.31). In Ifakara, high mortality rates were observed in babies who had 
difficulties in breathing or crying soon after delivery (RR=3.34, 95% CI: 1.09-10.25), 
and in those who had more than 12 seizures per year (RR=2.42, 95% CI: 1.12-5.21) 
and those with motor impairment (RR=4.07, 95% CI: 1.57-0.54). In Kilifi, high mortality 
rates were seen those with sickle cell disease (RR=7.51, 95% CI: 1.86-30.44) and 
motor impairment (RR=2.75, 95% CI: 1.87-4.07) Table 4-2. 
Overall estimates of excess mortality across the three sites as measured by SMR was 
4.8 (95% CI: 4.2-5.6) times higher in PWE than general population. Mortality estimates 
in PWE were higher than the general population in each HDSS sites. SMRs were 3.20 
(95%CI: 2.41-4.27) in Agincourt, 4.66 (95%CI: 3.46-6.29) in Ifakara and 6.22 (95%CI: 
5.15-7.50) in Kilifi. Analysis of excess mortality in PWE by site identified several sub-
populations with SMR greater than country specific estimates. Supplement Table S2 
provides estimates for SMR by sub-population and site. 
Discussion 
Excess mortality 
Understanding the magnitude of excess mortality in PWE as well as risk factors are 
important for developing epilepsy management programs aimed at reducing epilepsy 
related causes of deaths and morbidities. Our previous systematic review identified 
only 7 good quality population-based studies of excess mortality in PWE from LMIC in 
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the study period of approximately 25 years (1990-2014). (Levira et al., 2017) The 
median mortality rate in PWE was estimated to be 19.8 (95% CI: 16.7–23.5) deaths 
per 1000 person-years; 2.6 times higher than mortality rate of the general population 
(Levira et al., 2017). The review also indicated substantial uncertainties in estimates 
of excess mortality in PWE in sub-Saharan Africa and other LMICs. Using standard 
definitions and methodology, this study provides evidence of excess mortality of a 
magnitude of 5 times greater in people diagnosed with active convulsive epilepsy, 
compared to the general population in large community/population-based surveys in 
sub-Saharan Africa. The estimates are approximately twice of what has been 
previously reported in the literature. This study also identified sub-populations of PWE 
with greater excess mortality than the overall mortality in PWE and identified 
potentially modifiable risk factors for mortality in PWE. 
In high income countries (HICs), mortality in PWE is higher than general population; 
however the magnitude is lower than estimates observed in this study (Forsgren et al., 
2005b). In studies conducted in HICs, excess mortality as estimated through 
Standardized Mortality Ratio (SMR) was 1.3-3 times higher in population-based 
studies.(Thurman et al., 2016b) In clinical settings, mortality in PWE was much higher, 
especially in children where mortality was 7 times higher than general population 
(Thurman et al., 2016b). Other studies in developed countries have observed no 
change over time in both epilepsy mortality rate and excess mortality in PWE 
compared to general population (Neligan et al., 2010).  
The estimates of excess mortality in PWE were comparable across the three sub-
Saharan African countries. These results were expected given the observed similarity 
in high epilepsy treatment gaps, population attributable risk factors and clinical 
features in the studied population (Hunter et al., 2016, Kariuki et al., 2014, Ba-Diop et 
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al., 2014a, Newton et al., 2012a). Extended follow-up duration in Agincourt (from 4 to 
7.4 years) and Kilifi  (from 2.7 to 8 years) did not significantly change previous mortality 
in epilepsy and excess mortality (Ngugi et al., 2014a, Wagner et al., 2015). These 
findings indicate there are stable, but increased, mortality rates in PWE compared to 
the population without epilepsy in Agincourt and Kilifi cohorts. 
Risks factors analysis 
Risk factors for excess mortality in PWE include behaviors, health conditions and 
characteristics or exposures that increase than usual the probability of death. 
Convulsive seizures are the most important risk factor for excess mortality associated 
with traffic accidents, burns, falls, or drowns (Strauss et al., 2003). Poor access to anti-
epileptic drug (AED), seizures frequency, age onset of epilepsy, adverse perinatal 
events, and pre-existing health conditions such as cognitive and motor impairment are 
some of the risk factors for excess mortality in PWE (Ngugi et al., 2014a). Certain risk 
factors can be modifiable, meaning; health interventions can significantly reduce 
excess mortality in PWE such as reducing seizures frequency through increased 
access to AED. Some risk factors are associated with both occurrence of epilepsy and 
excess mortality, including but not limited to, specific epilepsy etiology such as 
parasitic infections, adverse perinatal events, cerebrovascular diseases, and road 
traffic injuries. Identifying and preventing these risk factors is expected not only reduce 
excess mortality in PWE but prevent the development of epilepsy.  
This study identified overall and site-specific risk factors for excess mortality in PWE. 
We identified social and demographic factors, clinical, clinical historical conditions, as 
well as cerebral activities related to excess mortality in PWE. It is worth noting that a 
substantial number of factors were found to be associated with having epilepsy and 
risk factors for excess mortality. These factors include; adverse perinatal events, 
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history of head injuries, illiterate, poor hygienic practices (eating soil), and 
cerebrovascular diseases. Mitigating these factors has the potential to reduce 
epileptogenic and excess mortality concurrently. 
Social and demographic factors 
Males were observed to experience higher mortality than females in this study; 
however, the reasons behind these differences have not well researched. Some 
studies have linked the differences to the different etiologies of epilepsy (Engberg Aa 
et al., 2001). Epilepsy in females are more idiopathic and generalized while in 
symptomatic and localized epilepsies are more common in males. Individuals with 
regular alcohol consumption were observed to experience high mortality, possibly due 
to high exposure to accident-related injuries. The increased mortality in adults or 
mothers of children with epilepsy who were illiterate is possibly a consequence of 
epilepsy on social demographic indicators. PWE who are educated are more likely to 
be well informed about their condition hence avoid misconceptions that may increase 
their risks of premature mortality. Educating PWE may also lead to participation in less 
risky jobs activities such as teaching and customer care compared to high risky jobs 
such as driving and physical labor. Higher mortality rates were observed among 
individuals who were divorced/separated/widowed than married. These findings 
demonstrate the negative social and psychological consequence of epileptic seizures. 
These individual are more likely to be suffering from psychosocial disabilities as a 
result of difficulties in social interaction (Sperling, 2004). High mortality in those in 
households with cats may be linked to severe brain complications caused by 
households contamination of pork  (Taenia solium, T. multiceps) and cat  (Toxoplasma 
gondii) tapeworms (Wagner et al., 2009). Eating soil or geophagia is an ancient 
practice in Africa and other parts of the world believed to be associated with psychiatric 
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disorders, culture, poverty, famine, and mineral deficiency in pregnant women 
(Woywodt et al., 2002). Regardless of the reasons for the practice, eating soil has 
been linked with soil-transmitted parasites some of which are responsible for epilepsy 
(Wagner et al., 2009, Kind et al., 2017). Limited to access to comprehensive health 
care during delivery, such as resuscitation and caesarean, may result in epilepsy 
cases with severe brain damage and increased risk of mortality compared to normal 
deliveries. Antenatal and perinatal events such as obstructed labor, difficulties 
breathing and crying have been well described in the literature as risk factors of severe 
form of childhood epilepsies in LMIC (Burton et al., 2012a) and have been found to be 
risk factors for death in this study. 
Clinical history 
High mortality in people with onset of epilepsy at older ages indicates that the etiology 
of epilepsy may be linked to cerebrovascular diseases, parasitic infections and 
accidents/cerebra trauma (Diop et al., 2005a, Brodie et al., 2005, Shorvon, 2011). In 
study areas where the epilepsy treatment gap is high, a positive association between 
seizure frequency and mortality was expected especially in those with daily seizure, 
seizure occurring both day and night, and in PWE having more than 12 seizures per 
year. Reducing seizure frequency and severity by expanding treatment with AED may 
be an effective approach in reducing both epilepsy and accident related causes of 
death in PWE (Strauss et al., 2003, Sperling, 2004). 
Clinical examination 
Co-morbidities with neurological disorders such as cardiovascular and 
cerebrovascular diseases have been observed to increase mortality in PWE in many 
developed countries as observed in this study (Forsgren et al., 2005b). Co-morbidities 
with motor and cognitive impairment were also found to be associated with an 
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increased mortality in PWE in this study as well as sickle cell disease. Addressing 
these co-morbidities could be effective in reducing premature mortality in epilepsy 
(Keezer et al., 2016). Premature mortality in PWE could be prevented by streamlining 
interventions targeting management of severe cases of neurological disorders and 
infections as well as severe cases of status epilepticus (Munyoki et al., 2010, Malek 
et al., 2016, Gilmore et al., 2015). Preventive measures against accidents (head 
injuries) which were also associated with higher mortality in PWE could reduce the 
incidence of epilepsy associated with cerebrovascular accidents. Excessive snoring is 
one factor found to be more common in people with epilepsy than healthy individuals 
(Im et al., 2016). Snoring is thought to be strongly associated with sleep apnea, a 
dangerous condition that, when untreated, can lead to death. We observed high 
mortality in PWE who were snoring more than 3 nights per week. Several studies 
suggest that up to 70% of SUDEP occurred during sleep (Ali et al., 2017). There is 
limited information on causes of sleep disorders in PWE but contribution of certain 
AED, seizures, and various epilepsy syndromes are likely (Bazil, 2017). 
EEG 
Generalized slowing of brain functions is often observed in PWE and is indicative of 
diffuse brain dysfunction. Severe abnormal EEG has been liked to increased seizures 
frequency. In this study, PWE with severe abnormal EEG features were observed to 
experience a higher mortality compared to those with normal EEG features. These 
results are consistent with other studies that linked abnormal EEG features in PWE 
with higher seizure recurrence (Moran et al., 2004). These findings demonstrate the 
need for health system’s investment in targeted EEG that will be essential in early 
identification of individual at risk of premature mortality not only in PWE but also in 
people with other neurological disorders (Phabphal et al., 2013) Other forms of 
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diagnosis such as prolonged implantable electrocardiography monitoring may be 
potential in reducing a high rate of misdiagnosis of epilepsy (Petkar et al., 2012). 
Limitations 
Based on our current knowledge, the SEEDS project is the largest, standardized 
population-based study of prevalence and mortality in PWE in sub-Saharan Africa. 
This study accounted for common and major methodological limitations such as 
epilepsy definition, cases identification, and mortality ascertainment previously 
identified in the epidemiological literature on epilepsy in sub-Saharan Africa (Ba-Diop 
et al., 2014a, Preux et al., 2005a, Logroscino et al., 2005). The focus on ACE in this 
study limits the ability to fully determine the excess mortality in PWE in sub-Saharan 
Africa. However, the choice to focus on ACE was due to the difficulty in ascertaining 
non-convulsive, non-active cases of epilepsy. 
Conclusions 
This study provides evidence of excess mortality, with a pooled magnitude of mortality 
5 times greater in PWE compared to those without epilepsy in sub-Saharan Africa. 
These findings indicate that PWE in sub-Saharan Africa are at substantially greater 
risk of death than people without epilepsy. In this study, we identified sub-populations 
and risk factors of excess mortality in PWE that could potentially mitigate the 
development of epilepsy and the increased mortality. These findings suggest that the 
mortality in PWE may be reduced by implementing interventions that strengthen 
clinical management of epilepsy, including better access to AED, reducing adverse 
perinatal events with improved care at birth, implementing community preventive 
measures against accidents, introducing behavior changes such as that of eating soil, 
properly managing parasitic infections in both human and domestic animals, 
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increasing access to education to PWE, empowering PWE with employment and 
adequately managing co-morbidities such as cerebrovascular, cardiovascular, and 
motor and cognitive impairment. 
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Supporting information 
Table S1: Estimates of mortality rate in PWE per 1000 person years by site and risk factors  
Risk factors 
Agincourt Ifakara Kilifi 
Mortality rate* (95%Confidence Interval) 
Females 22.52 (13.58-37.36) 21.38 (13.80-33.14) 24.96 (18.97-32.84) 
Males 47.82 (33.82-67.63) 26.12 (17.36-39.31) 27.11 (20.96-35.07) 
Facility deliveries 20.65 (8.60-49.62) 22.33 (12.68-39.33) 15.73 (6.55-37.79) 
Home deliveries 13.58 (1.91-96.42) 16.13 (7.25-35.91) 16.57 (11.84-23.19) 
Seizure history in family 39.19 (5.52-278.21) 46.92 (6.61-333.07) 28.24 (17.02-46.84) 
Seizure in family 22.76 (8.54-60.65) 20.10 (10.05-40.18) 33.43 (22.21-50.30) 
Head injury 111.82 (63.51-196.90) 55.05 (20.66-146.68) 29.65 (18.16-48.39) 
Recent hospital admission 41.06 (24.32-69.33) 30.27 (20.61-44.46) 27.24 (21.62-34.32) 
Eat cassava 35.89 (25.38-50.75) 23.22 (15.81-34.10) 24.29 (19.59-30.13) 
Eat soil 38.55 (26.95-55.13) 32.08 (20.92-49.20) 35.22 (27.82-44.59) 
Dog in the household 52.80 (32.82-84.93) 25.02 (18.13-34.53) 25.86 (18.47-36.19) 
Cat in the household 86.52 (32.47-230.53) 23.80 (17.39-32.58) 27.56 (21.44-35.42) 
                                              *Mortality rate per 1000 person years 
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Table S1: Estimates of mortality rate in PWE per 1000 person years by site and risk factors continue 
Risk factors 
Agincourt Ifakara Kilifi 
Mortality rate* (95%Confidence Interval) 
Eat pork 53.52 (31.70-90.37) 18.98 (12.61-28.56) 30.12 (20.79-43.62) 
Snore > 3 nights a week 33.18 (22.75-48.38) 28.20 (18.90-42.07) 29.49 (23.45-37.10) 
BMI <18 17.16 (2.42-121.80) 16.17 (6.07-43.09) 13.60 (8.05-22.96) 
BMI 18-24 24.90 (6.23-99.57) 11.97 (4.49-31.89) 21.72 (12.87-36.68) 
BMI 25-30 55.38 (28.82-106.44) 28.39 (15.72-51.26) 29.05 (20.06-42.08) 
BMI 30+ 37.81 (25.93-55.14) 21.90 (13.62-35.24) 27.38 (19.92-37.62) 
Adult specific risk factors    
Adult marital status    
Single 17.74 (9.23-34.09) 36.34 (21.91-60.28) 33.92 (24.36-47.25) 
Married 59.48 (36.98-95.68) 15.17 (6.82-33.77) 35.41 (23.31-53.77) 
Divorced/separated/widow 63.43 (37.56-107.09) 46.34 (17.39-123.46) 73.14 (42.47-125.96) 
Illiterate adult 77.97 (49.12-123.75) 44.94 (25.52-79.13) 42.05 (30.72-57.55) 
Alcohol consumption 101.39 (56.15-183.08) 20.62 (7.74-54.93) 41.72 (21.71-80.18) 
                                             BMI: Body mass index (Kg/m2), *Mortality rate per 1000 person years
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Table S1: Estimates of mortality rate in PWE per 1000 person years by site and risk factors continue 
Risk factors 
Agincourt Ifakara Kilifi 
Mortality rate (95%Confidence Interval) 
Child specific risk factors    
Maternal marital status    
Married 7.58 (1.07-53.83) 19.28 (11.63-31.99) 14.28 (9.86-20.69) 
Single 30.01 (11.27-79.97) 12.48 (1.76-88.57) 45.79 (11.45-183.10) 
Divorced/separated/widow 18.13 (2.55-128.72) 31.58 (7.90-126.28) 27.35 (13.68-54.69) 
Unemployed mother 21.62 (9.00-51.94)  16.61 (10.32-26.72) 
Illiterate mother 58.37 (8.22-414.34) 16.52 (5.33-51.24) 17.73 (11.78-26.69) 
Mother's history of seizure   56.34 (14.09-225.27) 
Delivery problem-Mothers 68.06 (17.02-272.14) 23.64 (5.91-94.51) 18.11 (8.14-40.32) 
Difficulties crying after birth 33.87 (4.77-240.47) 51.55 (19.35-137.34) 18.98 (6.12-58.86) 
Difficulties breathing after birth  49.41 (15.94-153.20) 23.01 (5.75-92.00) 
Incomplete immunization 38.11 (5.37-270.55)  20.26 (5.07-80.99) 
                                           *Mortality rate per 1000 person years
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Table S1: Estimates of mortality rate in PWE per 1000 person years by site and risk factors continue 
 
 
 
 Agincourt Ifakara Kilifi 
Risk factors Mortality rate (95%Confidence Interval) 
Clinical history    
Age onset 0-5 24.52 (13.19-45.57) 26.32 (16.98-40.79) 20.03 (15.30-26.22) 
Age onset 6-12 18.15 (7.55-43.60) 15.72 (7.06-34.98) 26.68 (16.35-43.56) 
Age onset 13-18 19.26 (6.21-59.70) 14.74 (5.53-39.28) 25.40 (13.22-48.82) 
Age onset 19-28 52.04 (26.03-104.07) 23.37 (8.77-62.27) 33.29 (16.65-66.57) 
Age onset 29+ 68.33 (42.48-109.91) 48.08 (22.92-100.86) 65.78 (42.89-100.88) 
Sickle cell disease   191.68 (47.94-766.43) 
< 12 seizure per year 38.18 (27.00-53.98) 13.79 (7.64-24.91) 20.35 (15.38-26.92) 
> 12 seizure per year 27.98 (15.05-52.00) 33.38 (20.45-54.48) 22.02 (14.21-34.14) 
Seizure type-Generalized 37.99 (25.87-55.79) 21.55 (13.74-33.78) 25.80 (17.69-37.62) 
Seizure type-Focal 36.11 (23.30-55.97) 26.55 (15.72-44.82) 27.14 (21.68-33.98) 
Seizure type-Others   31.61 (14.20-70.36) 
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Table S1: Estimates of mortality rate in PWE per 1000 person years by site and risk factors continue 
Risk factors 
Agincourt Ifakara Kilifi 
Mortality rate (95%Confidence Interval) 
Untreated with AED 26.17 (14.86-46.08) 20.09 (12.82-31.50) 23.63 (18.23-30.63) 
Number of different type of seizure-1 36.80 (26.78-50.58) 24.05 (17.27-33.50) 25.82 (20.95-31.82) 
Number of different type of seizure-2 21.75 (9.05-52.25) 26.29 (13.15-52.58) 26.90 (17.35-41.70) 
Number of different type of seizure-3   101.46 (14.29-720.26) 
Seizure frequency-Daily 31.06 (10.02-96.31) 41.48 (22.97-74.90) 44.37 (29.49-66.78) 
Seizure frequency-Monthly 43.45 (29.80-63.36) 26.76 (18.48-38.76) 23.77 (16.99-33.27) 
Seizure frequency-Weekly 31.02 (7.76-124.04) 7.19 (1.01-51.05) 40.36 (25.75-63.28) 
Seizure time-Day & Night 41.22 (28.64-59.31) 26.71 (19.18-37.20) 31.48 (25.36-39.09) 
Seizure time-Day 30.33 (17.22-53.41) 6.52 (0.92-46.26) 18.24 (12.12-27.45) 
Seizure time-Night 24.61 (10.24-59.13) 18.95 (8.51-42.18) 12.75 (4.78-33.97) 
                                   AED: Antiepileptic drug 
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Table S1: Estimates of mortality rate in PWE per 1000 person years by site and risk factors continue 
Risk factors 
Agincourt Ifakara Kilifi 
Mortality rate (95%Confidence Interval) 
Imaging    
EEG general background    
Mild 43.62 (24.16-78.77) 28.50 (12.81-63.44) 22.03 (13.49-35.95) 
Moderate 30.54 (4.30-216.78) 24.20 (7.81-75.05) 11.00 (2.75-43.97) 
Normal 30.90 (19.94-47.90) 19.64 (10.88-35.46) 20.81 (15.01-28.85) 
Severe 96.44 (40.14-231.71) 28.55 (4.02-202.67) 44.16 (25.08-77.76) 
EEG Asymmetry 35.20 (11.35-109.14) 31.83 (4.48-225.96) 21.59 (3.04-153.29) 
EEG Focal feature 39.79 (26.44-59.87) 16.92 (7.60-37.65) 27.81 (17.74-43.60) 
EEG epileptiform activity 53.28 (30.94-91.76) 10.88 (4.08-28.99) 18.21 (11.62-28.55) 
EEG Focal temporal 50.14 (27.77-90.55) 13.73 (5.15-36.58) 25.55 (16.30-40.06) 
EEG Focal extra temporal 49.24 (25.62-94.64) 10.54 (3.40-32.68) 16.38 (9.30-28.85) 
EEG involve Temporal lobe 62.95 (26.20-151.25) 12.23 (3.06-48.90) 30.03 (16.63-54.23) 
                                               EEG: Electroencephalogram 
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Table S1: Estimates of mortality rate in PWE per 1000 person years by site and risk factors continue 
Risk factors 
Agincourt Ifakara Kilifi 
Mortality rate (95%Confidence Interval) 
EEG Generalized 114.68 (16.15-814.11)  20.73 (8.63-49.81) 
EEG photosensitivity: abnormal 29.90 (4.21-212.26) 59.64 (22.38-158.91) 17.20 (4.30-68.76) 
EEG hyperventilation: abnormal 26.77 (8.63-83.00) 10.16 (1.43-72.16)  
EEG Summary-Abnormal 43.05 (28.07-66.03) 21.95 (12.47-38.65) 23.95 (17.63-32.53) 
EEG Summary-Normal 26.94 (13.47-53.87) 21.11 (10.56-42.21) 22.00 (14.98-32.32) 
EEG Summary-Undetermined 34.60 (16.49-72.57)   
Clinical features and examination    
Falls to the ground during seizure 42.58 (31.36-57.83) 23.88 (17.07-33.43) 25.85 (21.05-31.74) 
Seizure duration-10 min+ 24.16 (6.04-96.62) 25.33 (12.67-50.66) 32.50 (24.42-43.26) 
Seizure duration-5-9 minutes 29.84 (11.20-79.50) 23.81 (15.00-37.79) 20.83 (14.28-30.37) 
Seizure duration-< 5 minutes 41.98 (30.79-57.23) 24.04 (13.65-42.33) 22.98 (16.06-32.86) 
                                      EEG: Electroencephalogram 
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Table S1: Estimates of mortality rate in PWE per 1000 person years by site and risk factors continue 
Risk factors 
Agincourt Ifakara Kilifi 
Mortality rate (95%Confidence Interval) 
No BCG vaccine scar 30.67 (15.96-58.94) 16.67 (5.38-51.68) 38.01 (27.16-53.20) 
Burn marks 60.32 (34.26-106.21) 28.45 (13.56-59.67) 33.36 (23.18-48.00) 
Systolic blood pressure: > 140 73.59 (44.37-122.07) 75.72 (31.52-181.92) 63.92 (42.48-96.19) 
Diastolic blood pressure: > 90 71.62 (42.42-120.93) 61.83 (23.21-164.74) 76.83 (47.76-123.58) 
Pre-existing neurological 41.49 (25.79-66.74) 48.95 (27.11-88.38) 45.26 (31.83-64.36) 
Cognitive impairment 49.31 (30.65-79.31) 41.88 (21.79-80.50) 49.16 (36.58-66.06) 
Motor impairment 28.35 (12.74-63.10) 81.17 (33.79-195.01) 56.67 (41.57-77.25) 
Previous status epilepticus  47.03 (15.17-145.81) 23.63 (16.88-33.07) 
Febrile seizure   21.08 (14.13-31.44) 
History of encephalopathy  58.66 (8.26-416.40) 22.25 (14.65-33.79) 
History of febrile seizure 47.58 (17.86-126.78) 16.95 (8.47-33.88) 19.13 (13.03-28.10) 
                                       BCG: Bacillus Calmette–Guérin 
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Table S2: Standardized mortality ratio of death in PWE by risk factors and site 
Risk factors 
Agincourt Ifakara Kilifi 
Standardized Mortality Ratio (95%Confidence Interval) 
Overall 3.21 (2.41-4.27) 4.66 (3.46-6.29) 6.22 (5.15-7.50) 
Females 1.80 (1.09-2.99) 4.22 (2.72-6.54) 5.96 (4.53-7.84) 
Males 5.07 (3.59-7.17)† 5.14 (3.41-7.73) 6.49 (5.02-8.40) 
Facility deliveries 13.10 (5.45-31.48) † 11.56 (6.57-20.36) † 15.86 (6.60-38.11) † 
Home deliveries 10.59 (1.49-75.16) 7.76 (3.48-17.26) † 17.39 (12.43-24.3)† 
Seizure history in family 4.24 (0.60-30.12) 19.36 (2.73-137.46) 4.81 (2.90-7.97) 
Seizure in family 1.86 (0.70-4.97) 3.60 (1.80-7.20) 8.27 (5.49-12.44) † 
Head injury 8.63 (4.90-15.20) † 5.10 (1.92-13.60) 4.68 (2.87-7.64) † 
Recent hospital admission 3.35 (1.99-5.66) 5.58 (3.80-8.20) † 7.50 (5.95-9.45) † 
Eat cassava 2.85 (2.02-4.03) 4.50 (3.06-6.61) 5.96 (4.81-7.39) 
Eat soil 2.72 (1.90-3.89) 4.31 (2.81-6.61) 5.49 (4.34-6.95) 
Dog in the household 4.08 (2.53-6.56) † 4.89 (3.54-6.74) † 6.05 (4.32-8.46) 
Cat in the household 7.30 (2.74-19.46) † 4.77 (3.49-6.53) † 6.23 (4.85-8.00) 
                                                † Statistically significant different from the overall site estimate (Based on non-overlapping confidence intervals)
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Table S2: Standardized mortality ratio of death in PWE by risk factors and site 
Risk factors 
Agincourt Ifakara Kilifi 
Standardized Mortality Ratio (95%Confidence Interval) 
Eat pork 4.44 (2.63-7.50) † 3.62 (2.41-5.45) 4.53 (3.13-6.56) 
Snore > 3 nights a week 2.70 (1.85-3.94) 5.33 (3.57-7.95) † 6.74 (5.36-8.48) † 
BMI <18 10.53 (1.48-74.74) 5.53 (2.07-14.73) 14.25 (8.44-24.06) † 
BMI 18-24 13.48 (3.37-53.91) † 3.86 (1.45-10.29)  13.99 (8.28-23.62) † 
BMI 25-30 5.18 (2.69-9.95) † 5.68 (3.14-10.25) 4.94 (3.41-7.15) 
BMI 30+ 3.13 (2.15-4.57) 3.52 (2.19-5.66) † 4.25 (3.09-5.84) 
Adult specific risk factors    
Adult marital status    
Single 1.91 (0.99-3.67) 7.22 (4.35-11.98) † 12.44 (8.93-17.32) † 
Married 3.86 (2.40-6.21) 1.72 (0.77-3.84) 2.43 (1.60-3.70) 
Divorced/separated/widow 2.77 (1.64-4.68) 2.20 (0.83-5.86) 3.82 (2.22-6.57) 
Illiterate adult 4.20 (2.65-6.67) † 4.21 (2.39-7.41) 3.76 (2.75-5.14) 
Adult consuming alcohol 4.86 (2.69-8.77) † 2.07 (0.78-5.51) 2.46 (1.28-4.73) 
                                BMI: Body mass index (Kg/m2), 
                                † Statistically significant different from the overall site estimate (Based on non-overlapping confidence intervals)
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Table S2: Standardized mortality ratio of death in PWE by risk factors and site 
Risk factors 
Agincourt Ifakara Kilifi 
Standardized Mortality Ratio (95%Confidence Interval) 
Child specific risk factors    
Maternal marital status    
Married 5.34 (0.75-37.89) 9.69 (5.84-16.07) † 14.89 (10.28-21.5) † 
Single 18.51 (6.95-49.31) † 7.91 (1.11-56.13) 45.87 (11.4-183.4) † 
Divorced/separated/widow 12.69 (1.79-90.08) 11.97 (2.99-47.88) 29.11 (14.56-58.2) † 
Unemployed mother 15.74 (6.55-37.82) †  17.20 (10.69-27.6) † 
Illiterate mother 39.45 (5.56-280) † 9.62 (3.10-29.82) 18.87 (12.54-28.3) † 
Mother's history of seizure   61.25 (15.3-244.9) † 
Delivery problem-Mothers 28.61 (7.15-114.3) † 9.94 (2.49-39.74) 18.60 (8.36-41.41) † 
Difficulties crying after birth 12.99 (1.83-92.24) 20.10 (7.54-53.56) † 20.14 (6.49-62.43) † 
Difficulties breathing after birth  17.55 (5.66-54.42) † 25.02 (6.26-100.0) † 
Incomplete immunization 21.25 (2.99-150.8) †  21.59 (5.40-86.32) † 
                                         † Statistically significant different from the overall site estimate (Based on non-overlapping confidence intervals) 
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Table S2: Standardized mortality ratio of death in PWE by risk factors and site 
Risk factors 
Agincourt Ifakara Kilifi 
Standardized Mortality Ratio (95%Confidence Interval) 
Clinical history    
Age onset 0-5 4.46 (2.40-8.28) 9.45 (6.10-14.65) † 12.65 (9.66-16.55) † 
Age onset 6-12 2.36 (0.98-5.67) 6.37 (2.86-14.18) 10.25 (6.28-16.73) † 
Age onset 13-18 2.00 (0.64-6.19) 3.19 (1.20-8.49) 6.51 (3.39-12.52) † 
Age onset 19-28 3.51 (1.75-7.01) 3.59 (1.35-9.57) 5.16 (2.58-10.31) † 
Age onset 29+ 3.10 (1.93-4.99) 2.25 (1.07-4.71) 2.47 (1.61-3.78) 
Sickle cell disease   200.0 (50.0-799.9) † 
< 12 seizure per year 3.85 (2.72-5.45) † 2.45 (1.36-4.43) 4.06 (3.07-5.37) 
> 12 seizure per year 2.06 (1.11-3.84) 5.45 (3.34-8.89) 5.99 (3.87-9.29) 
Seizure type-Generalized 3.43 (2.34-5.04) 4.11 (2.62-6.44) 4.35 (2.98-6.34) 
Seizure type-Focal 3.14 (2.02-4.86) 5.78 (3.42-9.75) 7.24 (5.78-9.06) † 
Seizure type-Others   10.63 (4.78-23.66) 
                                                     † Statistically significant different from the overall site estimate (Based on non-overlapping confidence intervals)
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Table S2: Standardized mortality ratio of death in PWE by risk factors and site 
Risk factors 
Agincourt Ifakara Kilifi 
Standardized Mortality Ratio (95%Confidence Interval) 
Untreated with AED 2.81 (1.59-4.94) 3.36 (2.15-5.27) 6.29 (4.85-8.15) 
No of different type of seizure-1 3.23 (2.35-4.44) 4.37 (3.14-6.09) 5.87 (4.76-7.23) 
No of different type of seizure-2   19.53 (2.75-138.65) 
No of different type of seizure-3 2.31 (0.96-5.56) 8.58 (4.29-17.15) † 8.38 (5.41-12.99) † 
Seizure frequency-Daily 2.84 (0.92-8.81) 12.61 (6.98-22.77) † 21.05 (13.9-31.67) † 
Seizure frequency-Monthly 3.63 (2.49-5.29) † 4.49 (3.10-6.51) 5.54 (3.96-7.75) 
Seizure frequency-Weekly 2.31 (0.58-9.23) 2.08 (0.29-14.73) 15.69 (10.0-24.5) † 
Seizure time-Day & Night 3.46 (2.41-4.98) 5.25 (3.77-7.32) 7.81 (6.29-9.70) † 
Seizure time-Day 3.26 (1.85-5.74) 2.09 (0.29-14.82) 4.46 (2.96-6.71) 
Seizure time-Night 2.36 (0.98-5.66) 3.09 (1.39-6.87) 2.20 (0.82-5.85) 
                                             AED: Antiepileptic drug 
                                             † Statistically significant different from the overall site estimate (Based on non-overlapping confidence intervals) 
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Table S2: Standardized mortality ratio of death in PWE by risk factors and site 
Risk factors 
Agincourt Ifakara Kilifi 
Standardized Mortality Ratio (95%Confidence Interval) 
Imaging    
EEG general background    
Mild 2.66 (1.47-4.81) 6.06 (2.72-13.49) 8.82 (5.40-14.40) † 
Moderate 4.33 (0.61-30.70) 8.26 (2.66-25.62) 3.77 (0.94-15.09) 
Normal 2.73 (1.76-4.23) 3.33 (1.84-6.01) 3.78 (2.73-5.24) 
Severe 16.76 (6.97-40.26) † 14.37 (2.02-102.04) 21.21 (12.0-37.3) † 
EEG Asymmetry 3.94 (1.27-12.21) 19.37 (2.73-137.53) 13.80 (1.94-97.98) 
EEG Focal feature 3.35 (2.22-5.03) 3.44 (1.55-7.66) 7.04 (4.49-11.04) 
EEG epileptiform activity 5.41 (3.14-9.32) † 3.26 (1.22-8.68) 6.55 (4.18-10.26) 
EEG Focal temporal 5.00 (2.77-9.03) † 4.31 (1.62-11.47) 8.03 (5.12-12.58) † 
EEG Focal extra temporal 5.26 (2.74-10.11) † 3.21 (1.03-9.94) 5.63 (3.20-9.91) 
EEG involve Temporal lobe 8.39 (3.49-20.15) † 4.17 (1.04-16.66) 10.79 (5.98-19.49) † 
                                                   EEG: Electroencephalogram 
                                                   † Statistically significant different from the overall site estimate (Based on non-overlapping confidence intervals) 
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Table S2: Standardized mortality ratio of death in PWE by risk factors and site 
Risk factors 
Agincourt Ifakara Kilifi 
Standardized Mortality Ratio (95%Confidence Interval) 
EEG Generalized 38.84 (5.47-275.7) †  9.89 (4.11-23.75) 
EEG photosensitivity: abnormal 2.10 (0.30-14.93) 31.67 (11.88-84.37) 13.08 (3.27-52.28) 
EEG hyperventilation: abnormal 2.74 (0.88-8.50) 3.48 (0.49-24.68)  
EEG Summary-Abnormal 4.10 (2.67-6.28) † 4.45 (2.52-7.83) 6.93 (5.10-9.40) 
EEG Summary-Normal 2.14 (1.07-4.28) 4.00 (2.00-7.99) 4.01 (2.73-5.89) 
EEG Summary-Undetermined 2.21 (1.05-4.63)   
Clinical features and examination    
Falls to ground during seizure 3.55 (2.61-4.82) † 4.57 (3.26-6.39) 5.92 (4.82-7.27) 
Seizure duration-10 min+ 2.74 (0.69-10.98) 6.68 (3.34-13.36) 7.45 (5.60-9.91) † 
Seizure duration-5-9 minutes 2.97 (1.11-7.91) 4.03 (2.54-6.39) 4.17 (2.86-6.08) 
Seizure duration-< 5 minutes 3.57 (2.62-4.87) † 6.87 (3.90-12.09) † 7.13 (4.99-10.20) 
No BCG vaccine scar 4.10 (2.13-7.87) 2.63 (0.85-8.15) 3.28 (2.34-4.59) 
                                              EEG: Electroencephalogram, BCG: Bacillus Calmette–Guérin 
  † Statistically significant different from the overall site estimate (Based on non-overlapping confidence intervals) 
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Table S2: Standardized mortality ratio of death in PWE by risk factors and site 
Risk factors 
Agincourt Ifakara Kilifi 
Standardized Mortality Ratio (95%Confidence Interval) 
Burn marks 3.93 (2.23-6.91) 5.25 (2.50-11.01) 8.21 (5.71-11.82) † 
Systolic blood pressure: > 140 3.60 (2.17-5.97) 3.86 (1.61-9.28) 4.16 (2.76-6.26) 
Diastolic blood pressure: > 90 3.25 (1.92-5.48) 3.15 (1.18-8.39) 8.29 (5.16-13.34) † 
Pre-existing neurological 3.54 (2.20-5.70) 10.94 (6.06-19.75) † 15.35 (10.80-21.8) † 
Cognitive impairment 4.32 (2.69-6.96) † 9.80 (5.10-18.84) † 24.38 (18.14-32.7) † 
Motor impairment 2.61 (1.17-5.81) 24.76 (10.31-59.4) † 18.77 (13.77-25.5) † 
Previous status epilepticus  14.48 (4.67-44.90) † 11.44 (8.17-16.0) † 
Febrile seizure   12.78 (8.56-19.0) † 
History of encephalopathy  20.02 (2.82-142.09) 13.05 (8.59-19.8) † 
History of febrile seizure 14.95 (5.61-39.83) † 6.00 (3.00-11.99) 11.73 (7.99-17.23) † 
                                      † Statistically significant different from the overall site estimate (Based on non-overlapping confidence intervals) 
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Abstract 
Background 
Despite being the most affordable alternative, most countries in SSA opt not to use 
VA due to financial and human resources constrains. Probabilistic and mathematical-
based models have recently emerged as convenient and affordable alternative to 
physician in assigning causes of death in developing countries. 
Objective 
This study assess the design, process and output of InterVA-4 in ascertaining possible 
causes of death in people diagnosed with epilepsy in Studies of Epidemiology of 
Epilepsy in sub-Saharan Africa (SEEDS). 
Methods 
We reviewed the InterVA-4 model assessing key issues relevant to accuracy in predict 
causes of death in epilepsy specifically on signs, symptoms, and conditions, 
unconditional probabilities for causes of death, conditional probabilities for indicators  
and pre-defined list of causes of death. 
Results 
The assessment indicated that, InterVA-4 produces valuable data on causes of death 
statistics in PWE. Four area of improvements include; i) revising probabilities of signs 
and symptoms related to injuries, accidents, children, and depression, ii) creating 
separate categories for SE and SUDEP, iii) incorporating text mining technique 
techniques in capturing signs and symptoms that may be narrated on circumstances 
occurred prior to death as described by caretakers, and iv) proper training to 
interviewer on filling VA forms. 
 
91 
 
Conclusion 
Regular updates of the model is critical when more knowledge on risk factors for 
epilepsy are premature mortality are generated. 
Keywords: Epilepsy, text mining, verbal autopsy, InterVA-4, SUDEP, SE 
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Background 
With nearly 75% of deaths happen at home and never get to the hospital for post-
mortem investigation, causes of death statistics is nearly impossible to produce in 
most SSA countries (Jha, 2014). Verbal autopsy (VA) provides convenient and 
affordable alternative to post-mortem in producing causes of death statistics in most 
limited resources countries. Cause of death assignment for every death is normally 
certified with two independent trained physicians and in some cases a third physician 
is called in case of disagreement.  
With considerable limited resources, most SSA countries do not opt for death 
certification with VA as it require field VA interviewer and the use of multiple physicians 
to certify every death through time demanding review of VA questionnaires. 
Probabilistic and mathematical-based models have recently emerged as convenient 
and affordable alternative to physician in assigning causes of death in developing 
countries (Garenne, 2014). The most popular models that have rigorously reviewed 
and validated are Inter-VA, Random Forest, Tariff, Simplified Symptom Pattern (SSP) 
and King-Lu (Desai et al., 2014, Murray et al., 2014). The methods take use of signs, 
symptoms, and circumstances occurred prior to death and automatically determine 
probable causes of death at population level.  
Due to the growing use of these automatic models especially in Health and 
Demographic Surveillance System (HDSS) and other research settings, it is essential 
to understand their reliability and performance in accurately producing causes of death 
in the population. Murray’s publication compared automated models with 12,535 death 
cases from diverse populations for which the true cause of death had been clinically 
established and concluded that Tariff, SSP, and RF outperformed physician coding in 
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different sub-population and for the majority of causes of death investigated (Murray 
et al., 2014).  
Causes of death statistics are valuable public health tools needed in developing 
effective preventative measures aimed at reducing premature mortality in people with 
epilepsy PWE (Mu et al., 2011a). Critical to epilepsy is estimating epilepsy-related 
mortality rate as it is closely linked to access to care and treatment in PWE. The most 
relevant epilepsy-related causes of death accounting for majority deaths are in PWE 
are status epilepticus (SE), sudden unexplained death in epilepsy (SUDEP) and 
injuries (Walker, 1972, Gilmore et al., 2015). Epilepsy-related cause’s accounts for 
majority of death in PWE epilepsy in SSA compared to developed country possibly 
due to low coverage of interventions such as antiepileptic drugs (AED) aimed at 
managing epileptic seizures (Ngugi, 2012). 
Several studies have VA process in estimating neurological-related causes of deaths 
in LMIC focusing among others on epilepsy, stroke and cerebrovascular diseases 
(Mateen et al., 2012). To our best knowledge, there has been no study that has 
critically accessed the applicability of automated tools in accurately predicting causes 
of death in PWE.  
This article assess the design, process and output of InterVA-4 in ascertaining 
possible causes of death in people diagnosed with epilepsy in Studies of Epidemiology 
of Epilepsy in sub-Saharan Africa (SEEDS). The decision to assess InterVA-4 model 
is based on the fact that SEEDS sites and most HDSS sites are currently using the 
software for research purpose with substantial number of staff being trained on its 
application (Murray et al., 2014). 
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 Methods 
Study settings and populations 
SEEDS studies were designed to systematically collect comparable data on the 
prevalence and mortality of active convulsive epilepsy (ACE) in population-based 
house-to-house surveys (Ngugi et al., 2013a). The study populations were living in 
poor rural districts of Ifakara in Tanzania (Geubbels et al., 2015), Agincourt in South 
Africa (Kahn et al., 2012), and Kilifi in Kenya (Scott et al., 2012). Cohort of 1,308 
people identified with ACE are reported in this study; 366 in Ifakara, 245 in Agincourt, 
and 697 in Kilifi (Scott et al., 2012). The cohorts have been under HDSS’s continuous 
surveillance since diagnosis with the median follow-up durations of 7, 6 and 8 years in 
Agincourt, Ifakara and Kilifi, respectively.  
Mortality assessment and verbal autopsy 
Mortality assessment is conducted during continuous surveillance of updates of 
demographic events routinely implemented 1-3 times annually. Cause of death is 
ascertained using verbal autopsy (VA) because post-mortem examinations are not 
conducted in most LMIC (Sankoh et al., 2014a, Mikkelsen et al., 2015). VA involves 
in-depth structured interviews of the care taker of the diseased on signs, symptoms, 
conditions and health-seeking choices prior to death using structured questionnaires. 
Standard VA questionnaires adopted from World Health Organization (WHO) used in 
all study sites (World Health Organization, 2004). Questionnaires are further reviewed 
by trained physicians who at the end of process assign the cause of death using 
International Disease Classification version 10 (ICD10) (World Health Organization, 
2004).  
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InterVA-4 model 
InterVA-4 model is designed to produce causes of death using probability theorem 
conceived by Bayes (Bayes, 1991). Bayes’ theorem provides the probability of death 
from a particular cause (an event), based on symptom preceding death (prior 
knowledge) that might be associated to that cause. We describe the description of the 
theorem as detailed in the original article on the recent InterVA-4 model(Byass et al., 
2012). If Ci represent a causes of death and Ij symptoms, then, probability of death 
from cause 𝑖 condition of observing 𝑗 symptom is defined as;     
P(Ci|Ij)=
P(Ij|Ci)×P(Ci)
P(Ij|Ci) ×P(Ci)+P(Ij|!Ci) ×P(!Ci)
 
where P(!Ci)=1-P(Ci). 
Using a normalizing assumption, probabilities for each cause can be calculated such 
that conditional probability over all causes totals to 1: 
P(Ci|Ij)=
P(Ij|Ci)×P(Ci)
∑ P(Ci)
𝑚
𝑖=1
 
Using an initial set of unconditional probabilities for causes of death P(Ci) (also can be 
denoted as P(Ci|I0) and a matrix of conditional probabilities for indicators P(Ij|Ci), it is 
possible to repeatedly apply the same calculation process for each indicator (I1 … I𝑛)  
that applies to a particular death: 
P(Ci|I1…n)=
P(Ij|Ci)×P(Ci|I0…n-1)
∑ P(Ci|I0…n-1)
m
i=1
 
96 
 
Model assessment 
We reviewed the InterVA-4 model assessing key issues relevant to accurately predict 
causes of death in epilepsy specifically on symptoms I1 … I𝑛 , unconditional 
probabilities for causes of death P(Ci|I0) , conditional probabilities for indicators 
P(Ij|Ci) and pre-defined causes of death list Ci … Cm. 
Results 
Recent mortality status of PWE in SEEDS cohort is summarized in  Table 5-1. 
During mortality surveillance, overall 188 (14%) died; 43 (12%) in Ifakara, 39 (16%) in 
Agincourt and 109 (17%) in Kilifi. Causes of death from InterVA-4 were available in 
167 (89%) deaths ( Table 5-5). 
 Table 5-1: SEEDS residency and mortality status 
 
Agincourt Ifakara Kilifi Total 
Initial cohort size 245 366 697 1,308 
Lost to follow-up 2 4 27 33 
Final cohort 
    
Sex 
    
Males 128 171 340 639 
Females 115 191 327 633 
Age 
    
0-5 9 20 22 51 
6-18 43 113 233 389 
19-49 138 190 344 672 
50+ 53 39 71 163 
Total 243 362 670 1,275 
Residency status 
    
Alive 166 222 369 757 
Out-migration 41 97 192 330 
Deaths 36 43 109 188 
Median follow-up (years) 7.4 6.3 8.6 
 
InterVA-4 accept 245 signs, symptoms, conditions, demographic status, and health 
care seeking practices from standard VA tools, preferably WHO VA instruments of the 
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year 2012. Signs, symptoms and conditions relevant to epilepsy were age, sex, history 
of epilepsy, sudden death, convulsions, convulsions that lasting for 10 or more 
minutes, mental confusion, depression and injuries. 
Probabilities for sign and symptoms leading to death conditioning on disease status 
(P(Ij|Ci)) are estimated from a diversity of incomplete sources and moderated by 
expert opinion as there are no reliable source of data quantifying these probabilities. 
In case of expert opinion, meetings constituting expert of different discipline were 
convened to quantify relationships between indicators and causes. The latest scale of 
perceived probability is presented in Table 5-2. 
Table 5-2: Qualitative probability scale used by expert  
Label Value Interpretation 
I 1 Always 
A+ 0.8 Almost always 
A 0.5 Common 
A- 0.2  
B+ 0.1 Often 
B 0.05  
B- 0.02  
C+ 0.01 Unusual 
C 0.005  
C- 0.002  
D+ 0.001 Rare 
D 0.0005  
D- 0.0001  
E 0.00001 Hardly ever 
N 0 Never 
Source: Glob Health Action 2012, 5 
The highest probabilities (1-0.1) for sign and symptoms leading to death for people 
with epilepsy are described in Table 5-3. In the table, probabilities for convulsions and 
history of epilepsy were 1 in PWE. Probabilities for sudden death and convulsions 
lasted 10 minutes or more were considered high in PWE (0.8). 
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Table 5-3: Top probabilities of signs and symptoms in people with epilepsy 
Signs, symptoms, conditions, demographic status Probability Label 
History of epilepsy 1.00 Always 
Convulsions 1.00 Always 
Died suddenly 0.80 Almost always 
Convulsions lasted 10 minutes or more 0.80 Almost always 
Male 0.50 Common 
Female 0.50 Common 
Duration of final illness < 3 weeks 0.50 Common 
Duration of final illness 3 weeks or more 0.50 Common 
Dry season 0.50 Common 
Headache 0.50 Common 
Unconsciousness started suddenly 0.50 Common 
Convulsions lasted less than 10 minutes 0.50 Common 
Became unconscious immediately after convulsions 0.50 Common 
Received vaccines as appropriate for age at death 0.50 Common 
Age 65+ years 0.20 Common 
Age 50-64 years 0.20 Common 
Age 15-49 years 0.20 Common 
Age 5-14 years 0.20 Common 
Wet season 0.20 Common 
Unconscious for at least 24 hours before death 0.20 Common 
Cough lasting < 3 weeks 0.10 Often 
Diarrhoea lasting < 2 weeks 0.10 Often 
Discharged from hospital very ill 0.10 Often 
 
Children under five, history of depression and mental confusion and accidents were 
assigned the least probabilities (Table 5-4).  
Table 5-4: Least probabilities of signs and symptoms in people with epilepsy 
Sign, symptom, condition, demographic status Probability Label 
Age 1-4 years 0.02 Often 
Age 1-11 months 0.02 Often 
History of depression 0.005 Unusual 
Mental confusion for more than 3 months 0.005 Unusual 
History of mental confusion 0.002 Unusual 
Suffered any injury or accident that lead to death 0.00001 Hardly ever 
Road traffic accident 0.00001 Hardly ever 
Injured in non-road transport accident 0.00001 Hardly ever 
Accidental fall 0.00001 Hardly ever 
Drowning 0.00001 Hardly ever 
Burns 0.00001 Hardly ever 
Violence/assault 0.00001 Hardly ever 
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The model is designed to produce 62 causes of deaths that are aligned with the 
International Classification of Diseases version 10 (ICD-10). Special category is 
assigned to deaths of unknown cause. SUDEP and SE are not separately included in 
the list of causes of death. One category is assigned to all epilepsy deaths which was 
equivalent to ICD10 codes for epilepsy (G40) and status epilepticus (G41). Analysis 
of deaths in PWE resulted in 19 causes of deaths of death, where 46 were directly or 
indirectly related to epilepsy and 121 were unrelated to epilepsy ( Table 5-5). 
Proportion of death attributable to epilepsy (proportionate mortality ratio) (PMR) was 
estimated at 14.4%. There were more epilepsy-unrelated deaths (PMR=72.5%) 
compared to epilepsy-related death (PMR=27.5%). Epilepsy and accidents accounted 
for 14.4% and 13.1% of all epilepsy-related deaths. The leading causes of epilepsy-
unrelated death were HIV/AIDS related death (13.8%), neoplasm (11.4%), stroke 
(6.6%), and acute cardiac diseases (5.4%). 
 Table 5-5: Causes of deaths in people with epilepsy in SEEDS cohort 
Epilepsy-related Unrelated 
 Deaths PMR  Deaths PMR 
Direct   
Acute resp. infect incl. 
pneumonia 10 6.0 
Epilepsy 24 14.4 HIV/AIDS related death 23 13.8 
Indirect   Malaria 5 3.0 
Falls 4 2.4 Meningitis and encephalitis 6 3.6 
Downing 4 2.4 Pulmonary tuberculosis 8 4.8 
Burns 5 3.0 Neoplasm 19 11.4 
Intentional self-harm 3 1.8 Diabetes mellitus 5 3.0 
Traffic accidents 5 3.0 Acute cardiac diseases 9 5.4 
Poisoning from plant/animal 1 0.6 Stroke 11 6.6 
   COPD including Asthma 8 4.8 
   Maternal death 5 3.0 
   Others 12 7.2 
Total 46 27.5  121 72.5 
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Discussion 
Data collection 
Signs, symptoms and conditions relating to a disease of interest play an important role 
in accurately determining InterVA-4 the causes of death. Therefore, proper filling of 
the structured VA questionnaires with sufficient amount information plays an important 
role in the use of automated tools in general. With respect to epilepsy, history of 
epilepsy, convulsions, sudden death and convulsions lasted 10 minutes or more were 
the most important conditions highly likely to identify epilepsy deaths.  
Case 1 represents a scenario where the four key conditions were not captured; thus 
InterVA-4 classified the death as undetermined (Table 5-6). A review of circumstances 
occurred prior to death indicates the cause was possible epilepsy based on narratives 
from caretaker who reported; 
“The deceased was not sick even though he was epileptic. On the event day after 
lunch he went for a walk. He came back without notice. The next day he was found 
dead when family members tried to wake him up for farm activities” 
This probable epilepsy case was not picked by InterVA-4 mainly because the 
interviewer did not capture sudden death and history of epilepsy in the questionnaire 
despite being reported in narrative. Sudden deaths may be the most difficult cases for 
InterVA-4 to capture when the four key condition are not properly collected.   
Probabilities of signs, symptoms and conditions 
The probability for accidents and injuries in PWE was perceived to be extremely low 
by expects therefore the software was not primarily programmed to link epilepsy 
deaths with accidents. Most accidents-related deaths in PWE are attributed to epileptic 
seizures (Bifftu et al., 2017); however, InterVA4 software categorized most of these 
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deaths as accidents. Here is an example (Case 2) with InterVA-4 reporting “Falls” as 
the cause of death but physician coded this as epilepsy death; 
“The deceased had epileptic fit. He fell down and died instantaneously” 
Here is another narrative (Case 3) of a death of a person with history of epilepsy where 
InterVA-4 coded the death as “Accident exposure to smoke fire & flame” that should 
have otherwise be reported as epilepsy death. 
“The deceased had a fire accident. He was burnt all over the body. He was sent to 
Mngeta healthcare centre and later he was referred to St. Francis hospital in Ifakara 
where he continued with treatment. However, his condition worsened and eventually 
he died” 
An additional input indicator linking accidents to epilepsy may be necessary. The 
question could for example be phrased “did accident occurs during seizures?”. The 
main challenge here is the configuration choice on whether underlying or immediate 
cause of death information is preferred (Benn et al., 2009). Underlying cause of death 
if often preferred in public health due to its relevance in producing vital statistics related 
to cause of disease rather than its effect. Future configuration of automated cause of 
death should re-consider this issue so as to enable reliable burden of epilepsy 
mortality be estimated. 
Apart from accidents and injuries, higher perceived probabilities of conditions related 
to young age (younger than 5), history of depression, and history of mental confusion 
should be considered as these conditions are common in PWE than general 
population. In SEEDS study’s population, age onset of epilepsy is highest in at age 0 
through 5 and lowest in older ages (50 + year) (Figure 5-1) (Ngugi et al., 2013b).   
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Source: Lancet Neurol 2013; 12: 253–63 
Figure 5-1: Age-specific prevalence and age at onset of convulsive epilepsy 
Experts on the other hand perceived a constant probability of 0.2 in age categories 5-
14, 15-49, 50-64, and 65+. On the other hand, a lowest perceived probability of 0.02 
was deliberated for children younger than 5 years. The current perceived age-related 
conditional probability do not reflect the epidemiological profile of SSA countries, 
therefore needs to be adjusted. Depression and/or anxiety in PWE is not routinely 
diagnosed in most LMIC (Mbewe et al., 2013), however, it is estimated that 15 to 60% 
of PWE are likely to suffer from these conditions (Gilliam et al., 2005, Jacoby et al., 
1996, Heersink et al., 2015). 
Pre-defined list of causes of death 
InterVA4 highly associated sudden death and seizures lasting for at least 10 minutes 
with likelihood of epilepsy deaths, however, specific death’s categories for SUDEP and 
SE were not created respectively. Status epilepticus (SE) (persistent convulsive 
seizures lasting for over 5 minutes) is common in PWE, reported to be associated with 
premature mortality in PWE. Verbal autopsy information collected from caregiver of 
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the diseased can provide valuable information in identified SUDEP (Lathers et al., 
2009). SUDEP is not only excluded in the list of cause of death in InterVA4, but also 
with ICD10 in which “Epilepsy, unspecified” code is often used. On the other hand, SE 
is widely recognized and specific category has been assigned (i.e. G41.-). 
The distinction between SUDEP and SE is essential in understanding and determining 
the risk factors and monitoring deaths in PWE.  Mortality rate generally increased in 
PWE; however SE is associated with 61% increase in mortality. On the other hand, 
PWE without SE have been reported to experience 16% increase in mortality. In a 
lifetime of PWE, it is estimated that nearly 10% of adults and 20% of children will status 
epilepticus (Chin et al., 2004, Hauser, 1990). Creating a separate coding for SE could 
be improve with further probing for seizures lasted at least 10 minutes with an 
additional question such as “did seizure ended with death”. 
Circumstances prior to death 
VA interviews collects substantial amount of text information that are relevant in 
establishing causes of death in PWE. The WHO 2008 version of VA questionnaires 
requires the interviewer to collect and document the following information when 
available; 1) Short narrative of circumstances occurred prior to death from caretaker 
of the diseased, 2) Cause of death according to their best understanding of the patient, 
3) Cause of death as reported on death certificate if death certificate was provided, 4) 
Cause of death reported on burial permit, 5) Post-mortem report, 6) Antenatal care 
card, 7) Prescription information, 8) Medical records, 9) Discharge cards, and 10) 
Laboratory results.  
These free text narratives provides valuable clue in differentiating epilepsy and 
unrelated causes of death and improves the reliability and precision of death 
104 
 
certification among physicians (Table 5-6). Case 1 and 4 below provides a typical 
example of free text that may provide additional clue in additional to signs and 
symptoms entered in the model.  
“The deceased had epilepsy problem. When he had this problem, he encountered high 
fever, body inflammation, cough and tighten ribs. He was sent to St Francis hospital 
for further treatment. His condition worsened and he died” 
In majority of cases InterVA-4 perfectly captured what might be the real cause of death. 
For example in Case 4, neoplasm (02.03 Respiratory neoplasms) was assigned in a 
case with the narrative below; 
“The deceased had epilepsy problem. When he had this problem, he encountered high 
fever, body inflammation, cough and tighten ribs. He was sent to St Francis hospital 
for further treatment. His condition worsened and he died” 
In some cases physicians seems to have capture the possible cause of death right 
compared to InterVA-4 based on narratives as illustrated in the Case 8 where 
physician decided the cause of death was Malaria while InterVA-4 model capture this 
as meningitis (01.07 Meningitis and encephalitis) 
“The deceased suffered from a high fever as well as epileptic fit. The doctor prescribed 
ALU (for malaria treatment) however his condition worsened and he eventually died” 
Unfortunately, these text narratives are not utilized by automated models. Text mining 
technique can be used to analyse these text and improve predicted causes of death 
in epilepsy. Text mining involves computational extraction of selected information from 
unstructured text data. (Singh, 2005) The methods has shown promising results in 
medical research including in identify rate diseases and adverse drug events in clinical 
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trials (Harpaz et al., 2014). Future development of automated causes of death 
software’s needs to invest in integrating text mining in order to improve accuracy of 
causes of death statistics. 
Cause specific mortality fraction 
Epilepsy-related death in selected studies from SSA is reported to contribute to 30 up 
to 60% of deaths in PWE (Ngugi et al., 2014c, Carpio et al., 2005, Kamgno et al., 
2003b, Kaiser et al., 2007). In developed countries where epileptic seizures are 
properly managed, contribution of epilepsy-related causes of deaths are lower than 
causes unrelated to epilepsy such as neoplasms, cerebrovascular diseases, and 
cardiac diseases (Forsgren et al., 2005b, Cockerell et al., 1994, Nilsson et al., 1997, 
Lhatoo et al., 2005, Benn et al., 2009). 
Indirect causes are those associated with events such as falls, burns, drowning and 
road traffic accidents. Injuries in PWE are implicated to epilepsy due to presence of 
unprovoked seizures and in some countries are the leading causes of death in PWE  
(Si et al., 2016). The risks are much higher in active convulsive epilepsy (ACE) were 
death is likely to be the ultimate outcome of injuries. 
There were more epilepsy-unrelated deaths (72.5%) compared to epilepsy-related 
death (27.5%) when InterVA-4 model was applied. This may be possibly explained by 
the fact that, most epilepsy-related accidents were coded as accidents. In previous 
analysis of Kilifi and Agincourt cohort with fewer deaths and use of physicians; 
proportion of epilepsy related death were approximately 50% of all death, with 
accidents and injuries accounting for about 10% (Wagner et al., 2015, Ngugi et al., 
2014a). Stroke and acute cardiac diseases were coded in majority of deaths (12%) 
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possibly due to increased rate of cerebrovascular diseases in most SSA countries 
(Feigin et al., 2015). 
High number of HIV/AIDS related death may be associated with the variations in 
unconditional probability of death from HIV/AIDS (P(Ci|I0)) between South Africa 
(Agincourt) and East Africa (Tanzania and Kenya). The model allows location specific 
configuration on these diseases to either be “high” (1 death per 100), “low” (1 death 
per 1000) or “very low” (1 death per 10000). Agincourt used “high” prevalence setting 
while Tanzania and Kenya applied “low” settings for HIV/AIDS death. 
Conclusions 
Verbal autopsy procedure provide an opportunity for physicians to determine cause of 
death by reviewing detailed structured questionnaires of signs, symptoms, health 
conditions, and circumstances occurred to the diseased provided by caretakers. 
Causes of death certification are done using ICD10 intended to promote accuracy, 
consistency and comparability of causes of death across time and places. Despite 
being the most affordable alternative, most countries in SSA opt not to use VA due to 
financial and human resources constrains. 
InterVA-4 provides a unique opportunity to LMIC aiming at improving causes of death 
statistics. The assessment indicated that, InterVA-4 produces valuable data on causes 
of death statistics in PWE. The model could be further improved with continuous 
improvement specifically in; i) revising probabilities of signs and symptoms related to 
injuries, accidents, children, and depression/anxiety, ii) creating separate categories 
for SE and SUDEP, iii) incorporating text mining technique techniques in capturing 
signs and symptoms that may be narrated on circumstances occurred prior to death 
as described by caretakers, and iv) proper training to interviewer on filling VA forms. 
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Table 5-6: Narrative of reported on circumstances occurred prior to death 
Case Epilepsy Accident InterVA-4  ICD10 Narrative of circumstances prior to death 
1 No No 
 
Undetermined  The deceased was not sick even though he was epileptic. On the event day after lunch 
he went for a walk. He came back without notice. The next day he was found dead when 
family members tried to wake him up for farm activities. 
2 Yes Fall Other transport accident G40.9 The deceased had epilepsy. He fell down, had epileptic fits, and then died 
instantaneously. 
3 Yes Burn Accident expos to smoke 
fire & flame 
G40.9 The deceased had a fire accident. He was burnt all over the body. He was sent to 
Mngeta healthcare centre and later he was referred to St. Francis hospital in Ifakara 
where he continued with treatment. However, his condition worsened and eventually he 
died  
4 Yes No Respiratory neoplasms  The deceased had epilepsy problem. When he had this problem, he encountered high 
fever, body inflammation, cough and tighten ribs. He was sent to St Francis hospital for 
further treatment. His condition worsened and he died 
5 Yes Fall Other transport accident G40.9 The deceased had epilepsy. On the event day, he fell in a watery place and died 
instantly. 
6 Yes Drown Other transport accident  The deceased went for a bath. He fell in a pit and died.  
7 Yes Fall Acute respiratory infect 
including pneumonia 
 The deceased suffered from epileptic fit. He encountered hemoptysis and abdominal 
pain. He was sent to Mbingu dispensary however his condition worsened until he died. 
 
8 Yes No Meningitis and 
encephalitis 
B54 The deceased suffered from a high fever as well as epileptic fit. The doctor prescribed 
ALU (for malaria treatment) however his condition worsened and he eventually died 
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Abstract 
Background: Neurological disorders (ND) have a profound consequence on human 
productivity, quality of life and survival. There are limited data on the burden of ND in 
Tanzania due to insufficient coverage of civil and vital registration systems. 
Objectives: This study was conducted to estimate mortality of ND in all ages in 
Tanzania using data from the Sample Vital Registration with Verbal Autopsy (SAVVY) 
study. 
Methods: Multistage random sampling was employed to select 23 districts, 1397 
census enumeration areas and 154,603 households. During the baseline survey 
conducted between 2011 and 2014, deaths which occurred 12 months prior to the 
baseline survey were documented followed by verbal autopsy interviews. Causes of 
death were certified using International Classification of Diseases. 
Results: The baseline survey enrolled a total of 650,864 residents. A total of 6645 
deaths were reported to have occurred 12 months before the date of survey. Death 
certification was available for 5225 (79%) deaths. The leading causes of death were 
cerebrovascular diseases with a cause-specific mortality fraction (CSMF) of 1.64% 
(95% CI: 1.30–1.99) and 3.82% (95% CI: 2.92–4.72) in all ages and adults older than 
50 years, respectively. Stroke accounted for 92% of all cerebrovascular deaths. 
Mortality of epilepsy was estimated with a CSMF of 0.94% (95% CI: 0.68–1.20); 
meningitis with a CSMF of 0.80% (95% CI: 0.56–1.04); cerebral palsy and other 
paralytic syndromes with a CSMF of 0.46% (95% CI: 0.27–0.65); and intrauterine 
hypoxia in neonates with a CSMF of 2.06% (95% CI: 1.12–3.01). Overall, mortality of 
ND was estimated with a CSMF of 4.99% (95% CI: 4.40–5.58). 
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Conclusions: The SAVVY survey provides estimates of mortality burden of ND in 
Tanzania. The study provides a basis for monitoring trends of ND and contributes to 
advancing knowledge of the burden of diseases. Integrating morbidities measures into 
the SAVVY design will provide comprehensive measures of burden of ND taking into 
account lifetime disabilities created by ND. 
Keywords: Cerebrovascular, epilepsy, meningitis, cerebral palsy, intrauterine 
hypoxia.
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Background 
Neurological disorders (ND) have a profound consequence on human 
productivity, quality of life and survival in developed and developing countries. 
The most prevalent ND globally include dementia (progressive memory loss); 
Parkinson’s (impaired motor system); multiple sclerosis (problem with vision, 
movement, sensation or balance); epilepsy (sudden recurrence of unprovoked 
seizures); and stroke (two or one sides paralysis or numbness). 
Dementia and Parkinson’s disease are the most common ND in most developed 
countries with a reported increasing trend (Mackenbach et al., 2014). The 
increases in ND’s mortality in developed countries are higher than increases in 
other chronic diseases such as cancer and diseases of circulation (Pritchard et 
al., 2017). Substantial proportions of neurological disorders in developed 
countries are thought to be attributed to increased life expectancy (aging) and 
unhealthy lifestyle (Chin et al., 2014). 
In most developing countries, on the other hand, etiological studies reported 
that most ND originate from infections of the central nervous system (CNS)and 
brain trauma (Birbeck, 2001, Winkler et al., 2008c, Winkler et al., 2008b, Winkler et 
al., 2009a). The most common reported ND in sub-Saharan Africa (SSA) include 
stroke, epilepsy, meningitis, paraparesis, neuropathies, and traumatic brain 
injuries (Howlett, 2014, Winkler et al., 2009c, Smart et al., 2017).  
In 2010, Global Burden of Disease (GBD) report indicated that non-
communicable diseases (NCD) accounted for 54% of global burden of disease 
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(morbidities and premature mortality); an increase from 43% in 1990 (Murray et 
al., 2012). With the rapid epidemiological transition in developing countries, 
mortalities associated with age-related and lifestyle ND are expected to 
increase in the presence of infection-related ND; therefore, deliberate efforts in 
understanding the epidemiology of ND is necessary. 
The morbidity and mortality burden of stroke as an example is reported to 
increase in developing countries, accounting for 75% of global deaths and 81% 
stroke-related Disability Adjusted Life Years (DALYs) (Feigin et al., 2015). 
In SSA, there is a paucity of national data on the epidemiology of ND. Most 
references of national estimates of the burden of NDs are cited from the 
modelled estimates of GBD study. However, for most developing countries, 
input parameters used in modelling are obtained from inadequate vital 
registrations records or small local studies. Coverage of mortality and morbidity 
for China and India as an illustration was only 15% and 1%, respectively, for 
mental, neurological and substance abuse at the time GBD for the year 2013 
was estimated (Baxter et al., 2016). Model-based estimates from GBD not only 
are free from coverage limitations but also considerable reliance on geospatial 
data and experts' opinions (Feigin et al., 2015). Global estimates in some 
countries and cases deviate from the true epidemiological profile and thus are 
deemed unreliable for local planning by policy makers  (AbouZahr et al., 2017). 
Tanzania lacks national mortality data on ND due to the insufficient coverage of 
civil and vital registration systems as in many SSA countries (Dalal et al., 2011, 
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Dewhurst et al., 2012). Poor cover-age of civil and vital registration systems at a 
national level and over-reliance on global estimation have concealed crucial 
statistics necessary in understanding population health, improving health 
outcomes and monitoring disease trends (Pakpoor et al., 2017, Phillips et al., 
2015). Several studies have linked higher coverage of civil and vital statistics 
with improved health outcomes in several countries (Phillips et al., 2015).  
Several studies have linked higher coverage of civil and vital statistics with 
improved health outcomes in several countries (MEASURE Evaluation, 2018). 
SAVVY stands of SAmple Vital registration with Verbal autopsY, which is a 
community-based system implemented in a nationally representative cluster sample 
(MEASURE Evaluation, 2018). Since nearly 75% of deaths occur at home in most 
developing countries and cause of death determination is nearly absent in Tanzania 
as in many Low and middle-income countries (LMIC), VA remained the only tool 
reliable for providing vital statistics information (Mikkelsen et al., 2015, Sankoh et al., 
2014a, Setel et al., 2006). VA remained the only tool reliable for providing vital 
statistics information. 
We examined the SAVVY data to estimate mortality rates of the neurological 
disorders by sex, age, residence, and zones in Tanzania. 
Material and Methods 
Design and sampling 
SAVVY is a community-based system implemented in a nationally 
representative cluster sample (MEASURE Evaluation, 2018). Multistage random 
sampling was employed to select 23 districts, 1397 enumeration areas, and 
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154,603 households from mainland Tanzania, stratified by residency and zones 
to meet the proposed overall sample. The sampling frame for this study was 
based on the 2002 Population and Housing Census for Tanzania Mainland. A 
full description of design and methods has been published elsewhere (Kabadi et 
al., 2015). Figure 6-1 shows the map of Tanzania with shaded sampled districts. 
 
Figure 6-1: Geographic locations of 23 SAVVY districts on Tanzania map 
Baseline census 
Baseline censuses were sequentially conducted in 23districtsbetween 2011 
and 2014 in order to establish denominators for estimating different 
demographic indicators. During the baseline census, the socio-demographic 
information of the household members was collected which included: age, sex, 
education, and relationship to head of household. Deaths that had occurred 
during the 12 months prior to the census date were retrospectively documented 
in all households. 
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Verbal autopsy 
Verbal autopsy (VA) interviews were conducted for all documented deaths by 
trained SAVVY VA coordinators with the most appropriate person in the 
household after setting up an appointment. Standard verbal autopsy 
questionnaires (2007 version) that have been developed by the World Health 
Organization (WHO) in collaboration with other stakeholders were used (World 
Health Organization, 2007). Completed VA questionnaires were sent to 
physicians for a cause of death certification. 
Physician’s assignment of causes of deaths 
The cause of death for each interviewed death was determined using the 
International Classification of Diseases, tenth revision (ICD-10), as published 
by the WHO (World Health Organization, 2004). Each VA questionnaire of the 
deceased was reviewed independently by two physicians to ascertain causes 
of deaths and produce death certificates. In case of discrepancies, two 
independent physicians met to resolve the discrepancies. If disagreed, the 
cause of death was declared undetermined (meaning there was no sufficient 
information to determine the cause of death). Physicians reviewing VA 
questionnaires were medical doctors (not neurologists) independent of the 
research institution trained on death certification using ICD-10 classification.  
Death certificates were requested and documented during VA interviews. 
However, these certificates were rarely available and coded in ICD-10; 
therefore, for consistency reasons, we did not consider these certificates. 
Neurological causes of deaths were classified using code ranges of G00–G99 
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for diseases of nervous system, I60–69 for cerebrovascular diseases,P20 for 
intrauterine hypoxia, C71 for malignant neoplasm of brain, D33 for benign 
neoplasm of brain and other parts of the CNS, Q00–Q07 for congenital 
malformations of the nervous system, S06 for traumatic brain 
injuries/intracranial injury, and R25–R29 for symptoms and signs involving the 
nervous and musculoskeletal systems Neurological causes of deaths were 
classified using code ranges of G00-G99 for diseases of nervous system, I60-69 for 
cerebrovascular diseases and S06 for traumatic brain injuries/ intracranial injury for 
deaths (Jette et al., 2015, Roth et al., 2015).  
Statistical analysis 
National Population and Housing Census data were used to provide a basis for 
data weighting. The gross weight was estimated as the product of reciprocal of 
the probability of selection of districts within zones, enumeration area (EA) 
within districts and households within EA. Mortality rate was estimated as a 
weighted ratio of the number of deaths and population. Cause-specific mortality 
fraction (CSMF) was calculated as a ratio of 
deathsduetoaspecificcauseoverthetotalnumberofdeathsforwhichcauseofdeathi
nformationwasavailable.CSMFwere compared across the subpopulation by 
calculating the mortality rate fraction (MRF), which is the ratio of two CSMF. 
Females, urban, and age 50 and above and lake zone were set as the reference 
category for CSMF comparisons. Lake zone is known to have poor intervention 
coverage for a substantial number of health systems performance indicators; 
therefore, we set it as a reference category (Kumalija et al., 2015).  
117 
 
Results  
A total of 650,864 residents in 154,603 households were enrolled during the 
baseline census survey. There were 91, 329 (51%) households in rural areas 
and 63,274 (41%) in urban areas. The majority of households were headed by 
males (72%). The average household size was 4.5 in rural areas and 3.7 in 
urban areas. A total of 6645 deaths were documented to have occurred 12 
months prior to the baseline survey corresponding to an annual weighted crude 
death rate of 10.8 (95% CI: 10.8–10.9) deaths per1000 population. The age 
distribution of the reported deaths is shown in death pyramid in Figure 6-2.  
 
Figure 6-2: Age distribution of reported 6,645 deaths (3,509 males and 3,136 
females) from SAVVY districts 
VA interviews were conducted for 6608 (99%) of the documented 6645 deaths. 
Causes of death certification were completed for 5225 (79%) of 6608 VA 
interviewed deaths. Of 5225 deaths with complete cause of death, 872 (17%) 
were newborn aged 0–29 days (VA form 1), 1096 (21%) were children aged 29 
days−14 years (VA form 2) and 3257 (62%) were adults older than 15 years 
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(VA form 3). Causes of death could not be ascertained for 1383 deaths due to 
absence of a reliable caregiver to respond to the VA interview, incomplete VA 
inter-views, and incomplete cause of death determination by physicians, among 
other things.  
Causes of neurological deaths 
A total of 261 neurological deaths were determined; 72(27.6%) were children 
younger than 5 years, 22 (8.4%) were children aged 5–19 years, 65 (24.9%) 
were adults aged 20–49 years, and 102 (39.1%) were adults older than 50 
years. All neurological deaths were coded into30 three- or four-digit ICD-10 
causes and later grouped into nine major categories of cerebrovascular 
diseases, meningitis, epilepsy, cerebral palsy and other paralytic syndromes, 
intrauterine hypoxia, malignant and benign neoplasms of brain and CNS, 
congenital malformations of the nervous system, other neurological disorders, 
and symptoms and signs involving the nervous and musculoskeletal systems 
Table 6-1. 
Table 6-1: Distribution of causes of neurological death by age group 
 
Age group 
 
 
<5 5-19 20-49 50+ All ages 
Cerebrovascular diseases 1.4  27.7 65.7 33.0 
Stroke, not specified as haemorrhage or 
infarction 
1.4 24.6 60.8 30.3 
Hypertensive encephalopathy 
   
1.0 0.4 
Sequelae of stroke, not specified as 
haemorrhage or infarction 
  
3.1 2.9 1.9 
Sequelae of other and unspecified 
cerebrovascular diseases 
   
1.0 0.4 
Epilepsy 4.2 40.9 36.9 11.8 18.4 
Other generalized epilepsy and epileptic 
syndromes 
   1.0 0.4 
Epilepsy, unspecified 4.2 40.9 36.9 11.8 18.4 
Meningitis 34.7 22.7 10.8 4.9 16.1 
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Bacterial meningitis, not elsewhere classified 4.2 
   
1.2 
Meningitis due to other and unspecified 
causes 
1.4 
   
0.4 
Meningitis, unspecified 29.2 22.7 10.8 4.9 14.6 
Cerebral palsy and other paralytic syndromes 11.1 18.2 3.1 9.8 9.2 
Cerebral palsy 1.4 
   
0.4 
Cerebral palsy, unspecified 8.3 13.6 
  
3.5 
Hemiplegia, unspecified 
   
4.9 1.9 
Paraplegia, unspecified 
 
4.6 1.5 2.9 1.9 
Paralytic syndrome, unspecified 1.4 
 
1.5 2.0 1.5 
Intrauterine hypoxia 25.0 
   
6.9 
Malignant and benign neoplasms of brain and 
CNS  9.1 7.7 1.0 3.1 
Malignant neoplasm of brain 
 
3.1 
 
0.8 
Malignant neoplasm of spinal cord, cranial 
nerves and other parts of CNS 
 
9.1 3.1 1.0 1.9 
Benign neoplasm of brain and other parts of 
central nervous system 
  
1.5 
 
0.4 
Congenital malformations of the nervous 
system 12.5  1.5  3.8 
Congenital hydrocephalus 1.4 
 
0.4 
Congenital hydrocephalus, unspecified 4.2 
 
1.5 
 
1.5 
Spina bifida 1.4 
   
0.4 
Spina bifida, unspecified 4.2 
   
1.2 
Congenital malformation of nervous system, 
unspecified 
1.4 
   
0.4 
Other neurological disorders 4.2  6.2 2.9 3.8 
Migraine 
  
1.0 0.4 
Migraine, unspecified 
  
3.1 1.0 1.2 
Polyneuropathy, unspecified (Neuropathy 
NOS) 
  
1.5 1.0 0.8 
Hydrocephalus 4.2 
 
1.5 
 
1.5 
Symptoms and signs involving the nervous  
and musculoskeletal systems 6.9 9.1 6.2 2.9 5.4 
Other and unspecified symptoms and signs 
involving 
the nervous and musculoskeletal systems 
   
1.0 0.4 
Headache 
  
6.2 2.0 2.3 
Other and unspecified convulsions 6.9 9.1 
  
2.7 
Number of deaths 72 22 65 102 261 
 
Neurological disorders mortality 
Of the reported ND-related deaths, the leading causes were cerebrovascular 
diseases (33.0%), epilepsy (18.4%), meningitis (16.1%), cerebral palsy and 
other paralytic syndromes (CP) (9.2%), and intrauterine hypoxia (IH) (6.9%). All 
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causes mortality of ND was estimated with a CSMF of 4.99% (95% CI: 4.40–
5.59) (Table 6-2). There were no differences in CSMF among males (4.76%) 
and females (5.27%) (MRF = 0.90, 95%CI: 0.70–1.16). Compared to adults 
aged 50 years and above, mortality of ND was estimated to be lower among 
children aged 0–4 (MRF = 0.71, 95% CI: 0.52–0.97), and comparable in children 
aged 5–19 (MRF = 1.07, 95% CI: 0.64–1.72) and adults aged20–49 (MRF = 
1.07, 95% CI: 0.64–1.72). Mortality was lower by 23.0% in urban (4.35%) than 
rural (5.63%) areas (MRF = 0.77, 95% CI: 0.40–0.99). Mortality of ND was 
comparable across zones. Using census population and crude death rate of 
2012 and CSMF observed in this study, we estimated the number of 
neurological deaths to range from 18,000 to 22,000 in Tanzania in 2012. 
Table 6-2: Cause-specific mortality fraction (%) estimates of neurological disorders 
and epilepsy by sex, age, residency, and zone 
 
Neurological disorders Epilepsy 
 
D CSMF (95%CI) MFR (95%CI) D CSMF (95%CI) MFR (95%CI) 
Sex 
Males 134 4.76 (4-5.55) 0.90 (0.70-1.16) 36 1.28 (0.86-1.69) 2.37 (1.23-4.88) 
Females 127 5.27 (4.38-6.16) 
 
13 0.54 (0.25-0.83) 
 
Age 
<5 72 4.13 (3.19-5.06) 0.71 (0.52-0.97) 3 0.17 (0-0.37) 0.23 (0.04-0.84) 
5-19 22 6.25 (3.72-8.78) 1.07 (0.64-1.71) 9 2.56 (0.91-4.20) 3.45 (1.30-8.72) 
20-49 65 4.72 (3.6-5.84) 0.81 (0.58-1.12) 24 1.74 (1.05-2.43) 2.35 (1.15-5.03) 
50+ 102 5.82 (4.72-6.91) 
 
13 0.74 (0.34-1.14) 
 
Residency 
Rural 149 5.63 (4.75-6.50) 
 
30 1.13 (0.73-1.54) 0.65 (0.35-1.19) 
Urban 112 4.35 (3.56-5.13) 0.77 (0.60-0.99) 19 0.74 (0.41-1.07) 
 
Zone 
Western 31 4.74 (3.11-6.37) 0.75 (0.46-1.21) 7 1.07 (0.28-1.86) 1.00 (0.31-3.16) 
Northern 25 3.53 (2.17-4.88) 0.56 (0.33-0.93) 3 0.42 (0-0.90) 0.40 (0.07-1.65) 
Central 43 4.68 (3.31-6.04) 0.74 (0.48-1.15) 12 1.30 (0.57-2.04) 1.22 (0.46-3.45) 
Southern 
Highlands 
39 6.61 (4.60-8.61) 1.05 (0.67-1.64) 4 0.68 (0.01-1.34) 0.63 (0.14-2.37) 
Eastern 43 4.8 (3.41-6.21) 0.77 (0.49-1.18) 8 0.89 (0.28-1.51) 0.84 (0.27-2.56) 
Southern 33 4.65 (3.10-6.20) 0.74 (0.46-1.18) 7 0.99 (0.26-1.71) 0.92 (0.28-2.91) 
Lake 47 6.27 (4.54-8.01) 
 
8 1.07 (0.33-1.80) 
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Overall 261 4.99 (4.40-5.58) 
 
49 0.94 (0.68-1.20) 
 
Ref: Reference category, CSMF: Cause-specific mortality Fraction, MFR: Mortality Fraction Ratio, CI: 
Confidence interval 
 
Cerebrovascular mortality 
Cerebrovascular diseases are a category of a broader group of diseases of the 
circulatory system. Cerebrovascular diseases accounted for 19.0% of all deaths 
from diseases of circulation, after hypertension which accounted for 66.0% of 
deaths from diseases of circulation. A total of 86 cerebrovascular deaths were 
reported out of 5225 certified deaths. Among those who died of cerebrovascular 
diseases, stroke was the leading cause of death, constituting 92.0% of all 
reported cerebrovascular deaths. The remaining 8.0% constituted hypertensive 
encephalopathy, sequelae of stroke not specified as hemorrhage or infarction, 
and sequelae of other unspecified cerebrovascular diseases. The mortality of 
cerebrovascular-related deaths was estimated with a CSMF of 1.64% (95% CI: 
1.30–1.99); with a higher estimate in adults older than 50 years (3.82%) than 
adults aged 20–49(1.31%) (MRF = 3.4, 95% CI: 1.19–5.58) (Table 6-3).There 
was a comparable estimate in urban (1.98%) and rural (1.32%) populations 
(MRF = 1.5, 95% CI: 0.95–2.37). No significant differences were observed 
between lake zone and other zones. In adults older than 50 years, the mortality 
of cerebrovascular-related deaths was estimated with a CSMF of 3.82% (95% 
CI: 2.92–4.72). CSMF was lower in males (2.87%) than females (4.93%) (MRF 
= 0.58, 95% CI: 0.34–0.97), comparable in urban (4.19%) and rural (3.42%) 
(MRF = 1.23, 95% CI: 0.73–2.06), and lower in central zone (1.68%) compared 
to lake zone (6.22%) (MRF = 0.27, 95% CI: 0.08–0.76). 
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Epilepsy mortality 
Of all ND-related deaths, epilepsy accounted for 18.4%; 4.2% among children 
< 5 years, 40.9% among children aged 5–19, 36.9% among adults aged 20–49, 
and 11.8%among adults older than 50 years (Table 6-1). Unspecified convulsive 
epilepsy (98.0%) and other generalized epilepsy and unspecified epileptic 
syndromes (2.0%) were the category reported for all deaths. 
Of 5225 certified deaths, 49 were epilepsy-related with a CSMF of epilepsy of 
0.94% (95% CI: 0.68–1.20) with significantly higher estimates in males (1.28%) 
than females (0.54%) (MRF = 2.37, 95% CI: 1.23–4.88) (Table 6-2). Epilepsy 
mortality was higher in children aged 5–19 (MRF = 3.45, 95% CI: 1.30–8.72) 
and adults aged 20–49 (MRF = 2.35, 95%CI: 1.15–5.03) than adults aged 50 
years and above. Epilepsy mortality was observed to be comparable in urban 
(0.74%) and rural (1.13%) areas (MRF = 0.65, 95% CI: 0.35–1.19). Epilepsy 
mortality was also com-parable across zones.  
Table 6-3: Cause-specific mortality fraction (%) estimates of cerebrovascular 
disorders (95%CI) by sex, age, residency, and zone 
 
  Cerebrovascular diseases Cerebrovascular diseases (50+ years) 
 
D* CSMF (95%CI)  MFR (95%CI) D* CSMF (95%CI) MFR (95%CI) 
Sex 
Males 38 1.99 (1.43-2.55) 
 
27 2.87 (1.80-3.93) 0.58 (0.34-0.97) 
Females 48 1.35 (0.92-1.78) 0.68 (0.43-1.06) 40 4.93 (3.44-6.42) 
 
Age 
<5 1 0.06 (0.00-0.17) 0.02 (0.00-0.09)  
  
5-19 0 
     
20-49 18 1.31 (0.71-1.91) 0.34 (0.19-0.58) 
   
50+ 67 3.82 (2.92-4.72) 
    
Residency 
Rural 35 1.32 (0.89-1.76) 
 
29 3.42 (2.20-4.65) 
 
Urban 51 1.98 (1.44-2.52) 1.50 (0.95-2.37) 38 4.19 (2.89-5.50) 1.23 (0.73-2.06) 
Zone 
Western 11 2.14 (1.10-3.17) 0.79 (0.33-1.81) 9 6.08 (2.23-9.93) 0.99 (0.37-2.47) 
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Northern 9 1.27 (0.44-2.09) 0.59 (0.23-1.43) 7 2.30 (0.62-3.99) 0.37 (0.12-1.00) 
Central 8 0.87 (0.27-1.47) 0.41 (0.15-1.01) 6 1.68 (0.35-3.01) 0.27 (0.08-0.76) 
Southern 
Highlands 
12 2.03 (0.89-3.17) 0.95 (0.41-2.14) 10 6.54 (2.62-10.45) 1.05 (0.41-2.59) 
Eastern 18 2.01 (1.09-2.93) 0.94 (0.45-1.98) 12 3.87 (1.72-6.02) 0.62 (0.26-1.48) 
Southern 12 1.69 (0.74-2.64) 0.79 (0.34-1.78) 10 3.68 (1.44-5.91) 0.59 (0.23-1.46) 
Lake 16 1.68 (0.70-2.67) 
 
13 6.22 (2.94-9.49) 
 
Overall 86 1.64 (1.30-1.99) 
 
67 3.82 (2.92-4.72) 
 
 
Meningitis mortality  
Bacterial meningitis accounted for 16.1% of all ND deaths; 34.7% among 
children < 5 years, 22.7%among children aged 5–19, 10.8% among adults aged 
20–49, and 4.9% among adults older than 50years (Table 6-1). No viral-related 
meningitis deaths were identified by physicians. Of certified deaths, meningitis-
related mortality was estimated with a CSMF of 0.80% (95% CI: 0.56–1.04) 
(Table 6-4). Compared to adults older than 50 years (CSMF = 0.28%), meningitis 
mortality was high in children 0–4 (1.43%) (MRF = 5.02, 95% CI: 1.89–16.81) 
and those aged 5–19 years (1.42%) (CSMF= 4.98, 95% CI: 1.15–21.64). 
Meningitis mortality was comparable in urban (0.66%) and rural (0.94%) (MRF 
=0.70, 95% CI: 0.35–1.35) areas and among males (1.04%) and females 
(0.79%) (MRF = 1.04, 95% CI: 0.54–2.04). Subanalysis of meningitis mortality 
in children similar to the above indicated no differences in CSMF related to sex, 
age, residency, and zone. 
Table 6-4: Cause-specific mortality fraction (%) estimates of meningitis disorders by 
sex, age, residency, and zone 
  
  Meningitis Meningitis (age 0-19) 
 
D* CSMF(95%CI) MFR (95%CI) D CSMF (95%CI) MFR (95%CI) 
Sex 
Males 23 0.82 (0.48-1.15) 1.04 (0.54-2.04) 18 1.57 (0.85-2.29) 1.25 (0.57-2.84) 
Females 19 0.79 (0.43-1.14) 
 
12 1.26 (0.55-1.97) 
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Age 
<5 25 1.43 (0.88-1.99) 5.02 (1.89-16.81) 
 
1.43 (0.88-1.99) 1.01 (0.38-3.37) 
5-19 5 1.42 (0.18-2.66) 4.98 (1.15-21.64) 25 1.42 (0.18-2.66) 
 
20-49 7 0.51 (0.13-0.88) 1.78 (0.49-7.13) 5 
  
50+ 5 0.28 (0.03-0.53) 
    
Residency 
Rural 25 0.94 (0.57-1.31) 
 
19 1.57 (0.87-2.27) 
 
Urban 17 0.66 (0.35-0.97) 0.70 (0.35-1.35) 11 1.24 (0.51-1.97) 0.79 (0.34-1.75) 
Zone 
Western 5 0.76 (0.10-1.43) 0.67 (0.17-2.11) 5 1.26 (0.16-2.37) 0.58 (0.15-2.01) 
Northern 4 0.56 (0.01-1.11) 0.47 (0.10-1.68) 1 0.56 (0.00-1.65) 0.25 (0.01-1.91) 
Central 1 0.11 (0.00-0.32) 0.09 (0.00-0.65) 0 
  
Southern 
Highlands 
14 2.37 (1.14-3.60) 1.97 (0.80-5.17) 12 4.33 (1.93-6.73) 0.04 (0.02-0.03) 
Eastern 5 0.56 (0.07-1.05) 0.46 (0.12-1.55) 1 0.31 (0.00-0.91) 0.14 (0.00-1.05) 
Southern 4 0.56 (0.01-1.11) 0.47 (0.10-1.68) 3 1.39 (0.00-2.95) 0.64 (0.11-2.65) 
Lake 9 1.20 (0.42-1.98) 
 
8 2.18 (0.69-3.68) 
 
Overall 42 0.80 (0.56-1.04) 
 
30 1.43 (0.92-1.94) 
 
Ref: Reference category, CSMF: Cause-specific mortality Fraction, MFR: Mortality Fraction Ratio, CI: 
Confidence interval 
 
Cerebral palsy and other paralytic syndromes 
CP accounted for 9.2% of all ND deaths; 11.1% among children< 5 years, 
18.2% among children aged 5–19, 3.1% among adults aged 20–49, and 9.8% 
among adults older than 50 years (Table 6-1). Cerebral palsy deaths were 
reported in children younger than 20 years while paralytic syndromes 
(hemiplegia, paraplegia, and paralysis) were common in adults older than 20 
years. A total of 24 deaths from CP and other paralytic syndromes were 
identified with a CSMF of0.46% (95% CI: 0.27–0.65). Mortality of cerebral palsy 
in children younger than 5 years was estimated with a CSMF of 0.40% (95% 
CI: 0.10–0.70). 
Intrauterine hypoxia  
A total of 18 deaths from IH were coded. IH accounted for 6.9% of all ND deaths 
and 25.0%among children younger than 5 years died of ND. Given the fact that 
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IH is diagnosed at birth or the early days of neonatal life, mortality associated 
with IH in neonates was estimated with a CSMF of 2.06%(95% CI: 1.12–3.01). 
The remaining ND-related deaths were broadly grouped as malignant and 
benign neoplasms of the brain and CNS, congenital malformations of the 
nervous system, other neurological disorders, and symptoms and signs 
involving the nervous and musculoskeletal systems. The mortality of these ND 
combined were estimated with a CSMF of 0.80% (95% CI: 0.56−1.04). 
Malignant and benign neoplasms of the brain and CNS were reported and 
estimated in individuals aged < 5 years with a CSMF of 0.23% (95% CI: 0.07–
0.39). Congenital malformations of the nervous system were reported and 
estimated in children < 5 years with a CSMF of 0.52% (95% CI: 0.18–0.85). 
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Discussion 
This study provides the first detailed analysis of national data on neurological 
disorders in Tanzania. The study utilized a SAVVY approach developed to 
provide a standardized methodology in generating mortality estimates, causes 
of death and disease classification needed for local, regional and international 
comparability of mortality statistics. The adopted approach, which included 
national random samples of enumeration areas provided by the National 
Bureau of Statistics (NBS), multistage sampling methodology, use of two 
independent causes-of-death certifiers and ICD-10guarantee credibility of the 
study's findings.  
The main neurological disorders identified were cerebrovascular diseases, 
epilepsy, meningitis, cerebral palsy and other paralytic syndromes, and 
intrauterine hypoxia. Cerebrovascular disorders were the leading cause of 
death, most of which were attributed to stroke. We estimated that the number 
of neurological deaths in Tanzania ranged from 18,000 to 22,000 in 2012.
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Cerebrovascular diseases 
Hypertensive diseases are the major risk factor for ND, specifically stroke and 
dementia (Iadecola et al., 2008). The STEPwise approach to Surveillance 
(STEPS) survey designed by WHO estimated high blood pressure (>140/90 
mmHg)in 25.9% of adults aged 25–64 years in Tanzania in 2012 (Mayige et al., 
2013). High mortality estimates attributed to hypertension and cerebrovascular 
disorder observed in SAVVY are incoherent with the prevalence of hypertension 
reported in STEPS survey. A recent hospital mortality study for Tanzania 
mainland reported an increase of stroke-related mortality to 27% between 
2006–2010 and 2011–2015. In the study period from 2006 to 2015,deaths 
attributable to stroke were 3.1% while cardiorespiratory and cardio-circulatory 
diseases accounted for 6.6% and 5.6%, respectively (Mboera et al., 2007).  
Comparable estimates of cerebrovascular mortality by residency in this study 
indicate lifestyle-related diseases equally affect rural and urban residents. 
These observations deviate from the common knowledge that urban residents 
are at higher risk for NCD in general compared to rural residents. Insufficient 
coverage of human resources and medicine supply for cardiovascular diseases 
may also explain why Tanzania lags behind in slowing down the increasing 
trends in the majority of NCD. In 2014, the Tanzania Service Provision 
Assessment Survey (TSPA) indicated a lack of guidelines for healthcare 
providers for NCD service (Ministry of Health and Social Welfare (MoHSW) 
[Tanzania Mainland], 2015). 
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The TSPA indicated that less than 10% of facilities have providers who have 
recently received training in providing services for cardiovascular and other 
chronic diseases (Ministry of Health and Social Welfare (MoHSW) [Tanzania 
Mainland], 2015). 
Despite the fact that majority of Tanzanians access their health services through 
dispensaries and health facilities, the TSPA indicated the availability of essential 
medicines for cardio-vascular and other chronic diseases is lower in most 
dispensaries and health facilities than in hospitals. 
Epilepsy 
The population estimate of 7.3 (95% CI: 6.9–7.6) deaths per 100,000 was 
comparable to estimates in the three large demographic surveillance sites: 5.4 
(95% CI: 4–6.7) in Rufiji, 7.9 (95% CI: 6.1–9.7) in Ifakara Rural and 3.9 (95% 
CI: 1.3–6.4) deaths per 100,000 population in Ifakara Urban (Levira et al., 2018). 
Epilepsy mortality rate and CSMF were comparable to estimates reported 
elsewhere in most developing countries. The majority of interventions targeting 
epilepsy are those aimed at eliminating the Taenia solium tapeworm, which is 
responsible for the development of taeniosis, a major cause of preventable 
epilepsy (Blocher et al., 2007, Blocher et al., 2011). Tanzania, the National 
Schistosomiasis Control Program (NSCP) routinely implemented school-based 
mass drug administration targeting both schistosomiasis and systicercosis 
(Braae et al., 2017)
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Several interventions have been devised to reduce parasite infections in 
Tanzania; however, most of these interventions have proved to yield modest 
efficacy, and therefore need to be re-evaluated (Mwidunda et al., 2015). 
Despite these efforts, mortality of epilepsy has remained stable over the years 
in Tanzania with reference to the previous national demographic surveillance 
system’s study conducted in 1992–1995, which estimated an epilepsy mortality 
rate of 15 and 5 deaths per 100,000 population in males and females, 
respectively (Aspray, 2005).  
Probable contributors to stagnation in reduction of epilepsy mortality include the 
rise of cerebrovascular diseases attributed to epilepsy such as stroke, the 
increase in emerging infectious diseases such as HIV, and an increase in 
traumatic brain injuries as a result of wide use of bikes/motor bikes without a 
helmet and vehicles without a seatbelt. These factors probably explain why in 
this study we have more mortality due to epilepsy in adults than in children, who 
normally have more epilepsy in general in SSA, especially those originating 
from febrile seizures. 
Meningitis 
The mortality of meningitis was low, accounting for less than<0.8% of all deaths 
and 1.5% in children aged younger than 5 years. Analysis of WHO-reported 
cases of meningitis in Africa identified 11 regions (the ‘meningitis belt’) that 
account for 90% of all meningitis in SSA(Tanzania not included) (Zhao et al., 
2018). High meningitis mortality in children may be explained by the fact that the 
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meningitis pathogen that accounts for most cases of acute bacterial meningitis 
affects neonates and children. Observed meningitis deaths in adults may mostly 
constitute AIDS or TB-related deaths based on the fact that meningitis 
(cryptococcal) is a leading cause of death among HIV-infected individuals in 
SSA and in the studied population, where the latest HIV prevalence was 
estimated in adults aged 15–49. However, the unexpected low mortality of 
meningitis in adults may be explained by the fact that meningitis may be 
reported as immediate but not the underlying cause of death. The analysis in 
this study focused on underlying causes of death. 
Cerebral palsy and other paralytic syndromes 
Cerebral palsy is a lifelong disability in children of non-progressive brain 
damage which most likely occurred during the antenatal, perinatal, or early 
postnatal period. Clinical presentations include challenges in coordination, stiff 
and/or weak muscles, tremors, and in some cases problems in sense organs 
and reasoning. The burden of CP in Africa is estimated at 2–2.5 cases per 1000 
live births and globally affects 0.2% of neonates (Donald et al., 2014, Graham et 
al., 2016). Improving care at birth may have potential in reducing perinatal 
adverse events that are likely to result in the development of this disorder. There 
are scarce data on mortality in cerebral palsy in Africa, hence this study 
provides valuable statistics for future studies of the disorder. Mortality from 
paralytic syndromes (including hemiplegia and paraplegia) was more common 
in individuals older than 50 years. These disorders maybe sequelae of stroke, 
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degenerative diseases, or infection of the nervous system; therefore, further 
investigation of its epidemiology is needed. 
In general, IH is the form of birth asphyxia that affects the brain as a result of 
oxygen deprivation of the fetus (Hutter et al., 2010). Birth asphyxia is a more 
general term, and we anticipate that most clinicians would classify IH as birth 
asphyxia. Despite the possibility for misclassification, physicians were able to 
capture IH deaths, which were the second leading cause of neurological death 
in children under 5 years. Poor maternal health condition, fetus development, 
and adverse perinatal events are the major culprits for the development of these 
disorders (Hutter et al., 2010). Improving antenatal and care at birth by scaling-
up facility delivery and improving basic and comprehensive emergency 
obstetric and newborn care may significantly reduce pregnancy- or birth-related 
neurological morbidities such as cerebral palsy and mortality. 
Comparison with modeled estimates 
Our estimates were lower or higher than those reported by GBD reports Table 
6-5 (IHME, 2016). The estimated CSMFs of cerebrovascular diseases were 
comparable to estimates from the GBD for adults aged 15–49 years and close 
to estimates for all ages. SAVVY estimates of deaths attributable to epilepsy 
and road traffic injuries were higher in all age categories and overall than those 
reported in the GBD. On the other hand, the GBD reported higher estimates for 
deaths attributable to meningitis. The observed differences may be linked to 
methodological limitations in both approaches; however, SAVVY estimates are 
more likely to be closer to true population estimates. A substantial proportion of 
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data used in generating the GBD for Tanzania are those derived from health 
and demographic surveillance systems, most of which are located in poor rural 
areas (Mrema et al., 2015, Geubbels et al., 2015). Recently, the 2017 GBD report 
in Tanzania compiled cerebrovascular diseases data dated from 2010 to 1993 
due to the limited number of studies and poor coverage of civil and vital 
registration systems (Institute for Health Metrics and Evaluation, 2018). 
Missing and misclassifying neurological disorders was the main possible 
limitation of this study attributed to lack of clinical training in neurology among 
physicians conducting death certification. A substantial proportion of deaths 
were coded as malaria in this study; however, some of the clinical 
manifestations of cerebral malaria such as fever, vomiting, and convulsions are 
also clinical manifestations of neurological disorders such as meningitis and 
epilepsy. Other possible misclassifications include those related to 
misclassifying cerebrovascular disorder as hypertensive disease, or vice versa. 
We did not observe traumatic brain injuries or intracranial deaths in this study 
despite the high mortality of road injuries estimated at 2.4% in all ages and 5.8% 
(95% CI: 4.7–7.1) in adults aged 15–49 years (results not reported but provided 
for contextual reasoning). Road injuries are one of the main causes of brain 
injuries; therefore, lack of information from VA or medical records may have 
resulted in missing some traumatic brain injury deaths in this study (Smart et al., 
2017, Winkler et al., 2009c, Okeng'o et al., 2017). 
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 Table 6-5: Cause-specific mortality comparison to GBD 
 
 Age 0-4 years Age 15-49 years All ages  
SAVVY GBD SAVVY GBD SAVVY GBD 
Cerebrovascular 0.05 (0.01-0.36) 0.07 (0.04-0.09) 1.21 (0.77-1.92) 1.23 (0.96-1.52) 1.65 (1.34-2.03) 3.16 (2.66-3.63) 
Epilepsy 0.35 (0.17-0.74) 0.11 (0.08-0.14) 1.95 (1.36-2.80) 0.55 (0.43-0.69)  0.94 (0.71-1.24) 0.25 (0.22-0.30) 
Meningitis 1.47 (1.02-2.10) 3.53 (2.30-6.07) 0.47 (0.22-0.99) 1.53 (1.06-2.23) 0.78 (0.58-1.06) 2.10 (1.61-2.94) 
Road injuries 0.91 (0.57-1.44) 0.54 (0.36-0.84) 5.8 (4.71-7.11) 2.41 (1.89-2.99) 2.43 (2.05-2.88) 1.48 (1.29-1.67) 
          Legend:  
          Data sources  
          SAVVY: Analysis of Sample vital registration with verbal autopsy 
          GBD: Extracted from Global Burden of Disease report 
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With regards to comparability of this study across countries, regions, and 
internationally, adoptions of newer versions of ICD-10 and the tabulation list of 
neurological disorders are likely to result in different mortality estimates 
elsewhere (Mathers et al., 2005). The recent version of ICD-10 recommends 
grouping some hypertensive disorders as cerebrovascular deaths; such 
changes are likely to result in estimates that are incomparable to what was 
observed in this study (ICD10 Data, 2018). 
Conclusions 
The SAVVY survey provided estimates mortality burden of neurological 
disorders in Tanzania to the level of zones. Cerebrovascular diseases, epilepsy, 
meningitis, cerebral palsy and other paralytic syndromes, and intrauterine 
hypoxia are the leading causes of neurological mortality in Tanzania. The 
SAVVY sampling design strengthens the study in terms of representativeness 
for the nation and reliability of cause-of-death determination, and provides 
national baseline data on epidemiological information on neurological disorders 
needed for prevention and intervention programs. These estimates are rare in 
most SSA; therefore, we believe our archived data sets will contribute to 
advancing knowledge of neurological disorders. On the other hand, the burden 
associated with morbidities of neurological disorders might be far higher than 
that of mortality. In the case of stroke, mortality rates and deaths have 
substantially declined in most countries; however, the number of people living 
with stroke-related disabilities has been increasing. Reliable morbidity data can 
only be obtained when there is routine healthcare services data of good quality 
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and community-based surveys. Integrating measures of morbidities such as 
DALYs in SAVVY design may pro-vide a complete picture of disease, social 
and economic burden not only of neurological disorders but also of other 
prevalent diseases. 
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Paper context 
In the context of low- and middle-income countries, it has been established that the 
majority of neurological disorders are linked to infections and brain injuries. However, 
in the context of epidemiological transition, we hypothesize that there is high emerging 
incidence of age-related neurological disorders such as dementia, cerebrovascular 
and heart diseases. We utilize a SAVVY study; a national representative sample and 
explore mortality of neurological disorders in Tanzania by sex, residence, and special 
geographic areas (zone).
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Abstract 
Background 
Neurological disorders are associated with higher mortality than the general 
population. We determined the magnitude and changes in the mortality associated 
with neurological disorders from Health and Demographic Surveillance System 
(HDSS) sites in Tanzania from 1999 to 2014. 
Methods 
Study population constituted of all residents of Rufiji, Ifakara rural and Ifakara urban 
HDSS sites in Tanzania. Causes of death were obtained through verbal autopsy and 
classified using International Classification of Disease and Injuries version 10 (ICD10). 
Mortality rates and secular trends were estimated using survival models. 
Results 
We analysed a total of 25 060 deaths in a population surveillance of 275 331 residents. 
Causes of deaths were complete in 80% of deaths. Age-standardized mortality rates 
were 34.3 (95%CI 31.5-37.1), 30.1(95%CI 26.8-33.4) and 22.9(95%CI 17.3-28.6) 
deaths per 100 000 person-years in Rufiji, Ifakara rural and Ifakara urban respectively. 
Leading cause of neurological mortality were cerebrovascular diseases with mortality 
rate estimates of 24.5(22.3-26.7) in Rufiji, 15.1(12.8-17.5) in Ifakara rural and 12.9(9.1-
16.8) deaths per 100 000 in Ifakara urban. Annual mortality reduction of neurological 
disorders was observed in Rufiji (Hazard Ratio (HR) =0.96, 95%CI: 0.94-0.97) and 
Ifakara rural (HR=0.94, 95%CI: 0.90-0.97) HDSS but not in Ifakara urban (HR=1.02, 
95%CI: 0.86-1.22). 
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Conclusions 
This study provides evidence of no progress in the reduction of non-cerebrovascular 
neurological and all-cause neurological mortality in rural and urban HDSS sites 
respectively. This study calls for renewed efforts in addressing preventable causes of 
neurological disorders in LMIC were parasitic and viral infections are key aetiological 
factors for neurological dysfunction. 
Keywords: Cerebrovascular, epilepsy, meningitis, convulsions, seizure, verbal 
autopsy, ICD10, survival analysis, Kaplan Meier. 
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Background  
Neurological disorders are associated higher disability and mortality than the general 
population. The most prevalent neurological disorders in LMIC are stroke, Alzheimer 
diseases, epilepsy, Parkinson diseases, multiple sclerosis, and motor neuron 
diseases (Whiteford et al., 2013, IHME, 2016). Global Burden of Disease report (GBD) 
estimated neurological disorders (including stroke) account for 15% of global deaths 
(IHME, 2016, Global Burden of Disease, 2016). Some studies of mortality from 
neurological disorders, projected an increase for both high and low-income countries 
(Pritchard et al., 2013).  
The aetiology of some neurological disorder in LMIC is not well understood, but the 
contribution of viral and parasitic infections (Mallewa et al., 2013, Newton, 2013, 
Howlett, 2014, Belman et al., 1988). In addition to vital and parasitical infection, 
increases incidence of the neurological disorder has been linked to treatment's side 
effects such as those for malaria and HIV/AIDS. Antimalarial drugs have been 
associated with increased incidence of headache and dizziness (Bitta et al., 2017). 
Antiretroviral drugs prescriptions have emerged with several neurological 
complications in people living with HIV (Robertson et al., 2008, Hall, 2006, Newton, 
2006). AIDS-related neurological disorders include AIDS dementia complex; retinal 
abnormalities; areflexia; pyramidal tract signs and tremor and incoordination (Belman 
et al., 1988, De Cock, 1989).  
Limited expertise in neurology and insufficient diagnostic infrastructure are among the 
major challenges in understanding mortality associated with neurological disorders 
and in averting preventable deaths in LMIC (Smart et al., 2017, Winkler et al., 2009c, 
Okeng'o et al., 2017). Furthermore, people with neurological disorders are stigmatized 
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and marginalized in most communities in LMIC, hence not represented in health and 
mortality statistics (Whiteford et al., 2013). The most reliable source of mortality of 
neurological disorder globally and in LMIC is the GBD study. The mortality rate of 
neurological disorders in low-income countries was estimated at 33 (95% Confidence 
interval (CI): 27-39) deaths per 100 000 in 2015. The leading causes of neurological 
deaths in LMIC are cerebrovascular diseases with a mortality rate from ischemic 
stroke estimated at 68 (95%CI: 55-80) and hemorrhagic stroke at 81 (95%CI: 70-93) 
deaths per 100 000. Other disorders with high mortality rate include Alzheimer disease 
6 (95%CI: 5-7) and epilepsy 4 (95%CI: 3.5-4.79) deaths per 100,000 population. 
Tanzania, like many other LMIC, lack comprehensive vital registration system 
necessary for generating population estimates of deaths, their causes, and following 
trends (Chang et al., 2011, Ferreira Ide et al., 2009, O'Callaghan et al., 2004, Gomes, 
2011, O'Callaghan et al., 2000, Aspray, 2005, Tsai, 2005, Mikkelsen et al., 2015). This 
has resulted in absence of reliable data on magnitude, distribution, and trends of 
mortality of neurological disorder in the country. There are limited studies that provide 
the estimate of mortality of neurological diseases in Tanzania.  
In response to this lack of data on these vital statistics, Ifakara Health Institute 
established three HDSS sites, aimed at monitoring demographic and health statistics 
in large population cohorts in place of a civil and vital registration system. In addition 
to monitoring key health and demographic events in the selected area, causes of death 
are determined for every reported death using International Classification of Diseases 
and Injuries (ICD) (Mrema et al., 2015, Geubbels et al., 2015, Sankoh et al., 2014b). 
Epidemiology of mortality from neurological disorders has not been described before 
in these large population cohorts.  
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The objective of this study is to determine the magnitude and if there has been a 
reduction in mortality of neurological disorder in three HDSS sites from 1999 to 2014. 
Methods 
Study populations were all residents of the large three HDSS sites in Tanzania; Rufiji 
HDSS (R-HDSS), Ifakara Rural (IR-HDSS) and Ifakara Urban HDSS (IU-HDSS) 
(Figure 7-1). The three demographic surveillances had a total of about 275,331 active 
residents in 60,882 households at the time of data extraction. HDSS sites were 
designed as an open dynamic cohort, which enrolls individuals through baseline 
enumeration, birth, and in-migration and exits individuals throughout migration and 
deaths. 
 
Figure 7-1: Location map of HDSS areas within Tanzania and Africa 
To ascertain the cause of death, verbal autopsy (VA) was employed because post-
mortem examinations are not conducted routinely in Tanzania, similar to many LMIC 
(Sankoh et al., 2014a, Setel et al., 2006, Mikkelsen et al., 2015). The process involves 
in-depth structured interviews of the care taker of the diseased on signs, symptoms, 
pre-existing conditions and health-seeking choices prior to death using VA 
questionnaires. Questionnaires are further critically reviewed by trained physicians 
143 
 
who at the end of process assign the cause of death. Over the study period, two 
versions of VA tools have been employed in the study area. The first version was 
adopted from World Health Organization (WHO) and employed in the study area from 
1999 to 2007. The tools in the first version comprised of autopsy questionnaires with 
fewer questions and condensed list of causes of death based local disease burden. 
The second version was a fully-designed WHO verbal autopsy questionnaires and 
disease classification (ICD10) tool which was used from 2008 to 2014.  
Neurological causes of deaths were classified using ICD10 code ranges of G00-G99 
for diseases of nervous system, I60-69 for cerebrovascular diseases and S06 for 
traumatic brain injuries/ intracranial injury for deaths (Jette et al., 2015).  
Mortalities from neurological disorder were estimated using survival analysis models. 
HDSS residency episodes were organized in long format and merged with basic 
demographic variables including sex and causes of death variables from causes of 
death file from VA. Exposure time was estimated from individual’s residence episodes 
started at enrolment, birth or in-migration and ended at out-migration or death or at the 
end of the analysis period. Mortality rates estimates were grouped in time intervals 
(years) and mortality rate ratio compared by sex, age and time. Mortality rate ratios 
were estimated using Mantel-Haenszel method. International Network for the 
Demographic Evaluation of Populations and Their Health (INDEPTH) standard life 
table was used as standard population in comparing mortality between the three sites 
(Sankoh et al., 2014b). 
We used the Kaplan-Meier method to estimate the probability of neurological deaths 
in the population of adults aged 15 years and above. Kaplan-Meier estimates were 
stratified by site to ascertain trends in the probability of neurological deaths as 
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individual’s ages. Cox regression model was employed to estimate of the effect of 
potential covariates and secular trends of neurological mortality. Stata software 
version 13 (StataCorp LP, College Station, Texas) was used for descriptive statistics 
and statistical analysis (Boston et al., 2003).  
The study protocol was approved by Ifakara Health Institution Internal Review Board, 
National Institute of Health Research and Commission of Science and Technology, 
Tanzania. All participants were enrolled through verbal consent. Before enrolled in the 
population-based cohort, participants were introduced to the rationale of the 
demographic surveillance system and were informed about publication of their 
information without individual identification.  
Results 
There was total of 539,886 residents observed aggregated to 2,393,199 person-years 
of observations. Across three sites, there were 25,060 deaths over the analysis period; 
13,739 (55%) in R-HDSS, 9,345 (37%) in IR-HDSS and 1,985 (8%) in IU-HDSS. 
Causes of death were available for 20,046 (80%) of deaths, 1,480 (6%) had complete 
verbal autopsy interviews but the cause could not be determined and 3,534 (14%) had 
the missing cause of death. The reasons for the missing cause of death include 
migration, missing of the household during routine household surveillance, refusal of 
an interview and on-going causes of death assignment by physicians.  
Total of 907 deaths from neurological diseases in the three HDSS sites were observed 
over the study periods. An additional file describe in tabular form the number of deaths 
and by sex, age, year, cause of death and site (Supporting information Table S1). 
Cerebrovascular diseases (mainly stroke) contributed 618 (68.1%) deaths followed by 
146 (16.1%) epilepsy, 87(9.6%) meningitis and 56 (6.2%) other neurological deaths.  
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Neurological mortality 
The total follow-up periods were 16, 11, and 4 years in R-HDSS, IR-HDSS, and IU-
HDSS sites respectively. Standardized mortality rates were 34 (95%CI: 31-37), 30 
(95%CI: 27-33) and 23 (95%CI: 17-29) deaths per 100 000 person-years in R-HDSS, 
IR-HDSS, and IU-HDSS respectively ( Table 7-1).  
Within sites, the mortality rate was comparable for males and females in R-HDSS and 
IU-HDSS but higher in males than females in IR-HDSS (Rate Ratio (RR)= 1.29, 
95%CI: 1.02-1.64). Adults aged 50 years and above had the highest mortality rate 
(RR=14, 95% CI:10.5-18.8) than children under five years, children 5-14 years 
(RR=25.5, 95% CI:19-34), and middle-aged 15-49 years (RR=9.2, 95% CI:7.8-10.9). 
Estimates of mortality of disease of disease of neurological disorder and 
cerebrovascular diseases across sites were observed to fluctuate annually with the 
overall declining trend over the study period (Figure 7-2). 
The proportions of individuals died with a neurological disorder in the hypothetical 
population of 1000 increased by age reaching 16, 14 and 10 by age 60 (Table 7-3) in 
R-HDSS, IR-HDSS, and IU-HDSS respectively. No site differences were observed in 
the probability of dying per 1000 population age (Figure 7-3). Results of Cox 
regression analysis showed the decline in mortality rate in R-HDSS (Hazard rate 
ratio (HR)=0.96, 95% CI: 0.94-0.97), IR-HDSS (HR=0.94, 95% CI: 0.9-0.97), and no 
change in IU-HDSS (Table 7-4). No sex differences were also observed all sites. 
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 Table 7-1: Mortality rates of neurological diseases by type, sex, age and site 
 
Rufiji HDSS Ifakara Rural Ifakara Urban 
Variable Crude Adjusted* Crude Adjusted* Crude Adjusted 
Cerebrovascular diseases 
Males 72.3(63.4-82.5)  24(18.8-30.6)  19.2(10.9-33.9)  
Females 67.5(59.3-76.8)  23.8(18.7-30.2)  24(15.1-38)  
15-49 10.4(7.8-13.8)  4(2.5-6.4)  2.7(.9-8.5)  
50+ 218.4(198-240.7)  105.8(88.1-127.1)  98.2(67.4-143.3)  
15+ 69.8(63.6-76.5) 24.3(22.1-26.5) 23.9(20.1-28.3) 14.8(12.6-17.1) 21.8(15.3-31.2) 12.9(9.1-16.8) 
Overall 38.2(34.9-41.9) 24.5(22.3-26.7) 13.7(11.5-16.2) 15.1(12.8-17.5) 13.7(9.6-19.6) 12.9(9.1-16.8) 
Epilepsy 
Males 6.2(4.4-8.9)  10.3(7.6-14)  4.5(1.7-11.9)  
Females 6.3(4.5-8.9)  6.2(4.2-9.1)  4.9(2-11.7)  
5-14 4.4(2.6-7.3)  4(2.2-7.3)  
 
 
15-49 8(5.8-11.1)  11(8.3-14.6)  8.2(4.3-15.7)  
50+ 5.4(2.9-10.1)  7.4(3.7-14.9)  
 
 
5+ 6.3(4.9-8) 5.4(4-6.7) 8.2(6.5-10.5) 7.2(5.5-8.9) 4.7(2.4-9) 3.9(1.3-6.4) 
Overall 5.2(4.1-6.7) 5.4(4-6.7) 7.6(6.1-9.5) 7.9(6.1-9.7) 4.1(2.1-7.9) 3.9(1.3-6.4) 
Meningitis 
Males 6.1(3.5-10.8)  12.9(8.4-19.7)  3.7(.5-26.3)  
Females 2.6(1.6-4.3)  6.3(4.5-9)  1(.1-6.9)  
0-4 2.8(1.7-4.5)  3.4(2.1-5.5)  5.2(2.3-11.5)  
5-14 2(1-4.3)  2.6(1.2-5.4)  1.8(.3-13)  
15-49 1.3(.6-2.9)  3.4(2-5.6)  3.6(1.4-9.7)  
50+ 3.8(1.8-8)  4.6(1.9-11.1)  3.6(.5-25.8)  
Overall 2.7(1.9-3.8) 2.4(1.5-3.3) 4.9(3.7-6.4) 4.7(3.4-6.1) 3.2(1.5-6.7) 3(.7-5.2) 
 Adjusted for age using INDEPTH standard population [Sankoh O, Sharrow D, Herbst K, et al. The INDEPTH standard population for low- and 
middle-income countries, 2013. Glob Health Action 2014; 7: 2328
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 Table 7-2: Mortality rates of neurological diseases continue 
 
Rufiji HDSS Ifakara Rural Ifakara Urban 
Variable Crude Adjusted* Crude Adjusted* Crude Adjusted 
Neurological (excluding cerebrovascular deaths) 
Males 10.7(8.3-13.7)  18.2(14.8-22.4)  9.7(5.2-18)  
Females 10.1(7.8-13)  11.2(8.6-14.6)  9.5(5.2-17.1)  
0-4 7.1(4.2-12)  19(13.4-27)  18.5(7.7-44.5)  
5-14 7.6(5.2-11.2)  7.7(5-11.8)  1.8(.3-13)  
15-49 10.8(8.2-14.3)  15.5(12.3-19.6)  11.8(6.9-20.4)  
50+ 17.9(12.7-25.2)  22.3(14.9-33.2)  7.3(1.8-29.1)  
Overall 10.4(8.7-12.4) 9.8(8.0-11.6) 14.7(12.5-17.3) 15.0(12.5-17.4) 9.6(6.2-14.7) 10.0(5.7-14.2) 
All neurological conditions 
Males  49.2(43.8-55.3)   31.9(27.3-37.4)  21.4(14.1-32.4)  
Females 48.1(42.9-53.9)  24.8(20.8-29.6)  25(17.3-35.9)  
0-4 7.6(4.6-12.7)  20.8(14.9-29.2)  18.5(7.7-44.5)  
5-14 7.9(5.4-11.5)  7.7(5-11.8)  1.8(.3-13)  
15-49 21.2(17.4-25.9)  19.6(15.9-24.1)  14.5(8.9-23.7)  
50+ 236.2(215.1-259.5)  128.1(108.4-151.4)  105.5(73.3-151.9)  
Overall 48.6(44.8-52.8) 34.3(31.5-37.1) 28.3(25.2-31.9) 30.1(26.8-33.4) 23.3(17.7-30.6) 22.9(17.3-28.6) 
*Adjusted for age using INDEPTH standard population [Sankoh O, Sharrow D, Herbst K, et al. The INDEPTH standard population for low- and middle-income   countries, 
2013. Glob Health Action 2014; 7: 23286 
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Figure 7-2: Trends in neurological and cerebrovascular disorder 1999-2014. 
Cerebrovascular mortality 
Stroke was the dominant (89%) cause of death in cerebrovascular diseases and 
mainly occurred in adults older than 50 years (Supporting information Table S1). 
Standardized mortality rates for adults above 15 years of age were 24.3 (95%CI: 22.1-
26.5), 14 (95%CI: 12.6-17.1) and 12.9 (95%CI: 9.1-16.8) deaths per 100,000 person 
years in R-HDSS, IR-HDSS and IU-HDSS respectively ( Table 7-1).  
Within sites, mortality rate was comparable for males and females (Overall RR=1.13, 
95%CI: 0.97-1.33). Adults aged 50 years and above had the highest mortality rate 
than adults aged 15-49 (Overall RR=22.5, 95% CI: 17.5-29). Cerebrovascular 
mortality rate were observed to fluctuate annually with overall declining trend (Figure 
7-2). 
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Table 7-3: Kaplan Meier probability* of dying from neurological disorders  
 Neurological Cerebrovascular Epilepsy Meningitis 
Age Rufiji IR IU Rufiji IR IU Rufiji IR IU Rufiji IR IU 
15 1.2 1.8 1.1 0.1 0.1 0.0 0.4 0.6 0.0 0.5 0.9 0.4 
20 1.5 2.8 2.0 0.1 0.1 0.2 0.7 1.5 0.7 0.5 0.9 0.4 
25 2.7 3.5 2.5 0.2 0.2 0.2 1.6 2.1 1.2 0.6 1.0 0.4 
30 3.7 4.0 2.8 0.5 0.3 0.2 2.1 2.4 1.5 0.7 1.0 0.4 
35 4.9 5.4 3.7 1.3 0.6 0.5 2.3 3.0 1.8 0.8 1.4 0.6 
40 6.3 6.9 4.8 2.1 1.0 0.5 2.7 3.9 1.8 0.9 1.6 1.8 
45 7.3 7.9 5.8 2.8 1.4 1 2.9 4.1 2.4 0.9 2.0 1.8 
50 9.8 9.0 6.5 5.1 1.8 1 3.1 4.1 3.0 0.9 2.3 1.8 
55 11.8 10.4 8.0 7.0 3.1 2.4 3.1 4.3 3.0 0.9 2.3 1.8 
60 16.4 13.6 9.7 11.6 4.9 3.4 3.1 4.8 3.0 0.9 2.8 2.5 
  IR:Ifakara Rural, IU: Ifakara Urban, *Deaths per 1000 population 
The proportions of individuals died with cerebrovascular diseases in the population 
increased by age reaching 12, 5 and 3 deaths per 1000 by age 60 (Figure 7-3) in R-
HDSS, IR-HDSS and IU-HDSS respectively. No site differences were observed except 
in R-HDSS were high mortality were at old ages was observed (Figure 7-2). Results 
of cox regression analysis indicated decline in mortality rate in R-HDSS (HR=0.95, 
95% CI: 0.93-0.97), IR-HDSS (HR=0.89, 95% CI: 0.85-0.94), and no change in IU-
HDSS (Table 7-4). No sex differences were also observed all sites. 
Epilepsy mortality 
Total of 146 (16%) epilepsy deaths were observed in the three HDSS sites. Age 
standardized mortality rates were 5.4, 7.9 and 3.9 deaths per 100,000 person years in 
R-HDSS, IR-HDSS and IU-HDSS respectively ( Table 7-1). Mortality was 
comparable within sites for males and females, but overall mortality rate was higher 
for males than females (Overall RR=1.19, 9 5%CI: 1.05-1.36). Adults aged 50 years 
and above had the highest mortality rate than adults aged 15-49 (Overall RR=9.2, 95% 
CI: 7.8-10.9). Estimates of secular trend of mortality of epilepsy across sites were 
observed to fluctuate annually especially for IU-HDSS and IR-HDSS (Table 7-4). 
Results of Cox regression analysis indicated no change in epilepsy mortality rate in R-
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HDSS (HR=0.99, 95% CI: 0.94-1.04), IR-HDSS (HR=0.94, 95% CI: 0.87-1.01), and 
IU-HDSS (HR=1.19, 95% CI: 0.77-1.85) (Table 7-4). No sex differences were 
observed all sites (Table 7-4). 
Table 7-4: Hazard ratio estimates by site and cause of neurological death 
 
Female(Male 
in reference 
category) 
95% CI Year 95% CI 
Rufiji HDSS     
Neurological 0.87 0.73-1.02 0.96 0.94-0.97 
Cerebrovascular diseases 0.85 0.71-1.02 0.95 0.93-0.97 
Epilepsy 1.01 0.61-1.67 0.99 0.94-1.04 
Meningitis 1.08 0.54-2.17 1.07 0.99-1.16 
Ifakara rural HDSS     
Neurological 0.78 0.61-0.98 0.94 0.9-0.97 
Cerebrovascular diseases 0.98 0.7-1.37 0.89 0.85-0.94 
Epilepsy 0.63 0.39-1.00 0.94 0.87-1.01 
Meningitis 0.55 0.3-0.99 1.13 1.02-1.24 
Ifakara Urban HDSS     
Neurological 0.96 0.55-1.68 1.02 0.86-1.22 
Cerebrovascular diseases 0.94 0.45-1.97 0.96 0.76-1.22 
Epilepsy 1.09 0.29-4.08 1.19 0.77-1.85 
Meningitis 5.49 0.66-45.66 0.96 0.62-1.5 
Meningitis mortality 
Most meningitis deaths occurred in children and elderly in all HDSS sites. IR-HDSS 
and IU-HDSS had exceptionally high mortality rate in individuals aged 15-49 years of 
age (Supporting information Table S1). Standardized mortality rates were 2.4 (95%CI: 
1.5-3.3), 4.7 (95%CI: 3.4-6.1) and 3.2 (95%CI: (0.7-5.2) deaths per 100,000 person 
years in R-HDSS, IR-HDSS and IU-HDSS respectively ( Table 7-1). Within sites, 
mortality rate was comparable for males and females (Overall age adjusted RR=1.21, 
95%CI: 0.79-1.84) in R-HDSS and IU-HDSS but higher in males than females in IR-
HDSS (Age adjusted RR=1.84, 95% CI: 1.02-3.33). There were no age differences in 
mortality rate (Overall sex adjusted RR=1.78, 95% CI: 0.9-3.5). Meningitis mortality 
rate were observed to remain constant over the study period (Figure 7-4). 
151 
 
 
Figure 7-3: Probability of death from neurological cerebrovascular diseases 
The proportions of individuals died with epilepsy in the population cohort increased by 
age reaching 3.1, 4.8 and 3 deaths per 1000 by age 60 in R-HDSS, IR-HDSS and IU-
HDSS (Table 7-3). No site differences were observed (Figure 7-5). 
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Figure 7-4: Trends in epilepsy and meningitis mortality 1999-2014. 
The proportions of individuals died with meningitis in the population increased by age 
reaching 0.9, 2.8 and 2.5 deaths per 1,000 by age 60 R-HDSS, IR-HDSS and IU-
HDSS respectively (Table 7-3). Results of Cox regression analysis indicated no 
change in trends in meningitis mortality in R-HDSS (HR=1.07, 95% CI: 0.99-1.16) and 
IU-HDSS (HR=0.96, 95% CI: 0.62-1.5) and increasing trend in IR-HDSS (HR=1.13, 
95% CI: 1.02-1.24) (Table 7-4). No sex differences were also observed RHDSS and 
IU-HDSS while lower risks were observed in females than males (Age adjusted 
HR=0.55, 95% CI: 0.3-0.99). 
 
Figure 7-5: Probability of death from epilepsy and meningitis 1999-2014. 
Discussions 
This study provided evidence of site specific variations in the magnitude, distribution 
and trends of mortality from neurological disorders from HDSS sites in Tanzania. The 
total population followed from HDSS sites was approximately 275,000, which is 
sufficiently large to provide reliable estimates of magnitude, distributions and trends 
mortality of neurological disorders. Cause specific neurologic mortality distributions 
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were comparable across sites with highest mortality attributed to cerebrovascular 
disorder, followed by epilepsy and least by meningitis. The overall high mortality rates 
across sides were highly driven by high mortality rate from cerebrovascular disorders 
in older ages. Reduction in neurological mortality was observed in Rufiji HDSS only, 
due to substantial reduction in cerebrovascular deaths.  
This study categorized cerebrovascular deaths as neurological death. This 
classification however differs from GBD reporting which do not include 
cerebrovascular deaths as neurological deaths. Excluding cerebrovascular deaths to 
match GBD reporting produced mortality estimates of neurological disorder to 50% 
lower than estimates when cerebrovascular disorders were included. The estimated 
mortality rates across sites were within the range of estimates reported in GBD report 
(27-39 deaths per 100 000) for 2015 in low income countries. There was no reductions 
non-cerebrovascular mortality of neurological disorders across sites over the study 
period. 
As expected cerebrovascular mortality were highest among older individuals above 
fifty years old compared to young adults as observed from crude site specific mortality 
estimates. Most cerebrovascular deaths were stroke. GBD reported mortality from 
ischemic stroke at 68 (95%CI: 55-80) and haemorrhagic stroke at 81 (95%CI: 70-93) 
deaths per 100 000, comparable to estimates for individual aged 50 and above. 
Reductions in cerebrovascular mortality were observed in rural sites only (R-HDSS 
and IR-HDSS). 
Estimates of mortality from epilepsy were comparable across HDSS sites and 
remained within the range of estimates from GBD for low income countries (4-6 deaths 
per 100,000 annually) in R-HDSS and IU-HDSS but high in IR-HDSS (6.1-9.5 deaths 
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per 100,000). Epilepsy mortality were also within the estimates from recent GBD (6.9 
range 4.2-11.8 deaths per 100,000) report for Tanzania. All estimates of mortality from 
epilepsy were higher than global estimate as reported GBD report for 2015 with 
epilepsy mortality annual rate of 1.19 ranges from 1.14-1.23 deaths per 100 000 
population. Population based HDSS estimates from Adult Morbidity and Mortality 
Project (AMMP) implemented between 1992 and 1995 in Tanzania estimated epilepsy 
mortality annual rate of 15 male and 5 female deaths per 100,000 population (Aspray, 
2005, Ministry of Health, 1997). 
High mortality rate from neurological disorders in LMIC may be greatly associated with 
insufficient health care, poor access and adherence to medication such as antiepileptic 
drugs. Detailed analysis of epilepsy deaths revealed poor health seeking practices 
where almost a quarter of diseased had consulted witchdoctors or were treated at 
home and less than forty per cent attended government hospital. Poor access to health 
care for management of seizures may explain high frequency of convulsions (64%), 
lost conscious (42%), injuries (24%) and sudden fatal events (48%) that lasted within 
24hours.  
Limitations 
The study reported mortality rates of neurological deaths from large population-based 
cohort where causes of death were available 80% all deaths. Reasons for incomplete 
causes of death were mostly associated with on-going causes of death assignment by 
physicians and migrations therefore missing at random assumption were applied. 
Under this assumption, the actual mortality of neurological disorder may be higher 
than reported in this study. Most VA studies reported lower completeness than 
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reported in this study, typical example include Vietnam national mortality survey where 
completeness of 69% in males and 54% in females was reported (Ngo et al., 2010).  
High mortality decline of neurological disorders post 2008 may be influenced by the 
change in VA questionnaires in 2008. However this is only observed in 
cerebrovascular diseases but not in epilepsy, meningitis or the other neurological 
disorders. 
There were insufficient data across sites that may have assisted on analysis of risk 
factors for observed variations in the number of cases and mortality rates of 
neurological disorders across sites over time.  Reduced mortality in some sites may 
not necessarily mean decline in the number of cases in the population (Okeng'o et al., 
2017). Only one epilepsy prevalence study was available for IR-HDSS were 
prevalence of active convulsive epilepsy was estimated at 14.8 (95% CI: 13.8–15.4) 
per 1000 population screened and established an association between Active 
convulsive Epilepsy (ACE) with Onchocerca volvulus, Toxocara canis, Toxoplasma 
gondii, O. volvulus and adult onset of ACE with T. canis, Taenia solium and O. volvulus 
(Ngugi et al., 2013a). 
Conclusion 
The magnitude of mortality of neurological disorders from HDSS sites in Tanzania are 
within the estimates provided by GBD for low income countries. The estimates are 
higher than global estimates. Cerebrovascular diseases were the leading neurological 
mortality in the population, followed by epilepsy and meningitis. Reductions in 
neurological mortality were observed in HDSS sites in rural settings where reductions 
in cerebrovascular diseases were also observed. No change in neither neurological 
nor cerebrovascular mortality was observed in urban HDSS site. The combined 
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estimates of mortality of neurological disorder excluding cerebrovascular disorder did 
not change over the study period across all HDSS sites. 
This study provides evidence of no progress in the reduction of non-cerebrovascular 
neurological disorders in Rural HDSS site (R-HDSS and IR-HDSS) and any 
neurological disorder in IU-HDSS site. This study calls for renewed efforts in 
addressing neurological disorders in low income countries were parasitic and viral 
infections are key aetiological factors of neurological disorders. 
Supporting information 
Table S1: Number and per cent of neurological deaths by sex, age, year in Rufiji 
HDSS  
 
Cerebrovasc
ular Epilepsy Meningitis Others Total 
Male 223 (49) 30 (48) 15 (47) 17(59) 285 (49) 
Female 230 (51) 32 (52) 17 (53) 12(41) 291 (51) 
Age      
0-4 1 (0)  12 (38) 2(7) 15 (3) 
5-14 1 (0) 15 (24) 7 (22) 4 (14) 27 (5) 
15-49 48 (11) 37 (60) 6 (19) 7 (24) 98 (17) 
50+ 403 (89) 10 (16) 7 (22) 16 (55) 436 (76) 
Year      
1999 21(5) 1 (2) 2 (6) 5 (17) 29 (5) 
2000 43 (9)  1 (3) 2 (7) 46 (8) 
2001 33 (7) 5 (8)  2 (7) 40 (7) 
2002 32 (7) 5 (8) 1 (3) 3 (10) 41 (7) 
2003 27 (6) 5 (8)   32 (6) 
2004 35 (8) 4 (6) 1 (3) 1 (3) 41 (7) 
2005 27 (6) 4 (6) 4 (13)  35 (6) 
2006 38 (8) 4 (6)  4 (14) 46 (8) 
2007 40 (9) 4 (6) 1 (3)  45 (8) 
2008 23 (5) 6 (10) 4 (13) 1 (3) 34 (6) 
2009 30 (7) 5 (8) 4 (13) 2 (7) 41 (7) 
2010 34 (8) 5 (8) 3 (9) 5 (17) 47 (8) 
2011 24 (5) 7 (11) 2 (6) 3 (10) 36 (6) 
2012 23 (5) 5 (8) 4 (13) 1 (3) 33 (6) 
2013 8 (2) 1 (2) 3 (9)  12 (2) 
2014 15 (3) 1 (2) 2 (6)  18 (3) 
Total 453 (100) 62 (100) 32 (100) 29 (100) 576 (100) 
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Table S1: Number and per cent of neurological deaths by sex, age, year in Ifakara 
Rural  
 Cerebrovascular diseases* Epilepsy Meningitis Others Total 
Male 67 (50) 46 (61) 31 (65) 12 (55) 156 (56) 
Female 68 (50) 29 (39) 17 (35) 10 (45) 124 (44) 
Age      
0-4 3 (2) 7 (9) 21 (44) 3 (14) 34 (12) 
5-14  11 (15) 7 (15) 3 (14) 21 (8) 
15-49 18 (13) 49 (65) 15 (31) 5 (23) 87 (31) 
50+ 114 (84) 8 (11) 5 (10) 11 (50) 138 (49) 
Year      
2002 7 (5) 8 (11)  1 (5) 16 (6) 
2003 16 (12) 5 (7) 2 (4) 3 (14) 26 (9) 
2004 19 (14) 9 (12)  3 (14) 31 (11) 
2005 12 (9) 6 (8) 1 (2) 3 (14) 22 (8) 
2006 13 (10) 4 (5) 8 (17)  25 (9) 
2007 25 (19) 4 (5) 4 (8) 3 (14) 36 (13) 
2008 7 (5) 8 (11) 7 (15) 2 (9) 24 (9) 
2009 6 (4) 10 (13) 4 (8) 4 (18) 24 (9) 
2010 15 (11) 10 (13) 9 (19) 2 (9) 36 (13) 
2011 11 (8) 7 (9) 7 (15) 1 (5) 26 (9) 
2012 4 (3) 4 (5) 6 (13)  14 (5) 
Total 135 (100) 75 (100) 48 (100) 22 (100) 280 (100) 
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Table S1: Number and per cent of neurological deaths by sex, age, year in Ifakara 
Urban  
 
 Cerebrovascular diseases Epilepsy Meningitis Others Total 
Male 12 (40) 4 (44) 1 (14) 5 (100) 22 (43) 
Female 18 (60) 5 (56) 6 (86)  29 (57) 
Age      
0-4   1 (14) 4 (80) 5 (10) 
5-14   1 (14)  1 (2) 
15-49 3 (10) 9 (100) 4 (57)  16 (31) 
50+ 27 (90)  1 (14) 1 (20) 29 (57) 
Year      
2008 6 (20)  1 (14) 1 (20) 8 (16) 
2009 10 (33) 2 (22) 3 (43)  15 (29) 
2010 4 (13) 3 (33) 2 (29) 2 (40) 11 (22) 
2011 5 (17) 3 (33)  1 (20) 9 (18) 
2012 5 (17) 1 (11) 1 (14) 1 (20) 8 (16) 
Total 30 (100) 9 (100) 7 (100) 5 (100) 51 (100) 
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 Discussion and conclusions 
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Summary findings 
This thesis provides knowledge on uncertainties of epilepsy in SSA in relation to 
mortality, risk factors, and causes of death in PWE. The knowledge and evidence were 
generated from five studies using empirical data from community-based studies. 
Systematic review 
The first thesis objective was aimed at reviewing and summarizing available evidence 
on excess mortality in PWE compared to general population in LMIC. Systematic 
review in Chapter 3 identified only 7 studies in LMIC over the period of 25 years. 
Estimated excess mortality of ranged from 1.3-7.2 times higher in PWE compared to 
general population (median=2.6).  
Meta-analysis of this systematic review indicated that up to 80% of total variability’s in 
the estimate of excess mortality (SMR) was only due to differences between studies. 
These differences may be due to methodological variations between studies or other 
unknown factors. The estimated excess mortality of 2.6 was median value and not 
pooled estimate as large variability’s between studies could not allow combined 
estimate of 7 studies. 
In conclusion, until this systematic review was done, there were no sufficient data to 
provide empirical evidence of excess mortality in PWE in LMIC. 
SEEDS study: Excess mortality 
At the time the systematic review was completed, new data on mortality of PWE were 
emerging from SEEDS studies. SEEDS studies had already followed PWE for over 8 
years and documented deaths in people with and without epilepsy. Chapter 4 of this 
thesis was dedicated at pooling and generating new evidence of excess mortality in 
PWE from SEEDS studies.  
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The pooled excess mortality was 4.8 times higher in PWE than general population 
(95% CI: 4.2-5.6). SEEDS estimate is higher than summary findings from systematic 
review in reported in the literature in Chapter 3. SEEDS studies were conducted to 
account for methodological limitations encountered in most epilepsy studies related to 
screening, diagnosis, mortality and causes of death assessment, and population 
representativeness.  
SEEDS study: Risk factors 
The studies also identified modifiable risk factors potential for intervention programs 
and mitigating the negative impact of epilepsy. 
Causes of death automation 
In addition to summarizing excess mortality in PWE, systematic review in Chapter 3 
summarized causes of deaths in PWE from different studies. Summary estimates from 
different studies in LMIC indicated most PWE died of direct (SE and SUDEP) and 
indirect (injuries) causes of epilepsy death. These studies compiled causes of death 
information from variety of sources including physicians, verbal autopsies and death 
certificates. 
In Chapter 5, this thesis assessed the application of automated tools in ascertaining 
causes of death in PWE. The assessment indicated that, the use of automated tools 
is potentials, convenient and affordable alternative to post-mortem and physician 
death certification. Unlike the use of other sources of cause of death information, 
automated tool estimated lower number of epilepsy-related deaths (27.5%) compared 
to around 50% when physician make diagnosis of cause of death. Chapter 5 also 
provides valuable information and recommendation needed for further development 
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and refinement of these tools especially with regards to coding SUDEP, SE, and 
injuries. 
National estimates 
Chapter 6 and 7 provides national and community-based estimates of mortality of 
epilepsy and other neurological disorders from national (SAVVY) and community-
based studies (HDSS). The findings indicate epilepsy the second leading cause of 
death after cerebrovascular disorders. The estimates of mortality rate in the population 
ranged from 7-8 and 4-8 deaths per 100,000 populations in SAVVY and HDSS 
respectively. 
HDSS data 
HDSS sites have become platform for monitoring demographic indicators in most SSA. 
Analysis of HDSS data was aimed at ascertaining whether there has been declining 
trends in epilepsy and other neurological disorders over time. In Chapter 7 of this 
thesis, results of the analysis indicated epilepsy mortality did not change over the past 
15 years. 
Synthesis 
This thesis generated new insights into the epidemiology of epilepsy in SSA. Limited 
data of studies of burden of epilepsy mortality in SSA point to either lack of interest in 
the subject, resources limitations from governments and funding bodies, and lack of 
knowledge of the negative impact of epilepsy. This study provides rigorous evidence 
of excess mortality needed for advocacy to health care providers, governments, and 
funding bodies for increased investment in care, preventions and reduction of the 
negative impact of epilepsy in SSA. The community and health care providers will 
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benefit from evidence on modifiable risk factors for incidence and excess mortality 
from SEEDS study. 
Discussion 
Excess mortality in epilepsy: Systematic review in LMIC 
The median mortality rate in PWE is estimated at 20 deaths per 1,000 people with 
epilepsy (range 10-45) in population-based studies. The estimated excess mortality in 
LMIC is 2.6 times higher in PWE (range 1.3-7.2) than the general population. Epilepsy-
related deaths accounted for 50% of all reported deaths in PWE; with 27% being due 
to SUDEP and SE and the remaining injuries.  
Previous review of excess mortality reported much lower number of studies from SSA 
compared to this study (Nevalainen et al., 2014, Carpio et al., 2005). This reviews 
provided comprehensive summary of mortality estimates in epilepsy from high quality 
studies. Qualities of studies were judged according to criteria suggested by the ILAE 
for epidemiological studies based on methodological limitations identified in different 
studies (Preux et al., 2005a, Ba-Diop et al., 2014b, Logroscino et al., 2005). The 
methodological limitations were related to five key areas which are; epilepsy case 
ascertainment, diagnosis, mortality assessment, diagnosis of causes of death, and 
population representativeness.  
Case ascertainment refers to how PWE are identified. Door-to-door surveys are the 
best while identification in clinical settings is the least preferred option in studies 
conducted in SSA. Diagnosis by neurologist or through criteria issued by ILAE is likely 
to yield to optimal number of PWE. Mortality assessment relates to how PWE are 
followed over time and mortality in then captured with minimum lost to follow-up. 
Patient’s lost to follow-up in cohort studies is the major challenge in most SSA 
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countries where medical records and civil and vital registration is almost absent. Post-
mortem examination is the gold standard method for death certification, unfortunately, 
rarely implemented in SSA. Verbal autopsy and death certificates offered in clinical 
settings frequently used as alternative to post-mortem. Lastly, study population must 
representative of the general population. Deliberate efforts must be made to ensure 
population at high risk for epilepsy are not included.         
Qualities of studies were reviewed and those prone to yield biased estimates were 
excluded. In a review period of 25 years, 12 and 8 population-based and clinical cohort 
studies met the inclusion criteria. All clinical cohorts had quality < 80%. Majority of 
these studies were done in patients with refractory epilepsy, children, and in 
onchocerciasis-endemic areas. There were 7 good qualities (quality > 80%) 
population-based studies merit further review and meta-analysis. This indicates that 
there has been a significant less effort and funding dedicated to epilepsy given the 
wide geographic coverage of the review in sub-Saharan Africa, Asia, and South 
America.  
Scarcity in human and financial resources for epilepsy care, management, and 
research are among the key factors liked to low knowledge of epilepsy in most SSA 
countries (Newton et al., 2012a, Ba-Diop et al., 2014a). In HIC, PWE substantially 
benefits from high quality care, however funding for epilepsy research remains a major 
challenge. Adjusted for relative prevalence, US National Institute for Health’s funding 
for epilepsy was 1.8 times higher in stoke, 2.9 in Alzheimer disease, 6.9 times in 
Parkinson disease, 7.8 times multiple sclerosis, and 58.5 times amyotrophic lateral 
sclerosis (Meador et al., 2011).  The funding gap could not be explained by differences 
in the overall impact of these diseases relative to epilepsy especially Parkinson 
disease, multiple sclerosis, and amyotrophic lateral sclerosis. Possible explanations 
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for disproportionate funding among others were a poorer quality funding proposals and 
lack of expertise on grant review panels.  
The study estimated either weighed mean or median of mortality indicators rather than 
pooled estimate due to high heterogeneity across studies. The high heterogeneity 
observed illustrates high degree of uncertainty possibly due to differences in studied 
population and methods applied in screening, diagnosis, and mortality assessment. 
Despite the observed limitations, this review generated best available evidence of 
excess mortality of nearly three times higher than the general population. The review 
generated and contributed to a limited body of literature of the epidemiology of 
epilepsy in PWE and setup a platform for more focused investigation in light of data 
and methodological challenges observed. 
Excess mortality in epilepsy: SEEDS study 
SEEDS estimate of excess mortality is five times higher in PWE than the general 
population in SSA countries. SEEDS study provide more compelling evidence of 
mortality burden in PWE in SSA than previously thought as reviled in Chapter 3. 
SEEDS project is the largest, standardized population-based study of prevalence and 
mortality in PWE in sub-Saharan Africa. This study accounted for common and major 
methodological limitations identified in literature in Chapter 3. 
SEEDS studies were nested in HDSS, a reliable platform that guarantee 
homogeneous population, mortality assessment, and reliable causes of death 
estimation with standardized verbal autopsy tools and disease classification using ICD 
10. Door-to-door survey was employed in the entire HDSS site covering individuals of 
all ages with three stages screening tools recommended by ILAE strengthened 
SEEDS studies relative to others.  
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Risk factors for excess mortality 
Risk factors analysis identifies behaviours, health conditions, characteristics or 
exposures that increase than usual the probability of adverse outcomes. The analysis 
is necessary in designing appropriate interventions needed to mitigate negative impact 
of epilepsy. Systematic review in Chapter 3 provided substantial information on risk 
factors for mortality in epilepsy compiled from several studies. Estimates of risk factors 
were not uniformly estimated across studies making it difficult to generate pooled 
estimates. Taking the case of treatment with AED, the following classification were 
used; adherence vs. non adherence, good vs. poor adherence, AED vs. AED and 
traditional, and dosage levels of phenobarbital; 30–60, 90–180, and 210–240 mg. 
Regardless of the classification adopted by a study, high mortality were observed in 
PWE with suboptimal access treatment, recent diagnosis, younger, males, high 
seizures frequency, long duration in epilepsy, focal seizures, and symptomatic 
(acquired) epilepsy aetiology. 
SEEDS study provides site-specific and pooled estimates of impact of risk factors on 
excess mortality in epilepsy. Uncontrolled seizures were significantly increased the 
risk of death in PWE with high frequency of seizures (daily, seizure occurring during 
the day and night), and in those having more than 12 seizures per year. This study 
also observed higher mortality in PWE who experienced injuries in the past. High 
seizures frequency and injuries may possibly be linked with poor access to AED, 
however this study did not find lower mortality in those on treatment. This may be due 
the fact that majority of PWE are not receiving appropriate treatment and those who 
access AED, may not be receiving constant supply. 
Perinatal adverse events attributed to substantial increase in excess mortality in 
epilepsy in SEEDS study. Adverse events are difficulties occurred during birth and in 
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certain circumstances may lead to neurological complications in newborn. These 
events include obstructed labour, prolonged rapture of membranes, difficulty breathing 
and crying right after birth. These events are not predictable; however they are more 
likely to result in neurological complication if deliveries happen to occur at home or in 
facilities with poor delivery care. Children born in home or in poor resources settings 
are also less likely to be fully immunized. This study indicated increased mortality in 
children without “BCG vaccine scar”, an indication they were not protected against 
tuberculosis. Although there has been improvement in improving care at birth in SSA, 
majority of deliveries still occurs in at home or in facilities with limited resources. 
Perinatal events may also explain why majority of epilepsies in developing countries 
more prevalent in children younger than 20 years compared to older ages in developed 
countries. 
Co-morbidities with cardiovascular diseases in this study were linked to increased 
mortality in epilepsy. This study did not investigate causal pathways; however, other 
studies have observed significant cardiac changes in PWE (Jansen et al., 2010). 
Cognitive and motor impairments were associated with increased mortality in epilepsy 
therefore proper management of these co-morbidities is likely to decrease the burden 
of epilepsy mortality (Keezer et al., 2016). Co-morbidities with neurological deficit and 
severe deficit of cerebral function observed on EEG were linked to increased mortality 
in epilepsy. Evaluation of these risk factors in PWE could be potential in developing 
strategies targeting these individuals. 
Parasites infections are known risk factor for epilepsy in most SSA countries. This 
study found PWE living in household with cat are associated with increased mortality. 
Cats are carrier of the parasite Toxoplasma gondii, known to cause epilepsy in LMIC. 
Eating soil is another hygienic risk factor associated with soil transmitted parasitic 
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infection (Wagner et al., 2009, Kind et al., 2017). This study could not explain the 
mechanism for the increased risk of mortality in PWE with antibodies for Toxoplasma 
gondii relative to other parasites, and those eating soil. It is worth noting these factors 
are also responsible for epilepsy incidence therefore mitigating these factors may 
result in decreased incidence and mortality in PWE.  
Availability and use of information risk factors is essential in designing epilepsy 
intervention programs are likely to result in substantial improvement in health status 
of PWE. 
Automated causes of death in epilepsy deaths 
With nearly 75% of deaths happen at home and never get to the hospital for post-
mortem investigation, causes of death statistics is nearly impossible to produce in 
most SSA countries. Verbal autopsy procedure provide an opportunity for physicians 
to determine cause of death by reviewing detailed structured questionnaires of signs, 
symptoms, health conditions, and circumstances occurred to the diseased provided 
by caretakers. Causes of death certification are done using ICD10 intended to promote 
accuracy, consistency and comparability of causes of death across time and places. 
Several studies have applied VA on neurological diseases in LMIC focusing among 
others epilepsy, stroke and cerebrovascular diseases (Mateen et al., 2012).  
With considerable limited resources, most SSA countries do not opt for death 
certification with VA as it require field VA interviewer and the use of multiple physicians 
to classify every death through time demanding review of VA questionnaires. 
Mathematical and statistical model has been proposed as an alternative to physicians 
coding, however, their use has not been thoroughly evaluated in epilepsy deaths.  
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Several studies have been published comparing software and provide strength and 
limitation of each. The use of InteVA4 model has recently gained momentum due to 
funding limitations in most demographic surveillance system (Murray et al., 2014). 
Four key issues were observed on InterVA-4 output: i) the system was not design to 
produce SUDEP and SE as causes of death; ii) possible epilepsy deaths were 
frequently coded as injuries (accidents); and iii) circumstances occurred prior to death 
as described by caretakers may play an important role is precisely determine the 
cause of death; and vi) at population level, proportion of direct and indirect were lower 
than unrelated causes of epilepsy. 
Sudden death and seizures lasting for at least 10 minutes are the least parameters 
needed for certifying SUDEP and SE as cause of death in epilepsy respectively. 
Verbal autopsy information collected from caregiver of the diseased can provide 
valuable information in identified SUDEP (Lathers et al., 2009). InterVA4 highly 
associated sudden death and longer seizures with likelihood of epilepsy deaths, 
however, specific death’s categories for SUDEP and SE were not created respectively. 
The distinction between SUDEP and SE is essential in understanding and determining 
the risk factors for death in PWE. SUDEP is not only excluded in the list of cause of 
death in InterVA4, but also with ICD10 in which “Epilepsy, unspecified” code is often 
used. On the other hand, SE is widely recognized and specific category has been 
assigned to it (i.e. G41.-). Automatic coding for SE could improve with further probing 
for seizures lasted at least 10 minutes with an additional question “did seizure ended 
with death”. 
Most accidents-related deaths in PWE were attributed to epileptic seizures; however, 
InterVA4 software categorized these deaths as accidents. The software was not 
programmed to link accidents, epilepsy deaths and epilepsy status. An additional 
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question linking accidents to epilepsy may be phrased “did accident occurs during 
seizures?” On the other hand, these deaths were coded as epilepsy deaths by 
physicians. The main challenge here is the configuration choice on whether underlying 
or immediate cause of death information is preferred. Underlying cause of death if 
often preferred in public health due to its relevance in producing vital statistics related 
to cause of disease rather than its effect. Future configuration of automated cause of 
death should re-consider this issue so as to enable reliable burden of epilepsy 
mortality be estimated. 
VA interviews collects substantial amount of text information that are relevant in 
establishing causes of death in PWE. The WHO 2008 version of VA questionnaires 
requires the interviewer to collect and document the following information when 
available: i) Short narrative of circumstances occurred prior to death from caretaker of 
the diseased, ii) Cause of death according to their best understanding of the patient, 
iii) cause of death as reported on death certificate if death certificate was provided, iv) 
cause of death reported on burial permit, v) post-mortem report, vi) antenatal care 
card, vii) prescription information, viii) medical records ix) discharge cards; and x) 
laboratory results. 
These text narratives provides valuable clue in differentiating epilepsy and unrelated 
causes of death and improves the reliability and precision of death certification among 
physicians. Unfortunately, these text narratives are not utilized by automated models. 
Text mining technique can be used to analyse these text and improve predicted 
causes of death in epilepsy. Text mining involves computational extraction of selected 
information unstructured text data (Singh, 2005). The methods has shown promising 
results in medical research including in identify rate diseases and adverse drug events 
in unstructured text data (Harpaz et al., 2014). Future development of automated 
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causes of death software’s needs to invest in integrating text mining in order to improve 
accuracy of causes of death statistics. 
Epilepsy mortality in Tanzania 
This study provided comprehensive review of excess mortality in PWE in LMIC and in 
SSA. Chapter 6 and 7 were devoted to Tanzania as an illustrative country of SSA with 
comprehensive community-based to evaluate levels and trends of epilepsy mortality. 
SAVVY (Chapter 6) and HDSS (Chapter 7) focused empirical evidence of national 
level and secular trends in estimate of epilepsy and other neurological mortality. 
National levels and population trends data are rare in most SSA due to poor coverage 
of vital registration systems. This study utilized data from well-designed national 
representative mortality and causes of death survey. The survey adopted a design 
intended to generate mortality estimates and causes of death from the community 
using verbal autopsy rather than post-mortem examination. 
The results indicate epilepsy the second leading cause of death in Epilepsy after 
epilepsy with estimated mortality rate of 7.0 deaths per 100,000 population. There 
were no best national estimates to compare and contrast these estimates in SSA 
countries. Compared to GBD report, SAVVY estimates of epilepsy mortality were 
comparable to estimates from GBD report for Tanzania. SAVVY study provides first 
detailed analysis of national data on neurological disorders in Tanzania. 
Secular trend in epilepsy 
Ifakara Health Institute (IHI) established three HDSS sites in different settings in 
Tanzania to be used as a platform for assessing demographic events and trends, and 
evaluating impact of health intervention (Geubbels et al., 2015, Mrema et al., 2015). 
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This study utilized the platform and determined the magnitude and changes in the 
mortality associated with epilepsy from 1999 to 2014.  
This study provides evidence of no progress in the reduction of epilepsy in rural 
(Ifakara Rural and Rufiji HDSS) as well as semi-urban (Ifakara urban HDSS) settings 
over the past 15 years. These results shows epilepsy is the second leading cause of 
death that has persisted over years and demand renewed efforts. 
Limitations 
Verbal autopsy 
Deviations from true estimates may be associated to individual certification and coding 
practices among physicians who were involved in the study. High estimates malaria 
mortality far more than previous estimates from several epidemiological studies mainly 
due to the fact that malaria is common illness encountered by most physicians in their 
routine practice. However some of clinical manifestation of cerebral malaria such as 
fever, vomiting, and convulsions are also clinical manifestations of neurological 
disorders such as meningitis and epilepsy. With lack of clinical training in neurology 
among death certifiers, substantial number of neurological deaths may have been 
missed in this study. 
The study utilized population-based studies that never consider sample size needed 
to estimate mortality of neurological disorders. Diseases relatively smaller number of 
deaths such as epilepsy and meningitis may require larger sample size compared to 
diseases such as cerebrovascular diseases (Mateen et al., 2012). This may be the 
case with this study especially on studies conducted on HDSS sites. On the other 
hand, SAVVY sample size was large enough to account for sample size needed to 
estimate mortality rate of most common neurological disorders. 
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In SSA SAVVY approach has only been successfully in Zambia and Mozambique 
(Statistics; et al., 2012, Mudenda et al., 2011). SAVVY approach was developed to 
provide a standardized methodology in generating mortality estimates, causes of 
death and disease classification needed for local, regional and international 
comparability of mortality statistics. The limiting factor in the use of VA is cost 
(AbouZahr et al., 2010), due to the fact that, it the approach most often require trained 
interviewers and physicians during VA interview and death certification. The use of 
improved automated tools will greatly reduce SAVVY cost when combined with data 
collection using mobile devices and volunteer or community health workers. 
Non-convulsive epilepsy 
SEEDS study focused on convulsive epilepsies which accounts for 50-60% of all 
epilepsies in SSA. (Adamolekun, 1995) Verbal autopsies could in similar way missed 
non-convulsive epilepsies which may limit the ability to fully determine the excess 
mortality in PWE by excluding this subpopulation. However, the choice to focus on 
ACE is justifiable specifically with regards to human and technological resources. 
Morbidities of neurological disorders 
This study focused on mortality burden of neurological disorders. However, it is 
generally known that the burden associated with morbidities might be substantially 
higher than estimated in this study. Taking an example of stroke, stroke, mortality rates 
and deaths have substantially declined in most countries however the number of 
people living with stroke related disabilities has been increasing (Feigin et al., 2015). 
Reliable morbidity data can only be obtained when there is routine health care services 
data of good quality and community-based surveys. 
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Implications of public health 
Investment in epilepsy research in SSA 
The systematic review identified limited number of good quality studies of on epilepsy 
mortality in LMIC over the past 25 years. There may be multiple factors associated 
with this including lack of funders’ interest in financing epilepsy research, lack of 
expertise in neurology, and poorer quality funding proposals. This study provided 
important information on status of epilepsy research and call for renewed efforts to 
funding agencies and researchers to reconsider prioritizing SSA due to its high burden. 
Local and international organizations including ILAE, International Bureau for Epilepsy 
(IBE), Epilepsy Alliance Europe has been established to advocate and mobilize 
funding and research for care in PWE. These organizations have been substantially 
contributed in improving care, treatment and increased funding for epilepsy, however 
major activities has been less directed to developing countries where 90% of epilepsy 
burden reside.  
This study recommends and support for a more equitable approach earlier proposed 
by Chin to through establishing a global fund for epilepsy (Chin, 2013). The proposal 
includes include among others integrating epilepsy into primary health care, 
establishing geographically representative collaboration of major neurology and 
epilepsy societies and foundations, public health organizations, thought leaders, and 
industry. Activities of the funds may include “support expert and peer training of 
primary health workers, procurement of antiepileptic drugs, diagnostic testing, 
information and telecommunication technologies, and social services” (Chin, 2013). 
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Epilepsy care and management 
This study provided evidence of high excess mortality in PWE in SSA than reported 
elsewhere in the world. The excess mortality was associated with high frequency of 
seizures which is largely attributed to high treatment gap. This study recommends 
improving delivery of epilepsy treatment targeting major barriers to access to AED with 
a package of care proposed by Mbuba (Mbuba et al., 2009). Mbuba et al proposed, 
first; increasing capacity of identifying PWE through regular epidemiological surveys 
and training of teachers, and community health workers, second; train health care 
providers (nurses and clinical officers) in diagnosing epilepsy, third; providing 
education and psycho-educational interventions, fourth; ensure continuous supply of 
AEDs (when possible generic formulation), and fifth; increasing participation of NGO’s 
and other community-based organization who are actively involved with advocacy for 
mental health. Mbuba also detail on how, who and setting by which the proposed 
package can be practically implemented. 
Mitigating risk factors 
High prevalence and mortality of epilepsy in SSA can be prevented with cost-effective 
intervention. Most observed risk factors were modifiable; meaning the burden can 
significantly reduce with promotion of actions, behaviors and priorities. Mitigating risk 
factors for epilepsy requires participation of different sectors. New programs may not 
be needed; however strengthening the existing programs may provide spilling over 
effect to epilepsy. Table 8-1 provides summary of identified risk factors, action to be 
taken and responsible sector. Some of the actions proposed are adopted from Mbuba 
et al. (Mbuba et al., 2009).  
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Strengthen monitoring and evaluation platforms 
Scarcity of data on the burden of epilepsy in SSA if largely attributed to lack of civil 
and vital registration systems. Using SAVVY and HDSS platform, this study estimated 
levels and secular trend in epilepsy mortality in Tanzania. Managing SAVVY and 
HDSS is expensive thus many SSA fail to invest in these platform. Sustainable 
availability of burden of epilepsy will require strengthening of vital registration systems 
and community disease surveillance. 
With regards causes of death, the use of community health workers in conducting VA 
and the use of automated tools will timely provide epidemiologic data needed for 
planning of health care services in PWE. Establishing long term cohort of epilepsy 
patient will provide valuable platform needed to monitor and estimate the burden of 
epilepsy, related risk factors, causes of death and effectiveness of intervention. 
Conclusions 
This thesis provided evidence of higher excess mortality in PWE than estimated 
elsewhere in SSA using empirical data from large community based studies. Risk 
factors analysis indicates majority of premature deaths in PWE in SSA are 
preventable. Secular trend analysis shows epilepsy mortality has no declined in the 
past 15 years. With rapid demographic transition in SSA, the burden of epilepsy 
mortality is expected to substantially increase in future if no action is taken. 
 
 
Table 8-1 Proposed action for modifiable risk factors for excess mortality in PWE 
Risk factor Sector Action 
177 
 
Perinatal adverse events 
(obstructed labor, difficulties 
breathing and or crying) 
Health 1. Improve care at birth, 2. Provide training to 
midwifes, 3. Improve emergency obstetric care, 4. 
Promote safe facility delivery.  
1. Parasite infection 
2. Poor hygiene (eating soil) 
 
Health and 
agriculture 
1. Educate the public on animal human disease 
transition, 2. Assist community on deworming 
domesticated animal, 3. Educate the community on 
soil transmitted infections. 
Illiterate Education 
and health 
1. Improve access to education, 2. Health in primary 
education curriculum 
3. Develop advocacy strategies that target illiterate 
individuals such as radio programs, 4. Educate the 
public on causes of epilepsy and associated 
misconception such as those linking epilepsy with 
curse and demonic possession  
Marital status (divorced, 
separated, widowed). 
 
Health 1. Provide education and psychoeducational 
interventions to PWE 
2. Health care workers trained in psychological 
support and counselling 
High seizures frequency Health 1. Increase government support in procurement and 
supply of AED  
2. Improve access to AED especially in remote area  
Co-morbidities (sickle cell, 
hypertension, and motor, 
cognitive, and sleep 
disorders) 
 
Health 
Researchers 
1. Incorporate screening of co-morbidities on 
treatment guidelines 
2. Train health care providers in managing co-
morbidities. 
3. Conduct research on incidence of co-morbidities 
and associated risk factors in PWE. 
Head injuries Health 1. Develop community interventions on road safety 
2. Improve access imaging diagnosis (CT scan, MRI)  
Neurologic deficits Health 1. Train workers on diagnosing neurologic deficits 
2. Improve access imaging diagnosis (EEG) 
PWE: People with epilepsy, EEG: Electroencephalography, AED: Antiepileptic drugs, MRI: Magnetic resonance 
imaging, CT: computed tomography 
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